

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Paul TARDI, *et al.*

Serial No.: 10/417,631

Filing Date: April 16, 2003

For: COMPOSITIONS FOR DELIVERY OF
DRUG COMBINATIONS

Confirmation No.: 6691

Group Art Unit: 1616

Examiner: Ali Soroush

**DECLARATION OF LAWRENCE D. MAYER
UNDER 37 C.F.R. § 1.132**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Lawrence D. Mayer, declare as follows:

1. I am President and Head of Research of Celator Pharmaceuticals, Inc., the assignee herein. I have been actively engaged in drug delivery research, both academically and in industrial settings for over 22 years. A copy of my *curriculum vitae* is attached as Exhibit A.

2. I agree with the statement by the Examiner in his Office Action dated November 15, 2007, "...the state of the art is very high in terms of formulating the liposomal sustained release compositions..." Indeed there were numerous references in the art at the time

of the present application describing a wide range of approaches and methods for controlling the loading as well as release of liposomal agents with the latter being widely examined for a number of antineoplastic agents. Methods of modulating drug retention and release in multiple delivery vehicles, including liposomes and polymer-based nanoparticles, are well known to those of skill in the art. This literature includes an extensive compendium of data on actual release rates for a multiplicity of drugs from a multiplicity of particulate carriers.

3. Examples of methods for controlling liposomal drug release include:
 - a) the use of a transmembrane ion gradients, particularly pH gradients generated with, for example, citrate, ammonium sulfate or an ionophore as well as using various degrees of said pH gradients;
 - b) the use of transmembrane osmotic gradients of varying degrees;
 - c) modulating the class (*e.g.*, anionic, neutral, pegylated), acyl chain length and/or amount of individual phospholipids used in a mixture;
 - d) the addition of cholesterol;
 - e) altering the drug-to-lipid ratio;
 - f) selecting delivery vehicles with specific phase transition temperatures
4. Below is a list of references for each of the above categories. It should be noted

that his list is only meant to provide representative methods and numerous other examples and related approaches were readily available:

a) Ionic Gradients

- i. Cullis, P.R., *et al.*, Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. *Biochim. Biophys. Acta* (1997) 1331:187-211.

- ii. Burke, T., and Gao, X., Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. *J. Pharm. Sciences* (1994) July; 83(7):967-969.
- iii. Bowman, N., *et al.*, Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. *Cancer Res.* (1994) June 1; 54:2830:2833.
- iv. Haran, G., *et al.*, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. *Biochim. Biophys. Acta* (1993) Sept 19; 1151(2):201-215.
- v. Fenske, D.B., *et al.*, Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. *Biochim. Biophys. Acta* (1998) Nov 11; 1414(1-2):188-204.
- vi. Bowman, N., *et al.*, Optimization of the retention properties of vincristine in liposomal systems. *Biochim. Biophys. Acta* (1993) 1152:253-258.
- vii. Clerc, S., and Barenholz, Y., Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. *Biochim. Biophys. Acta* (1995) Dec 13; 1240(2):257-265.
- viii. Redelmeier, T., *et al.*, Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. *Biophys. J.* (1989) Aug; 56(2):385-393.
- ix. US Patent 5,077,056 (Published December 31, 1991) – see Example 1 Part A – “Active Loading Using Na⁺ /K⁺ Gradients”

b) Osmotic Gradients

- i. Mui, B.L., *et al.*, Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. *J. Biol. Chem.* (1994) Mar 11;269(10).
- ii. Allen, T.M., and Cleland, L.G., Serum-induced leakage of liposome contents. *Biochim. Biophys. Acta* (1980) 597:418-426.

c) Lipid Composition

- i. Horowitz, A.T., *et al.*, *In vitro* cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. *Biochim. Biophys. Acta* (1992) 1109:203-209.
- ii. Frezard, F., and Garnier-Sullerot, A., Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. *Biochim. Biophys. Acta* (1998) 1389:13-22.
- iii. Lim, H.J., *et al.*, Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. *J. Pharmacol. Exp. Ther.* (2000) Jan; 292(1):337-345.
- iv. Forssen, E.A., and Tokes, Z.A., Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. *Cancer Res.* (1983) Feb; 43:546-550.

d) Cholesterol Content

- i. Dos Santos, N., *et al.*, Improved retention of Idarubicin after intravenous injection obtained for cholesterol-free liposomes. *Biochim. Biophys. Acta* (2002) Jan; 1561:188-201.
- ii. Ogihara-Umeda, I., and Kojima, S., Cholesterol enhances the delivery of liposome-encapsulated gallium-67 to tumors. *Eur. J. Nucl. Med.* (1989) 15:612-617.
- iii. Fielding, R.M., and Abra, R.M., Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. *Pharm. Res.* (1992) Feb; 9(2):220-223.

e) **Drug-to-Lipid Ratio**

- i. Mayer, L., *et al.*, Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. *Cancer Res.* (1989) Nov. 1; 49:5922-5930.

f) **Phase Transition Temperature**

- i. Hays, L.M., *et al.*, Factors affecting leakage of trapped solutes from phospholipid vesicles during thermotropic phase transitions. *Cryobiology* (2001) Mar; 42(2):88-102.
- ii. Hayashi, H., *et al.*, Temperature-controlled release property of phospholipid vesicles bearing a thermo-sensitive polymer. *Biochim. Biophys. Acta* (1996) 1280:127-134.
- iii. Anyarambhatla, G., and Needham, D., Enhancement of the phase transitions permeability of DPPC liposomes by incorporation of MPPC: A new temperature-sensitive liposome for use with mild hyperthermia. *J. Liposome Res.* (1999) 9(4):491-506.
- iv. Kong, G., *et al.*, Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release. *Cancer Res.* (2000) Dec. 15; 60:6950-6957.

5. In addition, a similar database existed at the time of the invention describing methods for controlling drug release from natural and synthetic non-liposomal delivery vehicles including micelles, nanoparticles, microspheres and drug-polymer conjugates. Below is a list of references which detail various methods for controlling the release of therapeutic agents from non-liposomal delivery vehicles:

- a) Genta, I., *et al.*, Different molecular weight chitosan microspheres: influence on drug loading and release. *Drug Dev. Ind. Pharm.* (1998) Aug; 24(8):779-784.

- b) Kim, H., and Fassihi, R., Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. *J. Pharm. Sci.* (1997) Mar; 86(3):323-328.
- c) Kawaguchi, T., *et al.*, Control of drug release with a combination of prodrug and polymer matrix: Antitumor activity and release profiles of 2',3'-Diacyl-5-fluoro-2'-deoxyuridine from Poly(3-hydroxybutyrate) microspheres. *J. Pharm. Sci.* (1992) June; 81(6):508-512.
- d) Anderson, B.C., *et al.*, Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. *J. Control Release* (2001) Jan 29; 70(1-2):157-167.
- e) Muller, R.H., *et al.*, Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. *Eur. J. Pharm. Biopharm.* (2000) Jul; 50(1):161-177.

6. Not only does the art describe various release rates for various drugs in various combinations, the above-cited documents also describe factors that can be controlled in predictable ways to accelerate or decelerate the release of any particular drug, such as a lipophilic drug, a hydrophilic drug, a charged drug or a neutral drug. For example, the rate of release of a lipophilic drug can be decelerated by employing phospholipids with longer acyl chains and can be controlled by adjusting the pH of the internal solution.

7. While the Examiner acknowledges that there is significant skill in the state of the prior art for controlling drug release of single drugs from drug delivery vehicles, he asserts in the November 15, 2007 Office Action that the state of the prior art is not high in terms of "...releasing the two neoplastic agents in the same non-antagonistic ratios." Actually the amount of knowledge of this subject was high at the time of the invention, but experiments were not

reported in the prior art until the present invention, since the knowledge that *ratios* are important AND must be maintained *in vivo* was never appreciated in the art. Therefore the known methods of controlling drug release were never applied to coordinating the release of drug combinations even though practitioners knew how to do it. Once the desirability of controlling ratios was revealed as a result of the present invention, those of skill in the art are able to use the abundant references available to construct delivery vehicles with matched release kinetics of two active agents thereby controlling their ratio after *in vivo* administration.


8. For drugs with dissimilar characteristics in which a single delivery vehicle coordinating release of the two drugs is not ideal as described in the specification (paragraphs 0023-0024, 0115, 0117 and 0130), two different carriers modulating the release kinetics of each drug individually can be designed to coordinate the ratio in the blood as demonstrated in Examples 8, 12, and 15 in the specification. The two drug-containing delivery vehicles can be mixed and co-administered *in vivo*. Thus, for example, a combination of a negatively charged drug with a positively charged one might be handled in this way. Coordinated release both from co-encapsulated drugs and drugs formulated separately is illustrated in Examples 8-9, 12-13 and 15-16.

9. Given the breadth of methods available in the prior art for controlling drug release, there are multiple features of each delivery vehicle which could be readily designed to achieve the coordinated release of two encapsulated agents whether co-encapsulated or encapsulated in separate delivery vehicles such that a desired synergistic ratio is maintained in the blood. This could be achieved without undue experimentation based on the extensive data-

base on actual drug release rates from drug delivery vehicles available in the literature for a wide range of drug classes and delivery vehicles.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed at Vancouver, CANADA, on January 14, 2008



Lawrence D. Mayer

Curriculum Vitae

DR. LAWRENCE D. MAYER

EXHIBIT A

EDUCATION

- Ph.D. Biochemistry (1983) University of Minnesota, Dr. Gary L. Nelsestuen, Supervisor
Thesis: Protein-Membrane Interactions Involved in the Prothrombinase System
- B.Sc. Majors in both Chemistry and Biology (1978, *Summa Cum Laude*) Wartburg College

PROFESSIONAL EMPLOYMENT

- 2003-Present **Founder, President and Head of Research, Celator Pharmaceuticals**
- 1999-2002 **Founder, President and Chief Executive Officer, Celator Pharmaceuticals**
- 2004-Present **Adjunct Scientist, BC Cancer Agency**
- 1992-Present **Adjunct Professor, Faculty of Pharmaceutical Sciences, University of B.C.**
- 1992-2003 **Senior Research Scientist, Division of Medical Oncology, B.C. Cancer Agency**
Research programs in the development of liposomal drug delivery systems, multidrug resistance and novel chemotherapeutic agents. Graduated 7 Ph.D. students, 3 M.Sc. students and supervised 16 postdoctoral fellows. Awarded over \$4M in research funding.
- 1999-2001 **Research Supervisor, Experimental Medicine, University of B.C.**
- 1992-2002 **Director, Investigational Drug Program, B.C. Cancer Agency**
Established and directed translational research and development activities of the Investigational Drug Program including GMP production of clinical supplies in the BCCA clean room facility and GLP testing. Co-ordinated proposals for preclinical and clinical testing of new anticancer agents for outside companies as well as development programs for agents generated within the Agency.
- 1990-1992 **Program Director, QLT Inc.**
Project manager for topical photosensitizer development program. Responsible for implementation of Quality Management system to ensure compliance with HPB and FDA regulatory requirements. Also responsible for directing formulation efforts of topical photosensitizers, coordinating activities between various departments (toxicology, pharmacology, clinical, etc.), preparing budget estimates and project administration. Member of Development Management Group responsible for establishing short term and long term corporate drug development strategy.
- 1987-1990 **Scientific Director, The Canadian Liposome Co. Ltd.**
Project leader of lead liposomal anticancer agent (TLC D-99) at CLC and its parent company The Liposome Co., Inc. (Princeton, N.J.). Responsible for coordinating R&D activities with current time tables for ongoing clinical trials and anticipated production requirements for future trials. Participated in preparing IND submissions to US FDA and Canadian HPB for clinical testing of TLC D-99. Co-directed research projects concerning the mechanism of action of liposomal anticancer pharmaceuticals. Responsible for developing budget requirements for active research projects.

1986-1987 **Research Associate, Biochemistry Dept., University of B.C.**

1983-1986 **Canadian MRC Postdoctoral Fellow, Biochemistry Department, University of B.C.**

AREAS OF SPECIAL INTEREST AND ACCOMPLISHMENTS

- Spearheaded the translation of Celator's CombiPlex fixed-drug ratio combination chemotherapy technology from the lab into the clinic, resulting in two products being evaluated in clinical trials.
- Part of Celator Senior Management team responsible for securing \$10M CDN Series A and \$40M US Series B Venture Capital financings
- Established new paradigm for developing drug combinations for cancer chemotherapy where synergistic drug:drug ratios are fixed inside liposomes for delivery to tumors. This allows drug combinations to be developed based on maximum efficacy rather than on tolerability.
- Co-founder of Celator Technologies as a spin-off of BCCA laboratory focussed on delivery of drug combinations
- Identified novel applications for and characterized the molecular and therapeutic activities of Bcl-2 antisense oligonucleotides used to chemosensitize human solid tumor xenografts which were implemented by Genta, the company developing Genesense.
- Established novel liposome delivery platform based on reactive, cholesterol-free membranes for enhanced disease site-selective activity.
- Identified enhanced lung cancer antitumor activity of vinca alkaloid derivative anhydrovinblastine and led translational research activities that resulted in IND submission for Phase I clinical testing.
- Discovered and characterized use of liposomal anticancer drug formulations in combination with P-glycoprotein inhibitors to effectively treat multidrug resistant tumors, an approach that was validated in later clinical trials.
- Led discovery and translational research activities to develop an optimized liposomal vincristine formulation and led preparation of the IND submission.
- Played leading role in basic and applied research for development of liposomal doxorubicin formulation currently approved for market use in Europe.
- Established and directed operations of the Investigational Drug Program at the BC Cancer Agency. This Program has been granted an Establishment License by the Canadian TPP as a GMP manufacturing clean room and testing facility for clinical trial supplies. This is the only academic center in Canada to hold such accreditation.

HONOURS AND AWARDS

- Nomination in the Ernst & Young Entrepreneur of the Year awards program, in recognition of determination and inspiration in building a thriving business – and a strong and vibrant country (2003)
- Canadian Medical Research Council Postdoctoral Fellow (1983-1986)
- Dissertation Fellowship, University of Minnesota (1982)
- Wayne Page Memorial Outstanding Student-Athlete Award, Wartburg College (1977)

TEACHING

Areas of special interest and accomplishments

- Worked on course coordination committee to develop Cancer Biology graduate course (Path 500)
- Active yearly participation in training of undergraduate students through summer research programs with Faculty of Pharmaceutical Sciences, Pharmacology Dept. and Biochemistry Dept. at UBC

Courses Taught at UBC

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
1996-1997	MedGen 421		150	4			
1996-1997	Path 531		17	4			
1997-1998	MedGen 421		150	4			
1997-1998	Path 531		13	4			
1997-1998	Path 548		7	3			
1998-1999	MedGen 421		150	4			
1999	Phar 414				40		
1999-2000	Phar 510		12	8			
2001	Phar 550		50	4			
2001	Phar 414				30		

Graduate students supervised: 7

Students co-supervised: 3

Member of supervisory committees: 12

Postdoctoral fellows supervised: 17

SUMMARY OF GRANTS & CONTRACTS

Total # of grants/contracts held: 29

Range of years: 1992 -- 2006

Total amount of grant money: \$9,345,248

INVITED PRESENTATIONS

- "Association of prothrombin, Factor X and Factor V with phospholipid monolayers" FASEB meetings, Chicago, Illinois, May 1982.
- "Protein-membrane interactions involved in the prothrombinase system" Biomembranes Discussion Group, University of British Columbia, December 1982.

- "Influence of transmembrane ion gradients on the transbilayer distribution of dibucaine" Pharmacology Seminar Series, University of British Columbia, October 1985.
- "Optimization of the therapeutic activity of liposomal doxorubicin" FASEB Liposomal Drug Delivery Conference, Saxton, Vermont, July 1987.
- "Liposomal anticancer formulations with improved therapeutic potential" Oncology Experimental Therapeutics Seminar Series, Roswell Park Memorial Institute, Buffalo, New York, March 1990.
- "Development of liposomal vincristine preparations with improved therapeutic potential" Advanced Therapeutics Seminar Series, British Columbia Cancer Agency, Vancouver, B.C., October 1990.
- "Liposomes as intravenous drug delivery systems" Canadian Society of Hospital Pharmacists Annual General Meeting, Vancouver, B.C., November 1990.
- "Pharmacodynamics of liposomal anticancer agents" University of British Columbia, Faculty of Pharmaceutical Sciences Invited Lecture Series, Vancouver, B.C., March 1994.
- "Formulation, toxicity and pharmacology of liposomal doxorubicin" Liposome Research Days Conference, Vancouver, B.C., June 1994.
- "Pharmacology of vincristine encapsulated in sphingomyelin-cholesterol liposomes" AACR Annual General Meeting Discussion Session, Toronto, Ontario, March 1995.
- "Cellular pharmacology of verapamil in P388-ADR cells in vitro" AACR Annual General Meeting Discussion Session, Toronto, Ontario, March 1995.
- "Preclinical and clinical studies with liposomal vincristine" Third Drug Delivery Symposium, Shizuoka, Japan, June 1995.
- "Membrane Properties Control the Therapeutic Activity of Liposomal Vincristine" Fourth Liposomal Research Conference, Freiburg, Germany, August 1995.
- "The Use of Liposomes to Target Anticancer Agents to Solid Tumors" Gordon Research Conference on Drug Carriers in Biology and Medicine, Ventura, CA, February 1996.
- "Strategies for Optimizing Liposomal Anticancer Agents" PharmTech Conference, East Rutherford, N.J., September 1996.
- "The Use of Liposomes in Therapeutic and Mechanistic Studies of Multidrug Resistance" Canadian Multidrug Resistance Roundtable Meeting, Toronto, Ont., March 1997.
- "Current Trends in Cancer Chemotherapy" Bridging the Strait of Georgia Cancer Research Symposium, Sidney, B.C., May 1997.
- "Therapeutic and Mechanistic Studies on the Pharmacology of Multidrug Resistance" Univ. of British Columbia Dept. of Surgery Seminar Series, Vancouver, B.C., July 1997.
- "In Vivo Entrapment of Doxorubicin Utilising pH Gradient Liposomes" Gordon Research Conference on Drug Carriers in Biology and Medicine, Ventura, CA, February 1998.
- "Strategic Development of Biopharmaceuticals" Pictet Biotechnology Seminar, Vancouver, B.C., September 1998.
- "Designing Liposomal Anticancer Agents to Overcome MDR in Combination with the P-glycoprotein Inhibitor PSC 833" International Conference of Anticancer Research, Thessaloniki, Greece, October, 1998.
- "Optimization of Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications" University of London Liposomes in Biomedical Applications Symposium, London, UK, Dec. 1999.
- "Therapeutic and Pharmacokinetic Properties of Doxorubicin combined with Bcl-2 Antisense Oligonucleotide Treatment" Poster Discussion Session, AACR Annual Meeting, San Francisco, CA, April 2000.
- "Matching Drug Release Kinetics with Therapeutic Applications for Liposomal Anticancer Drug Formulations" International Liposome Research Society Conference, Napa, CA, April 2000.
- "Characterization of a Novel Thermosensitive Liposomal Doxorubicin Formulation for Tumor Specific Drug Exposure" Congress of International Society of Hyperthermia Oncology, Taegu, Korea, April 2000.

- "Application of Liposomal Drug Delivery Systems for Treating Multidrug Resistant Tumors"
Pharmacology 2001, Vancouver, BC, March 2001.

CONFERENCE PARTICIPATION (ORGANIZER, KEYNOTE SPEAKER, ETC.)

- Session Chair, "Drug Delivery and Tumor Vascular Targeting" Amer. Assoc. Cancer Res. General Meeting, Philadelphia, PA, April 13, 1999.
- Session Chair, "Gene Targeting" Bridging the Strait of Georgia Cancer Symposium, Vancouver Island, 1998,
- Organizer, Bridging the Strait of Georgia Cancer Symposium, Vancouver Island, 1996 and 1998.
- Session Chair, "Developments in Antisense Technologies", Gordon Research Conference on Drug Carriers in Biology and Medicine, Ventura, CA, February, 1996.
- Session Chair, "Steric Stabilisation", Fourth Liposomal Research Conference, Freiburg, Germany, August 1995.

MEMBERSHIPS ON SCHOLARLY SOCIETIES, INCLUDING OFFICES HELD AND DATES

- 2005-present: Editorial Academy of the *International Journal of Oncology* (invited)
- 2003-present: American Association for the Advancement of Science
- 1997-present: International Liposome Society
- 1994-present: Parenteral Drug Association
- 1992-present: American Association of Cancer Research
- 1992-present: American Association of Pharmaceutical Sciences
- 1994-present: B.C. Biotechnology Alliance
- 1989-1993: Stanley Park Zoological Society (Elected member of Board of Directors)
- 1992-1994: Biopharmaceutical Innovation Resource Centre/Economic Regional Diversification Agreement Steering Committee

EDITORSHIPS

- 2001-Present: Journal of Experimental Therapeutics and Oncology
- 2001-Present: Molecular Cancer Therapeutics
- 1999-present: International Journal of Oncology

JOURNAL REVIEWER

- 2007-Present European Journal of Pharmaceutical Biopharmaceutics
- 2001-Present Molecular Cancer Therapeutics
- 2001-Present Journal of Pharmaceutical Research
- 1999-Present International Journal of Oncology
- 1998-Present Journal of Pharmaceutical Sciences
- 1998-Present: Cytometry
- 1997-Present Clinical Cancer Research
- 1996-Present: Molecular Pharmacology

- 1996-Present: European Journal of Pharmaceutical Science
- 1996-Present: Journal of Pharmacology and Experimental Therapeutics
- 1995-Present: International Journal of Cancer
- 1994-Present: European Journal of Cancer
- 1993-Present: Journal of Liposome Research
- 1992-Present: Journal of the American Chemical Society
- 1991-Present: Cancer Chemotherapy and Pharmacology
- 1991-Present: British Journal of Cancer
- 1990-Present: Journal of Biological Chemistry
- 1990-Present: Cancer Research
- 1987-Present: Biochemistry
- 1987-Present: Biochimica et Biophysica Acta

GRANTING AGENCY REVIEWER

- 2000-2004: Medical Research Council of Canada, Pharmaceutical Sciences Panel
- 1999-2004: Canadian Breast Cancer Research Foundation
- 1997, 1998, 2000: Alberta Cancer Board (External Reviewer)
- 1995-2001: National Cancer Institute of Canada, Panel G, Pharmacology,
- 1995, 1997, 1998: Medical Research Council of Canada (Pharmaceutics Panel, Cancer B Panel)
- 1995-1996: National Cancer Institute of Canada, Panel J

CONSULTANT (ORGANIZATION AND DATES)

- Photovision Pharmaceuticals, Inc., Jenkintown, PA 2000-2001
- Duke University Hyperthermia Program (M. Dewhirst, Chair), Durham, N.C. 1998-2002
- Elan Pharmaceuticals, Inc., Ireland 1998-1999
- IGT Pharma, Inc., Vancouver, B.C. 1997-2001
- Angiogenesis Technologies, Vancouver B.C. 1995-1997
- QLT Phototherapeutics, Vancouver, B.C. 1993-2000
- Inex Pharmaceuticals, Corp., Burnaby, B.C. 1993-1999

EXTERNAL EXAMINER

- University of Sydney (Pharmaceutical Sciences) June, 2000
- Simon Fraser University (Biology Department) July, 1998

OTHER SERVICE TO THE COMMUNITY

Guest Science Lectures at Mulgrave School, 1997, 1998, 2000
Mulgrave School (North Vancouver) Planning Committee, 1996-1997

PUBLICATIONS

Journals/Refereed

1. **Mayer LD** and Nelsestuen GL (1981) "Calcium and Prothrombin-Induced Lateral Phase Separation in Membranes" *Biochemistry* 20, 2457-2463.
2. Pusey ML, **Mayer LD**, Wei GJ, Bloomfield VA and Nelsestuen GL (1982) "Kinetic and Hydrodynamic Analysis of Blood Clotting Factor V-Membrane Binding" *Biochemistry* 21, 5262-5269.
3. **Mayer LD** and Nelsestuen GL (1983) "Membrane Lateral Phase Separation Induced by Proteins of the Prothrombinase Complex" *Biochim Biophys Acta*. 734, 48-53.
4. **Mayer LD**, Nelsestuen GL and Brockman HL (1983) "Prothrombin Association with Phospholipid Monolayers" *Biochemistry*, 22, 316-321.
5. **Mayer LD**, Pusey ML, Griep MA and Nelsestuen GL (1983) "Association of Blood Coagulation Factors V and X with Phospholipid Monolayers" *Biochemistry*, 22, 6266-6233.
6. Nayar R, **Mayer LD**, Hope MJ and Cullis PR (1984) "Phosphatidic Acid as a Calcium Ionophore in Large Unilamellar Vesicle Systems" *Biochim Biophys Acta*. 777, 343-346.
7. **Mayer LD**, Bally MB, Hope MJ and Cullis PR (1985) "Uptake of Dibucaine into Large Unilamellar Vesicles in Response to a Membrane Potential" *J. Biol. Chem.* 260, 802-808.
8. **Mayer LD**, Bally MB, Hope MJ and Cullis PR (1985) "Uptake of Antineoplastic Agents into Large Unilamellar Vesicles in Response to a Membrane Potential" *Biochim Biophys Acta*. 816, 294-302.
9. **Mayer LD**, Hope MJ, Cullis PR and Janoff AS (1985) "Solute Distributions and Trapping Efficiencies Observed in Freeze-thawed Multilamellar Vesicles" *Biochim Biophys Acta*, 817:193-196.
10. Richards RL, Habbersett RC, Scher I, Janoff AS, Schieren HP, **Mayer LD**, Cullis PR and Alving CR (1986) "Influence of Vesicle Size on Complement-Dependent Immune Damage to Liposomes" *Biochim Biophys Acta*. 855:223-230.
11. **Mayer LD**, Bally MB and Cullis PR (1986) "Uptake of Adriamycin into Large Unilamellar Vesicles in Response to a pH Gradient" *Biochim Biophys Acta*. 857:123-126.
12. **Mayer LD**, Hope MJ and Cullis PR (1986) "Vesicles of Variable Sizes Produced by a Rapid Extrusion Procedure" *Biochim Biophys Acta* 858:161-168.
13. **Mayer LD**, Bally MB, Hope MJ and Cullis PR (1986) "Techniques for Encapsulating Bioactive Agents into Liposomes" *Chem. Phys. Lipids* 40, 333-345.
14. Hope MJ, Bally MB, **Mayer LD**, Janoff AS and Cullis PR (1986) "Generation of Multilamellar and Unilamellar Phospholipid Vesicles" *Chem. Phys. Lipids* 40, 89-107.

15. Wong KF, Parmar YI, **Mayer LD**, Pritchard PH and Cullis PR (1987) "Detection of Protein-free Lipoprotein Analogues with an Apolar Lipid Core by Freeze-etch Electron Microscopy" *Biochim Biophys Acta.* 921:411-414.
16. Brenner DE, Arakali AV, **Mayer LD**, Ginsberg RS and Kanter P (1988) "Comparison of Liposomal Doxorubicin and Free Doxorubicin Pharmacokinetics in Rabbit" *Clin. Pharmacol. Therapeut.* 43, 125.
17. **Mayer LD**, Wong KF, Menon K, Chong C, Harrigan PR and Cullis PR (1988) "Influence of Ion Gradients on the Transbilayer Distribution of Dibucaine in Large Unilamellar Vesicles" *Biochemistry* 27, 2053-2060.
18. Bally MB, **Mayer LD**, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ and Cullis PR (1988) "Dopamine Accumulation in Large Unilamellar Vesicle Systems Induced by Transmembrane Ion Gradients" *Chem. Phys. Lipids* 47, 97-107.
19. Janoff AS, Kurtz CL, Jablonski RL, Minchey SR, Boni LT, Gruner SM, Cullis PR, **Mayer LD** and Hope MJ (1988) "Characterization of Cholesterol Hemisuccinate and Alpha Tocopherol Hemisuccinate Vesicles" *Biochim Biophys Acta.* 941:165-175.
20. Balazsovits JAE, **Mayer LD**, Bally MB, Cullis PR, Ginsberg RS and Falk RE (1989) "Analysis of the Effect of Liposome Encapsulation on the Vesicant Properties, Acute and Cardiac Toxicities, and Antitumour Efficacy of Doxorubicin" *Cancer Chemother. Pharmacol.* 23, 81-86.
21. Redelmeier TE, **Mayer LD**, Wong KF, Bally MB and Cullis PR (1989) "Proton Transport in Large Unilamellar Vesicles in Response to Electrical Potentials and Ph Gradients" *Biophys. J.* 56, 385-393.
22. **Mayer LD**, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR and Bally MB (1989) "Influence of Vesicle Size, Lipid Composition and Drug-to-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin" *Cancer Research* 49, 5922-5930.
23. Cullis PR, **Mayer LD**, Bally MB, Madden TD and Hope MJ (1989) "Generation and Loading of Liposomal Systems for Drug Delivery Applications" *Advanced Drug Delivery Reviews* 3, 267-282.
24. **Mayer LD**, Bally MB, Loughrey H, Masin D and Cullis PR (1990) "Liposomal Vincristine Preparations Which Exhibit Decreased Toxicity and Increased Anti-tumour Activity Against Murine L1210 and P388 Tumours" *Cancer Research* 50, 575-579.
25. Madden TD, Harrigan PR, Tai LCL, Bally MB, **Mayer LD**, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinish LW and Cullis PR (1990) "The Accumulation of Drugs Within Large Unilamellar Vesicles Exhibiting a Proton Gradient: A Survey" *Chem. Phys. Lipids* 53, 37-46.
26. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR and **Mayer LD** (1990) "Liposomes with Entrapped Doxorubicin Exhibit Extended Blood Residence Times" *Biochim Biophys Acta.* 1023: 133-139.
27. Thies RL, Cowens W, Cullis PR, Bally MB and **Mayer LD** (1990) "Method for Rapid Separation of Liposome-Associated Doxorubicin from Free and Doxorubicin in Plasma" *Anal. Biochem.* 188, 65-71.

28. **Mayer LD**, Bally MB, Cullis PR, Wilson SL and Emmerman JT (1990) "Comparison of Free and Liposome Encapsulated Doxorubicin Entrapped Tumour Drug Uptake and Antitumour Efficacy in the SC115 Murine Mammary Tumour" *Cancer Letters* 53, 183-190.
29. **Mayer LD**, Tai LCL, Bally MB, Mitlenes GN, Ginsberg RS and Cullis PR (1990) "Characterization of Liposomal Systems Containing Doxorubicin Entrapped in Response to pH Gradients" *Biochim Biophys Acta*. 1025:143-151.
30. Bally MB, Nayar R, Masin D, Cullis PR and **Mayer LD** (1990) "Studies on the Myelosuppressive Activity of Doxorubicin Entrapped in Liposomes" *Cancer Chemotherapy and Pharmacology* 27, 13-19.
31. **Mayer LD**, Bally MB and Cullis PR (1990) "Strategies for Optimizing Liposomal Doxorubicin" *J. Liposome Res.* 4, 463-480.
32. Cullis PR, Bally MB, Madden TD, **Mayer LD** and Hope MJ (1991) "pH Gradients and Membrane Transport in Liposomal Systems" *TIBCH* 9, 268-272.
33. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, **Mayer LD**, Cullis PR and Pavelic ZP (1993) "Comparison of the Cardiotoxic Effects of Liposomal Doxorubicin (TLC D-99) Versus Free Doxorubicin in Beagle Dogs" *In Vivo* 7, 17-26.
34. Kanter PM, Bullard GA, Pilkiewicz FG, **Mayer LD**, Cullis PR and Pavelic ZP (1993) "Preclinical Toxicology Study of Liposome Encapsulated Doxorubicin (TLC D-99): Comparison with Doxorubicin and Empty Liposomes in Mice and Dogs" *In Vivo* 7, 85-96.
35. Embree L, Gelmon KA, Lohri A, **Mayer LD**, Coldman AJ, Cullis PR, Palaitis W, Pilkiewicz F, Hudon NJ, Heggie JR and Goldie JH (1993) "Chromatographic Analysis and Pharmacokinetics of Liposome Encapsulated Doxorubicin (TLC D-99) in Non Small Cell Lung Cancer Patients" *J. Pharmaceutical Sciences*, 82, 627-634.
36. **Mayer LD**, Nayar R, Thies RL, Bowman NL, Cullis PR and Bally MB (1993) "Identification of Vesicle Properties Which Enhance the Antitumour Activity of Liposomal Vincristine Against Murine L1210 Leukemia" *Cancer Chemother. Pharmacol.*, 33, 17-24.
37. Boman NL, **Mayer LD** and Cullis PR (1993) "Optimization of Vincristine Retention in Liposomes In Vitro and In Vivo" *Biochim Biophys Acta*. 1152:253-260.
38. Bally MB, Masin D, Nayar R, Cullis PR and **Mayer LD** (1994) "Transfer of Liposomal Drug Carriers from the Blood to the Peritoneal Cavity of Normal and Ascitic Tumors - Bearing Mice" *Cancer Chemother. Pharmacol.*, 34, 137-146.
39. Bowman NL, Masin D, **Mayer LD**, Cullis PR and Bally MB (1994) "Liposomal Vincristine Which Exhibits Increased Drug Retention and Increased Circulation Longevity Cures Mice Bearing P388 Tumors" *Cancer Res.* 54, 2830-2833.
40. **Mayer LD**, Cullis PR and Bally MB (1994) "The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin" *J. Liposome Res.* 4, 529-553.

41. Kanter PM, Klavich GM, Ballard GA, King JM, Bally M, Brand M and **Mayer LD** (1994) "Liposome Encapsulated Vincristine: Preclinical Toxicologic and Pharmacologic Comparison with Free Vincristine and Empty Liposomes in Mice, Rats and Dogs" *Anticancer Drugs*, 5: 579-590.
42. Alaoui-Jamali M, Wang T, Chen DZ, **Mayer LD** and Batist G (1995) "Effect of Tumor Grafts on Doxorubicin Host Toxicity" *Cell. Pharmacology*, 2:29-33.
43. **Mayer LD**, Masin D, Nayar R, Boman NL and Bally MB (1995) "Pharmacology of Liposomal Vincristine in Mice Bearing L1210 Ascitic and B16/BL6 Solid Tumors" *British J. Cancer*, 71:482-488.
44. de Jong G, Gelmon KS, Bally MB, Goldie JG and **Mayer LD** (1995) "Modulation of Doxorubicin Resistance in P388/ADR Cells by R044-5912, a Tiapamil Derivative" *Anticancer Research*, 15:911-916.
45. Webb MS, Wheeler JJ, Bally MB and **Mayer LD** (1995) "Improved Retention of Cationic Drugs in Liposomes Containing the Cationic Lipid Stearylamine" *Biochim Biophys Acta*, 1238:147-155.
46. Webb MS, Harasym TO, Masin D, Bally MB and **Mayer LD** (1995) "Sphingomyelin-cholesterol Liposomes Significantly Enhance the Pharmaceutic and Therapeutic Properties of Vincristine in Murine and Human Tumor Models" *British J. Cancer*, 72:896-904.
47. **Mayer LD** and St-Onge G (1995) "Determination of Free and Liposome Associated Doxorubicin and Vincristine Levels in Plasma Under Equilibrium Conditions Employing Ultrafiltration Techniques" *Analytical Biochemistry*, 232:149-157.
48. Boman NL, Bally MB, Cullis PR, **Mayer LD** and Webb MS (1995) "Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy" *J. Liposomes Res.*, 5:523-541.
49. **Mayer LD** (1996) "Optimized Activity of Liposomal Vincristine (LIPOVINC) Through Liposome Manipulations" *J. Liposome Res.* 6:203-206.
50. **Mayer LD**, Dougherty G, Harasym TO and Bally MB (1996) "The Role of Tumour-Associated Macrophages in the Delivery of Liposomal Doxorubicin to Solid Murine Fibrosarcoma Tumours" *J. Pharmacol. Exp. Therapeutics*, 280: 1406-1414.
51. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Webb M, Bally M & **Mayer LD** (1997) "Validation of a High-Performance Liquid Chromatographic Assay Method for Quantification of Total Vincristine Sulfate in Human Plasma Following Administration of Vincristine Sulfate Liposome Injection." *J. Pharmaceut. Biomed. Anal.*, 16: 675-687.
52. Cullis PR, Hope MJ, Bally MB, Madden TD, **Mayer LD** and Fenske DB (1997) "Influence of pH Gradients on the Transbilayer Transport of Drugs, Lipids, Peptides and Metal Ions into Large Unilamellar Vesicles" *Biochim Biophys Acta*, 1331: 187-211.
53. Zhang, X, Burt, HM, Mangold, G, Dexter, D, Von Hoff, D, **Mayer, L** and Hunter, WL (1997) "Antitumor Efficacy and Biodistribution of Intravenous Polymeric Micellar Paclitaxel" *Anti-Cancer Drugs*, 8: 696-701.

54. Krishna R and **Mayer LD** (1997) "Liposomal Doxorubicin Circumvents PSC-833-Free Drug Interactions, Resulting in Effective Therapy of Multidrug-Resistant Solid Tumors" *Cancer Res.* 57: 5246-5253.
55. Krishna R, deJong G and **Mayer LD** (1997) "Pulsed Exposure of SDZ PSC 833 to Multidrug Resistant P388/ADR and MCF7/ADR Cells in the Absence of Anticancer Drugs Can Fully Restore Sensitivity to Doxorubicin" *Anticancer Res.* 17: 3329-3334.
56. Embree L, Gelmon K, Tolcher T, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB and **Mayer LD** (1998) "Pharmacokinetic Behaviour of Vincristine Sulfate Following Administration of Vincristine Sulfate Liposome Injection" *Cancer Chemother. Pharmacol.* 41: 347-352.
57. Webb MS, Saxon D, Wong FMP, Lim HS, Bally MB, Choi LSL, Cullis PR and **Mayer LD** (1998) "Comparison of Different Hydrophobic Anchors Conjugated to Poly(ethylene glycol): Effects on the Pharmacokinetics of Liposomal Vincristine" *Biochim Biophys Acta.* 1372: 272-282.
58. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, **Mayer LD** and Bally MB (1998) "Preclinical Pharmacology, Toxicology and Efficacy of Sphingomyelin/ Cholesterol Liposomal Vincristine for Therapeutic Treatment of Cancer" *Cancer Chemother. Pharmacol.* 42: 461-470.
59. Bally MB, Lim H, Cullis PR and **Mayer LD** (1998) "Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations" *J. Liposome Res.* 8(3):299-335.
60. **Mayer LD**, Reamer J and Bally MB (1998) "Intravenous Pretreatment with Empty pH Gradient Liposomes Alters the Pharmacokinetics and Toxicity of Doxorubicin through In Vivo Active Drug Encapsulation." *J. Pharma. Sci.* 88: 96-102.
61. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Burge C, Logan P and **Mayer LD** (1999) "Phase I Study of Liposomal Vincristine" *J. Clin. Oncol.* 17: 697-705.
62. Krishna R, McIntosh NL, Riggs KW and **Mayer LD** (1999) "Doxorubicin Encapsulated In Sterically Stabilized Liposomes Exhibits Renal and Biliary Clearance Properties That Are Independent of Valspodar (PSC 833) under Conditions That Significantly Inhibit Nonencapsulated Drug Excretion." *Clin. Cancer Res.* 5: 2939-2947.
63. Gelmon K, Eisenhower E, Bryce C, Tolcher A, **Mayer L**, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, and Iglesias J (1999) "Randomized Phase II Study of High-Dose Paclitaxel with or without Amifostine in Patients with Metastatic Breast Cancer" *J. Clin. Oncol.*, 17(10): 3038-3047.
64. Krishna R and **Mayer LD** (1999) "In vitro Evaluation of Doxorubicin Cytotoxicity and Cellular Uptake in the Presence and Absence of Multidrug Resistance Modulators" *Pharm. Pharmacol. Commun.* 5: 511-517.
65. Krishna R and **Mayer LD** (1999) "The Use of Liposomal Anticancer Agents to Determine the Roles of Drug Pharmacodistribution and P-glycoprotein (PGP) Blockade in Overcoming Multidrug Resistance" *Anticancer Res.*, 19:2885-2892.

66. Saxon DN, **Mayer LD** and Bally MB (1999) "Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs" *J. Liposome Res.*, 9:507-522.
67. Krishna R, St.-Louis M and **Mayer LD** (2000) "Increased Intracellular Drug Accumulation and Complete Chemosensitization Achieved in Multidrug-Resistant Solid Tumors by Co-administering Valsopodar (PSC 833) with Sterically Stabilized Liposomal Doxorubicin." *Int. J. Cancer*, 85:131-141.
68. Dragowska WH, Lopez de Menezes D, Sartor J and **Mayer LD** (2000) "Quantitative Fluorescence Cytometric Analysis of Bcl-2 Levels in Tumor Cells Exhibiting a Wide Range of Inherent Bcl-2 Protein Expression: Correlation with Western Blot Analysis" *Cytometry*, 40:346-352.
69. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Uyeda RT, Moran EJ, Dixon R, Tomlinson ES and **Mayer LD** (2000) "Discovery and Characterization of OC144-093, a Novel Inhibitor of P-Glycoprotein-Mediated Multidrug Resistance" *Cancer Res.*, 60:2964-2972.
70. Johnstone SA, Gelmon K, **Mayer LD**, Hancock RE and Bally MB (2000) "*In Vitro* Characterization of the Anticancer Activity of Membrane-Active Cationic Peptides. I. Peptide-Mediated Cytotoxicity and Peptide-Enhanced Cytotoxic Activity of Doxorubicin against Wild-Type and P-glycoprotein Over-Expressing Tumor Cell Lines" *Anti-Cancer Drug Design*, 15:151-160.
71. Chi KN, Wallis AE, Lee CH, Lopez de Menezes D, Sartor J, Dragowska V and **Mayer LD** (2000) "Effects of Bcl-2 Modulation with G3139 Antisense Oligonucleotide on Human Breast Cancer Cells Are Independent of Inherent Bcl-2 Protein Expression" *Breast Cancer Res. Treat.*, 63:199-212.
72. Lopes de Menezes D, Hudon N, McIntosh N and **Mayer LD** (2000) "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligodeoxynucleotide G3139 Combined with Free and Liposomal Doxorubicin" *Clin. Cancer Res.*, 6: 2891-2902.
73. Krishna R and **Mayer LD** (2000) "Multidrug Resistance (MDR) in Cancer Mechanisms, Reversal Using Modulators of MDR and the Role of MDR Modulators in Influencing the Pharmacokinetics of Anticancer Drugs" *European J. of Pharma. Sciences*, 11:265-283.
74. Zhang L, Scott MG, Yan H, **Mayer LD**, Hancock REW (2000) "Interaction of Polyphemusin I and Its Structural Analogues with Bacterial Membranes, Lipopolysaccharide and Lipid Monolayer" *Biochemistry*, 39:14504-14514.
75. Chiu GNC, Bally MB and **Mayer LD** (2001) "Selective Protein Interactions with Phosphatidylserine Containing Liposomes Alter the Steric Stabilization Properties of Poly(ethylene glycol)" *Biochim Biophys Acta*. 1510:56-69.
76. **Mayer LD**, Lim KT and Hartley D (2002) "Identification of Two Distinct Intracellular Verapamil Pools that Contribute to the Modulation of Multidrug Resistant P388-ADR Cells Expressing P-Glycoprotein" *J. Exp. Therapeut. Oncol.*, 2:107-120.

77. Waterhouse DN, Tardi PG, **Mayer LD** and Bally MB (2001) "Changing Toxicity Profiles: A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form" *Drug Safety*, 24(12):903-920.
78. Johnstone SA, Masin D, **Mayer L** and Bally MB (2001) "Surface Associated Serum Proteins Inhibit the Uptake of Phosphatidylserine and Poly(ethylene glycol) Liposomes by Mouse Macrophages" *Biochim Biophys Acta*. 1513(1):25-37.
79. Krishna R, Webb MS, St. Onge G and **Mayer LD** (2001) "Liposomal and Non-Liposomal Drug Pharmacokinetics after Administration of Liposome-Encapsulated Vincristine and Their Contribution to Drug Tissue Distribution Properties" *J. Pharmacol. Exp. Therapeut.*, 298:1206-1212.
80. Krishna R, Chiu G and **Mayer LD** (2001) "Visualization of Bioavailable Liposomal Doxorubicin Using a Non-Perturbing Confocal Imaging Technique" *Histology Histopath*, 16:693-699.
81. Waterhouse DN, Dos Santos N, **Mayer LD** and Bally MB (2001) "Drug-Drug Interactions Arising from the Use of Liposomal Vincristine in Combination with Other Anti-Cancer Drugs" *Pharm. Res.*, 18(9):1331-5.
82. Li WM, Xue L, **Mayer LD** and Bally MB (2001) "Intermembrane Transfer of Polyethylene Glycol Modified Phosphatidylethanolamine as a Means to Reveal Surface Associated Binding Ligands on Liposomes" *Biochim Biophys Acta*. 1513:193-206.
83. **Mayer LD** and Shabbits JA (2001) "The Role for Liposomal Drug Delivery in Molecular and Pharmacological Strategies to Overcome Multidrug Resistance" *Cancer Metast. Reviews*, 20:87-93.
84. Hu Y, Dragowska WH, Wallis A, Duronio V and **Mayer LD** (2001) "Cytotoxicity Induced by Manipulation of Signal Transduction Pathways Is Associated with Down-regulation of Bcl-2 but Not Mcl-1 in MCF-7 Human Breast Cancer" *Breast Cancer Res. and Treatment*, 70:11-20.
85. Shabbits JA, Krishna R and **Mayer LD** (2001) "Molecular and Pharmacological Strategies to Overcome Multidrug Resistance" *Expert Review of Anticancer Therapy* 1(4):585-94.
86. Krishna R and **Mayer LD** (2001) "Modulation of P-Glycoprotein (PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances in the Design of Selective MDR Modulators" *Curr. Med. Chem. – Anti-Cancer Agents*, 1:163-174.
87. Guns ES, Bullock PL, Reimer MLJ, Dixon R, Bally M and **Mayer LD** (2001) "Assessment of the Involvement of CYP3A in the In Vitro Metabolism of a New Modulator of MDR in Cancer Chemotherapy, OC144-093, by Human Liver Microsomes." *Eur J Drug Metab Pharm*, Oct-Dec; 26(4):273-82, 2001.
88. Denyssevykh T, Lestou VS, Knesevich S, Robichaud M, Salski C, Tan R, Gascoyne RD, Horsman DE and **Mayer LD** (2002) "Establishment and Comprehensive Analysis of a New Human Transformed Follicular Lymphoma B-Cell Line, Tat-1" *Leukemia*, 16:276-283.

89. Lopes de Menezes DE and **Mayer LD** (2002) "Pharmacokinetics of Bcl-2 Antisense Oligonucleotide (G3139) Combined with Doxorubicin in SCID Mice Bearing Human Breast Cancer Solid Tumor Xenografts" *Cancer Chemother. Pharmacol.*, 49:57-68.
90. Chiu GNC, Bally MB and **Mayer LD** (2002) "Effects of Phosphatidylserine on Membrane Incorporation and Surface Protection Properties of Exchangeable Poly(ethylene glycol)-Conjugated Lipids" *Biochim Biophys Acta.* 1560(1-2):37-50.
91. Shabbits JA and **Mayer LD** (2002) "P-Glycoprotein Modulates Ceramide-Mediated Sensitivity of Human Breast Cancer Cells to Tubulin-Binding Anticancer Drugs" *Mol Cancer Ther.* 1:205-213.
92. Li WM, **Mayer LD** and Bally MB (2002) "Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids" *J. Pharmacol. Exp. Therapeut.*, 300(3):976-983.
93. Guns ES, Denyssevykh T, Dixon R, Bally MB and **Mayer LD** (2002) "Drug Interaction Studies Between Paclitaxel (Taxol) and OC144-093 - A New Modulator of MDR in Cancer Chemotherapy." *Eur J Drug Metab Pharm.* 27(2):119-126.
94. Dos Santos N, **Mayer LD**, Abraham SA, Gallagher RC, Cox KAK, Tardi PG and Bally MB (2002) "Improved Retention of Idarubicin after Intravenous Injection Obtained for Cholesterol-Free Liposomes" *Biochim Biophys Acta.* 1561:188-201.
95. Abraham SA, Edwards K, Karlsson G, MacIntosh S, **Mayer LD**, McKenzie C and Bally MB (2002) "Formation of Transition Metal-Doxorubicin Complexes Inside Liposomes" *Biochim Biophys Acta.* 1565/1:41-54.
96. Allen C, Dos Santos N, Gallagher R, Chiu GNC, Shu Y, Li WM, Johnstone SA, Janoff AS, **Mayer LD**, Webb MS and Bally MB (2002) "Controlling the Physical Behavior and Biological Performance of Liposome Formulations through Use of Surface Grafted Poly(ethylene glycol)" *BioScience Reports*, 22(2):225-250.
97. Shabbits JA, Chiu GN and **Mayer LD** (2002) "Development of an In Vitro Drug Release Assay that Accurately Predicts In Vivo Drug Retention for Liposome-Based Delivery Systems." *Journal of Controlled Release* 84:161-170.
98. Fung VWH, Chiu GNC and **Mayer LD** (2003) "Application of Purging Biotinylated Liposome from Plasma to Elucidate the Influx and Efflux Processes Associated with Accumulation of Liposomes in Solid Tumors" *Biochim Biophys Acta.* 1611:63-69.
99. Shabbits JA and **Mayer LD** (2003) "Intracellular Delivery of Ceramide Lipids Via Liposomes Enhances Apoptosis In Vitro" *Biochim Biophys Acta.* 1612(1):98-106.
100. Lopes de Menezes DE, Hu Y and **Mayer LD** (2003) "Combined Treatment of Bcl-2 Antisense Oligodeoxynucleotides (G3139), P-glycoprotein Inhibitor (PSC833) and Sterically-Stabilized Liposomal Doxorubicin Suppresses Growth of Drug-resistant Growth of Drug-resistant Breast cancer in SCID Mice" *J. Exp. Therapeut. Oncol.* 3:72-82.

101. Hu YP, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, **Mayer LD**, and LaCasse EC (2003) "Antisense Oligonucleotides Targeting XIAP Induce Apoptosis and Enhance Chemotherapeutic Activity against Human Lung Cancer Cells *in vitro and in vivo*" Clin. Cancer Res. 9:2826-2836.
102. Chiu GNC, Bally MB and **Mayer LD** (2003) "Targeting of Antibody Conjugated, Phosphatidylserine-Containing Liposomes to Vascular Cell Adhesion Molecule 1 for Controlled Thrombogenesis" Biochimica et Biophysica Acta. 1613(1-2):115-21.
103. Hu Y, Bally M, Dragowska WH and **Mayer LD** (2003) "Inhibition of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Enhances Chemotherapeutic Effects on H460 Human Non-Small Cell Lung Cancer Cells through Activation of Apoptosis" Mol Cancer Ther. 2(7):641-9.
104. Ickenstein LM, Arfvidsson MC, Needham D, **Mayer LD** and Edwards K (2003) "Disc Formation in Cholesterol-Free Liposomes During Phase Transition" Biochimica Biophys Acta. 1614(2):135-8.
105. Shabbits JA, Hu Y and **Mayer LD** (2003) Minireview "Tumor Chemosensitization Strategies Based on Apoptosis Manipulations" Mol Cancer Ther. 2(8):805-813.
106. Shabbits JA and **Mayer LD** (2003) "High Ceramide Content Liposomes with In Vivo Antitumor Activity" Anticancer Research 23:3663-3669.
107. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, **Mayer LD** and Bally MB (2004) "In vitro and In vivo Characterization of Doxorubicin and Vincristine Co-encapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading" Clinical Cancer Research, 10:728-738.
108. Waterhouse DN, Dragowska WH, Gelmon KA, **Mayer LD** and Bally MB (2004) "Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model" Cancer Biology and Therapy 3(2):1-8.
109. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, **Mayer LD**, Allen C and Bally MB (2004) "pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enhancing Drug Loading Rates Through Use of Ethanol" Biochim Biophys Acta. 1661:47-60.
110. Hu YP, Krishan A, Nie WJ, Sridhar KS, **Mayer L** and Bally M (2004) "Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide and Topotecan in Drug Resistant Tumor Cells" Clin. Cancer Res. 10(3):1160-9.
111. Fedoruk MN, Giménez-Bonafé P, Guns ES, **Mayer LD** and Nelson CC (2004) "P-Glycoprotein Increases the Efflux of the Androgen Dihydrotestosterone and Reduces Androgen Responsive Gene Activity in Prostate Tumor Cells" Prostate 59(1):77-90
112. Abraham SA, Edwards K, Karlsson G, Hudon N, **Mayer LD** and Bally MB (2004) "An Evaluation of Transmembrane Ion Gradient-Mediated Encapsulation of Topotecan Within Liposomes" J. Control Res. 96(3):449-461

113. Messerer CL, Ramsay EC, Waterhouse DN, Ng R, Simms E-M, Harasym N, Tardi P, **Mayer LD** and Bally MB (2004) "Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer" *Clinical Cancer Research*, 10(19):6638-49.
114. Bally M, Tardi P, Harasym T, Harasym N, Swenson C, Janoff A, **Mayer LD** (2004) "Spotlight:CTI" *Controlled Release Society Newsletter*, 21, No 2.
115. Hu YP, Bebb G, Tan S, Ng R, Yan H, **Mayer LD** and Bally MB (2004) "Anti-Tumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non-Small Cell Lung Cancer" *Clinical Cancer Research*, 10(22):7662-70
116. Abraham SA, Waterhouse DN, **Mayer LD**, Cullis PR, Madden TD and Bally MB (2005) "The Liposomal Formulation of Doxorubicin" *Methods Enzymol.* 391:71-97
117. Waterhouse DN, Madden TD, Cullis PR, Bally MB, **Mayer LD** and Webb MS (2005) "Preparation, Characterization, and Biological Analysis of Liposomal Formulations of Vincristine" *Methods Enzymol.* 391:40-57
118. Guns ES, Xie X, Fedoruk M, Madera C, Cowell S, **Mayer LD**, Skov K, Gleave ME and Koslowski P (2005) "pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumour bearing mice" *The Prostate*, 64(3):316-22
119. Sandström MC, Ickenstein LM, **Mayer LD**, Edwards K (2005) "Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes" *Journal of Controlled Release*, 107(1):131-42
120. Ickenstein LM, Sandström MC, Mayer LD, Edwards K (2005) "Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transition" *Biochim Biophys Acta – Biomembranes* (in press)
121. **Mayer LD**, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS (2006) "Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice" *Mol Cancer Ther.* 5(7):1854-63
122. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragawska WH, **Mayer LD**, Bally MB (2007) "In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine" *Eur J Pharm Biopharm* 65 (3):289-299
123. Dicko A, Tardi P, Xie X, Mayer LD, (2007) "Role of copper gluconate/triethanolamine in irinotecan encapsulation inside liposomes" *Int J Pharm.* 37: 219-228.
124. Tardi P, Gallagher R, Johnstone S, Harasym N, Webb M, Bally MB and **Mayer LD**, (2007) "Coencapsulation of irinotecan and flouxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo" *Biochim. Biophys. Acta* 1768: 678-687

125. Harasym T, Tardi P, Harasym N, Harvie P, Johnstone S and **Mayer LD**, (2007) "Increased preclinical efficacy of irinotecan and floxuridine co-encapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios" *Oncol Res.*, 16(8):361-74 PMID: 17913044
126. Saad W, Prud'homme B, Ansell S and **Mayer LD** (2007) "Drug nanoparticle formation via flash nanoprecipitation: conjugation to encapsulate and control the release of paclitaxel" *J. Amer. Assoc. Pharm. Sci.* (in press)
127. Batist, G, Louie A, Chi K, Chia S, Gelmon K, Jewish General Hospital, McGill University, Montreal, PQ, Canada, Celator Pharmaceuticals Inc., Princeton, NJ, Miller, W., Swenson C. Janoff A, **Mayer LD** (2007) "Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase 1 trial: A new approach for enhancing the activity of combination chemotherapy." *Proc. American Society of Clinical Oncology* 25: 109s
128. **Mayer, LD**, and Janoff, AS, (2007) "Optimizing combination chemotherapy by controlling drug ratios." *Mol Interv.* Aug. 7 (4):216-23. PMID: 17827442

Journals/Non-refereed

1. **Mayer LD** (1998) "Future Developments in the Selectivity of Anticancer Agents: Drug Delivery and Molecular Target Strategies" *Cancer and Metastasis Reviews* 17:211-218.
2. **Mayer LD** (2000) "Pharmaceutical Drug Delivery Systems; Medicine's Trojan Horse" *Helix*, 9:48-55.
3. **Mayer LD**, Krishna R, Webb M and Bally MB (2000) "Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications" *J. Liposome Res.*, 10(2&3):99-115.

Books/Authorred

1. Cullis PR, Hope MJ, Bally MB, Madden TD and **Mayer LD** (1987) "Liposomes as Pharmaceuticals" *In: Liposomes, from Biophysics to Therapeutics.* (M Ostro, ed.) pp. 39-72, Marcel Dekker Inc., NY.
2. Bally MB, Hope MJ, **Mayer LD**, Madden TD and Cullis PR (1988) "Novel Procedures for Generating and Loading Liposomal Systems" *In: Liposomes as Drug Carriers.* (G Gregoriadis, ed.) pp. 841-853, John Wiley and Sons Ltd., NY.
3. **Mayer LD**, Bally MB, Madden TD and Cullis PR (1992) "pH Gradient Mediated Drug Entrapment in Liposomes" *In: Liposome Technology, Vol. II.* (G Gregoriadis, ed.) pp. 27-44, CRC Press, Inc., Boca Raton, FL.
4. Bally MB, **Mayer LD**, Hope MJ and Nayar R (1992) "Pharmacodynamics of Liposomal Drug Carriers: Methodological Considerations" *In: Liposome Technology, Vol. III.* (G Gregoriadis, ed.) pp. 27-42, CRC Press, Inc., Boca Raton, FL.

5. Hope MJ, Nayar R, **Mayer LD** and Cullis PR (1992) "Reduction of Liposome Size and Preparation of Unilamellar Vesicle by Extrusion Techniques" *In: Liposome Technology*, Vol. I. (G Gregoriadis, ed.) pp. 123-140, CRC Press, Inc., Boca Raton, FL.
6. **Mayer LD**, Gelmon K, Cullis PR, Boman NL, Webb MS, Embree L., Tolcher T and Bally MB (1995) "Preclinical and Clinical Studies With Liposomal Vincristine" *In: Progress in Drug Delivery Systems*, Vol. IV, (S. Hirota, ed.) pp. 151-161, Biomedical Research Foundation, Tokyo, Japan.
7. Boman NL, Cullis PR, Bally MB and **Mayer LD** (1996) "Preclinical and Clinical Activity of Liposomal Doxorubicin" *In: Liposomes in Biomedical Applications* (P.N. Shek, ed.) Academic Publishers, Australia, pp.85-103.
8. Boman NL, Cullis PR, **Mayer LD**, Bally MB and Webb MS (1997) "Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations" *In: Long Circulating Liposomes: Old Drugs, New Therapeutics*, G. Storm and M. Woodle, Eds., Lands Bioscience, N.Y., pp 29-49.
9. Krishna R and **Mayer LD** (1998) "Applications of Liposome Technology to Overcome Multidrug Resistance in Solid Tumors" *In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems* (Ed. G. Gregoriadis), Plenum Press, NY, pp. 95-107.
10. **Mayer LD**, Cullis PR and Bally MB (1998) "Designing Therapeutically Optimized Liposomal Anticancer Delivery Systems: Lessons from Conventional Liposomes" *In: Medical Applications of Liposomes*, D.D. Lasic and D Papahadjopoulos, eds., Elsevier, N.Y., pp. 231-257.
11. **Mayer LD**, Krishna R and Bally, MB (2001) "Liposomes for Cancer Therapy Applications" *In: Polymeric Biomaterials*, 2nd Edition (S. Dumitriu, ed.) Marcel Dekker (New York, NY), 823-841.
12. Tardi P, Ickenstein L, Bally M and **Mayer LD** (2001) "The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors" *In: Cancer Drug Discovery and Development: Tumor Targeting in Cancer Therapy*, pp. 119-135 (M. Pagé, Ed), Humana Press Inc., Totowa, NJ.
13. Krishna R and **Mayer LD** (2001) "Modulation of p-glycoprotein (PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances in the Design of Selective MDR Modulators" *In: Current Trends in Medicinal Chemistry – Anticancer Drugs*, *in press*.
14. Waterhouse DN, Bally MB, **Mayer LD**, Madden TD, Cullis PR and Webb MS (2003) "Preparation, Characterization and Biological Analysis of Liposomal Formulations of Vincristine" *In: Methods in Enzymology*, *In Press*.
15. Abraham SA, Waterhouse DN, **Mayer L**, Cullis P, Madden T and Bally MB (2003) "Liposomal Formulations of Doxorubicin" *In: Methods in Enzymology*, *In Press*.
16. Harasym T, Tardi P, Johnstone S, **Mayer LD**, Bally MB and Janoff A (2007) "Fixed Drug Ratio Liposome Formulations of Combination Cancer Therapeutics" *In Liposome Technology Third Edition Volume III Interactions of Liposomes with Biological Milieu*. (G Gregoriadis, ed) pp. 25-46, Informa Healthcare USA, Inc. NY

Conference Proceedings

1. Cowens JW, Kanter P, Brenner DE, Ginsberg R, **Mayer L**, Bally M, Cullis P, Pavelic Z, Douglass H, Petrelli N, Karakousis C and Creaven PJ (1989) "Phase I Study of Doxorubicin Encapsulated in Liposomes" Proc. ASCO 8, 69, Abs. No. 268.
2. **Mayer LD**, Nayar R, Thies RL, Thomas NL, Cullis PR and Bally MB (1990) "The Influence of Vesicle Properties on the Antitumor Activity of Liposomal Vincristine" Proc. AACR 31, 427, Abs. No. 2538.
3. Nayar R, **Mayer LD**, Masin D, Cullis PR and Bally MB (1990) "Antitumor Activity of Liposomal Encapsulated Doxorubicin in Different Murine Tumor Models: Implications for Mechanisms of Action" Proc. AACR 31, 429, Abs. No. 2549.
4. Cowens JW, Creaven PJ, Brenner DE, Ginsberg R, Petrelli N, Huben R, Karakousis C, Douglass H, **Mayer L**, Bally M, Cullis P, Goolsby H and Solomon J (1990) "Phase I Study of Doxorubicin Encapsulated in Liposomes" Proc. ASCO 9, 87, Abs. No. 338.
5. Lohri A, Gelmon KA, Embree L, **Mayer L**, Cullis P, Saletan S and Goldie J (1991) "Phase I/II Study of Liposome Encapsulated Doxorubicin (TLC D-99) in Non-Small Cell Lung Cancer (NSCLC)" Proc. ASCO 10, 106, Abs. No. 292.
6. Embree L, Lohri A, Gelmon K, **Mayer L**, Cullis P, Pilkiewicz F, Hudon N, Heggie J, and Goldie J (1991) "Liposome-Encapsulated Doxorubicin Pharmacokinetics in Patients with Non-Small Cell Lung Cancer" Proc. AACR 32, 4, Abs. No. 279.
7. Bally MB, **Mayer LD** and Nayar R (1991) "Peritoneal Influx of Intravenously Administered Liposomal Doxorubicin: A Model for Extravasation of Liposomal Drug Carriers" Proc. AACR 32, 74, Abs. No. 2337.
8. Batist G, **Mayer L**, Pilkiewicz F, Wang T, Skrutkowska M, Zukiwski A, Ahlgren P, Skelton J, Gruner P and Leyland-Jones B (1991) "Liposomal Doxorubicin (TLC D-99) in Experimental and Clinical Breast Cancer is Effective and Less Toxic" Proc. AACR 32, 91, Abs. No. 1090.
9. Kanter PM, Pilkiewicz FG, Pavelic Z and **Mayer L** (1991) "Comparison of the Cardiotoxic Effects of Liposomal Doxorubicin (TLC D-99) Versus Free Doxorubicin in Beagle Dogs" Proc. AACR 32, 122, Abs. No. 2266.
10. Logan PM, **Mayer LD**, Comiskey S, Randazzo T, Straight R, Dube J, Brown L and McCullough JL (1992) "Photodynamic Therapy of Papillomavirus Disease Using Topical Benzoporphyrin Derivative" Proc. Amer. Soc. Photobiol.
11. Gelmon KA, Embree L, Lohri A, **Mayer L**, Cullis P, Saletan S, Hudon N, Heggie J and Goldie J (1992) "Clinical and Pharmacokinetic Results of a Phase I/II Study of Liposome Encapsulated Doxorubicin (TLC D-99) in Non-Small Cell Lung Cancer (NSCLC)" Proc. NCI-EORTC Symposium.

12. **Mayer LD**, Harasym T, Masin D, Zhang GY and Bally MB (1994) "Role of Tumor Associated Macrophages in the Delivery of Liposomal Anticancer Agents to Tumors" Proc. AACR 35, 418, Abs. No. 2493.
13. **Mayer LD** and Hartley D (1995) "Identification of Two Distinct Intracellular Verapamil Binding Pools that Contribute to the Reversal of Multidrug Resistance in P388-ADR Cells" Proc. AACR 36, 341.
14. Webb MS, Masin D, Harasym T, Heggie J, Bally M and **Mayer L** (1995) "Formulation, Pharmacokinetic and Therapeutic Properties of Vincristine Entrapped in Sphingomyelin Cholesterol Liposomes" Proc. AACR 36, 306.
15. Zhang Z, Kim N, **Mayer LD**, Cruz T and Hunter W (1996) "In Vitro Evaluation of the Antitumour Activity of Orthovanadate and Vanadyl Sulfate". Proc. AACR 37,396.
16. Embree L, Gelmon KA, Tolcher T, Heggie JR, Hudon NJ, Dedhar C, Bally MB and **Mayer LD** (1996) "Clinical Pharmacokinetics of vincristine sulphate liposome injection (VSLI)". Proc. AACR 37,179.
17. Krishna R, deJong G, Masin D, and **Mayer LD** (1996). "Pharmacology of multidrug resistance (MDR) reversal by PSC 833 and improved in vivo activity when combined with liposomal doxorubicin". Proc. AACR 37,331.
18. Harris AL, Rodarte JC, Chang Y, Moran EJ, Mjalli AM, **Mayer LD**, Bally MB, Shapiro AB and Toyonaga BE (1996) "The use of combinatorial chemistry and high throughput screening to discover a novel and potent multi-drug resistance (MDR) reversing agent". Proc. AACR 37,410.
19. Toleikis PM, Zhang Z, Cruz TF and **Mayer LD** (1997) "Antitumor Activity of a Novel Vanadium Compound (NVC) in Pre-clinical Evaluations" Proc. AACR 38, 105.
20. Xue LY, Longman SA, **Mayer LD** and Bally MB (1997) "Enhanced Tumor Delivery of Liposomes: Is it Really a Function of Carrier Circulation Levels?" Proc. AACR 38,259.
21. Krishna R, Masin D and **Mayer LD** (1997) "Pharmacokinetics of Free and Liposomal Doxorubicin in the Presence and Absence of SDZ PSC 833 in Mice Bearing P388/ADR Solid Tumors" Proc. AACR 38, 593.
22. McIntosh NL, Bally MB, Schmidt BA, Gelmon KA, Tolcher TW and **Mayer LD** (1998) "Novel in vitro and in vivo Activity of the Vinca Alkaloid 3',4' dehydrovinblastine (AVLB)" Proc. AACR 39, 166.
23. Krishna R, McIntosh N, Masin D and **Mayer LD** (1998) "Effective therapy of multidrug resistant MDA435LCC6 solid tumor bearing RAG2 mice using liposomal doxorubicin and PSC 833: influence of lipid composition on antitumor activity" Proc. AACR 39, 75.
24. Krishna R and **Mayer LD** (1998) "Designing liposomal anticancer agents to overcome multidrug resistance (MDR) in combination with the P-glycoprotein inhibitor PSC 833" Anticancer Res. 18, suppl. 6C, 4913.

25. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Uyeda RT, Moran EJ, Ripka WR, Toyonaga B, Dixon R, Tomlinson ES and **Mayer LD** (1999) "Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance" Proc. AACR 40, 315, 1999.
26. Krishna R, McIntosh N, Riggs KW and **Mayer LD** (1999) "Influence of Liposomal encapsulation on the renal and hepatobiliary disposition of doxorubicin in the presence and absence of valspodar (PSC 833) Proc. AACR 40, 417, 1999.
27. Chi KN, Lee CH, Wallis AE and **Mayer LD** (1999) "Chemosensitivity of breast cancer cell lines in response to Bcl-2 down-regulation and p-glycoprotein inhibition" Proc. AACR 40, 592, 1999.
28. Newman MJ, Rodarte JC, Romano SJ, Ripka WC, Dixon R, Guns ES, Denyssevykh T and **Mayer LD** (2000) "Novel in vivo mechanism of action and lack of pharmacokinetic interaction with plasma paclitaxel by the P-glycoprotein inhibitor OC144-093" Proc. AACR 41, 398.
29. Lopez de Menezes DE, Hudon N, McIntosh N and **Mayer LD** (2000) "Therapeutic and pharmacokinetic properties of doxorubicin combined with Bcl-2 antisense oligonucleotide G3139 treatment" Proc. AACR 41, 642.
30. Dragowska WH, Lopes de Menezes DE, Sartor J and **Mayer LD** (2000) "Quantitative flow cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: Correlation with western analysis" Proc. AACR 41, 653.
31. Lopez de Menezes DE and **Mayer LD** (2001) "Combination of Bcl-2 antisense oligodeoxynucleotide (G3139), P-glycoprotein inhibitor (PSC833) and liposomal doxorubicin can suppress the growth of drug-resistant human breast cancer xenografts in SCID mice" Proc. Amer. Assoc. Cancer Res. 42:154, Abs. 2018.
32. Saxon DN, Gelmon KA, **Mayer LD** and Bally MB (2001) "Anti-HER-2/Neu antisense oligonucleotides in the treatment of MDA435/LCC6 ascites tumors" Proc. Amer. Assoc. Cancer Res. 42, Abs. 3901.
33. Shabbits JA and **Mayer LD** (2001) "Differentiating between PDMP induced chemosensitization VIA drug transport and ceramide signaling pathways" Proc. Amer. Assoc. Cancer Res. 42:268, Abs. 4378.
34. Sartor JR, Dragowska WH, Masin D and **Mayer LD** (2001) "Bcl-2 levels in transfected breast carcinoma cell lines MCF-7 and MDA-435/LCC6: Effect on the growth characteristics and chemosensitivity to doxorubicin and taxol in vitro and in vivo" Proc. Amer. Assoc. Cancer Res. 42:303, Abs. 5010.
35. Dos Santos N, **Mayer L** and Bally M (2001) "Prolonged Circulation Longevity of the Anthracycline Idarubicin Encapsulated in Cholesterol-Free Liposomes" Proc. Amer. Assoc. Pharmaceut. Scientists, October 20-26, 2001, Abs.M2327.
36. Abraham SA, Edwards K, Karlsson G, **Mayer L** and Bally M (2001) "Formulation of Doxorubicin-Metal Chelates Inside the Liposome" Proc. Amer. Assoc. Pharmaceut. Scientists, October 20-26, 2001.

37. Chiu GN, Shabbits JA, Bally MB and **Mayer LD** (2001) "Exchangeability of Poly(ethylene Glycol)-Lipid Conjugates Regulates the Membrane Reactivity of Phosphatidylserine Containing Liposomes. AAPS Annual Meeting and Exposition, October 21-25, 2001, Denver, CO, USA. Abstract # W4358.
38. Hu Y, Dragowska V, Korneluk R, Cherton-Horvat G, Durkin J, Lacasse E and **Mayer L** (2002) "Antisense Oligonucleotides Targeting XIAP Induce Apoptosis and Enhance Therapeutic Activity Against Human Lung Cancer Cells when Combined with anticancer Drug In Vitro and In Vivo" American Association for Cancer Research 93rd Annual Meeting, San Francisco, April 6-10, 2002; Abs. #2856.
39. Dos Santos N, Cox KA, Allen C, Gallagher RC, Ickenstein L, **Mayer LD** and Bally MB (2002) "Ethanol Induced Increases in the Rate of Doxorubicin Loading in Cholesterol-Free Liposomes" Liposome Research Days Conference, Berlin-Buch, Germany, May 21-24, 2002. J. Liposome Res. 13(1), 64-65, 2002.
40. Ickenstein LM, Arfvidsson M, Edwards K, Karlsson G and **Mayer LD** (2002) "Drug Release Mechanisms in Thermosensitive Liposomes During Phase Transition", presented as a poster at the 8th Liposome Research Days Conference in Berlin-Buch, Germany, May 21-24, 2002.
41. Chiu GNC, Bally MB and **Mayer LD** (2002) "Designing Lipid-Based Therapeutics for the Induction of Tumor Specific Thrombosis" The First International Conference on Vascular Targeting, June 12-14, 2002, Cambridge, MA, USA.
42. Hu YP, Masin D, Tan S, Ng R, Yan H, Harasym N and **Mayer L** (2003) "Anti-Metastatic and Anti-Tumor Efficacy of G3139, a Bcl-2 Antisense Oligonucleotide, as Single Agent or in Combination with Vinorelbine, in Murine Orthotopic and Ectopic Xenograft Models of Human Non-Small Cell Lung Cancer" 94th Annual Meeting, Washington, July 11-15, 2003. Proceedings of the American Association for Cancer Research, 44 #6432.
43. Shabbits JA and **Mayer LD** (2003) "Intracellular Delivery of Ceramide Lipids via Liposomes Enhances Apoptosis In Vitro and In Vivo" 94th Annual Meeting, Washington, July 11-15, 2003. Proceedings of the American Association for Cancer Research, 44 #640.
44. Chiu GNC, Tan S, Warburton C, Waterhouse DN, Webb M, **Mayer LD** and Bally MB (2003) "Liposome Conjugated Herceptin®: Coupling of a therapeutic antibody to liposomes does not inhibit antibody mediated antitumor activity" 94th Annual Meeting, Washington, July 11-15, 2003. Proceedings of the American Association for Cancer Research, 44 #3664.
45. Harasym T, Shu Y, Suragh C, Shew C, Tardi P, Bally MB and **Mayer LD** (2004) "Significance of Drug Ratio in Defining Optimal Synergistic Interactions of Approved Anticancer Drug Combinations" American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of the American Association for Cancer Research_45 #127
46. **Mayer LD**, Harasym T, Harasym N, Tardi P, Shu Y, Suragh C, Simms E-M and Bally MB (2004) "A Pharmaceutical Approach to Achieve Synergy In Vivo: A Fixed Ratio Formulation of Irinotecan and Floxuridine for Treatment of Colorectal Cancer" American Association for Cancer Research

95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of the American Association for Cancer Research 46 #126-127

47. **Mayer LD**, Harasym N, Harasym T, Tardi P, Shu Y, Suragh C, Simms E-M and Bally MB (2004) "The Therapeutic Activity of Fixed Ratio Formulations of Irinotecan and Floxuridine are Ratio Dependent: Therapeutic Assessment in the Capan-1 Human Pancreatic tumour Xenograft Model" American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of the American Association for Cancer Research 47 #126
48. Ramsay E, Alnajim J, Anantha M, Denyssevyh T, Harasym T, Masin D, Tardi P, **Mayer LD** and Bally MB (2004) "Development and Characterization of a Fixed Ratio Formulation of Cisplatin and Irinotecan: In Vitro and In Vivo Activity Against the Human H460 Lung Carcinoma Model" Proc. American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of the American Association for Cancer Research 48 #126
49. Ramsay E, Alnajim J, Anantha M, Dicko A, Harvie P, **Mayer LD**, Bally MB and Tardi P (2004) "A Novel Approach to Prepare a Liposomal Irinotecan Formulations that Exhibit Significant Therapeutic Activity In Vivo" American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of American Association of Cancer Research 49 #148
50. Tardi P, Webb M, Dumont A, Gallagher R, Johnstone S, Harasym N, Harasym T, Shew C, Dragowska WH, **Mayer LD** and Bally MB (2004) "Therapeutic Potential of a Drug Combination Consisting of Vinorelbine Encapsulated in Liposomes Containing a Therapeutically Active Lipid, Phosphatidylserine: In Vitro and In Vivo Characterization" American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of the American Association of Cancer Research 50 #145-146
51. Ramsay E, Alnajim J, Anantha M, Denyssevyh T, Harasym T, Masin D, Tardi P, **Mayer LD** and Bally MB (2004) "Drug Ratio Dependence of Combination Chemotherapy: Use of Delivery Vehicles to Optimize Therapeutic Effects" American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, March 27-31, 2004. Proceedings of the American Association of Cancer Research 51 #148
52. Johnstone S, Harvie P, Shew C, Kadhim S, Harasym T, Tardi P, Harasym, N and **Mayer, LD** (2005) "Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt.): Daunorubicin (Daun) against preclinical leukaemia models" April 2005. Proceedings of American Association of Cancer Research 52 #329
53. Johnstone S, Harvie P, Kadhim S, Harasym T, Tardi P, Harasym N and **Mayer LD** (2006) "Cytarabine (Cyt): Daunorubicin (Daun) combined inside liposomes at a fixed synergistic ratio leads to potent therapeutic activity against a range of preclinical leukaemia models" April 2006. Proceedings of the American Association of Cancer Research 53 #720

PATENTS

Granted

1. US Patent # 4,975,282 (1990), "Multilamellar Liposomes having Improved Trapping Efficiencies", Inventors: Cullis, P.R., Bally, M.B., Hope, M.J., Janoff, A.S. and **Mayer, L.D.**
2. US Patent # 5,077,056 (1991), "Encapsulation of Antitumour Agents in Liposome(s) After Generating Trans-membrane Potential", Inventors: Bally, M.B., Cullis, P.R., Hope, M.J., Madden, T.D., **Mayer, L.D.** and Loughrey, H.
3. European Patent # 0295248 (1993 & 1999), "Liposome Preparation and Antibiotic", Inventors: Bally, Marcel, B.; Bolcsak, L.E., Cullis, P.R., Janoff, A.S., **Mayer, L.D.**, Lenk, R.P., Jedrusiak, J.A.
4. European Patent # 0191824 (1993), "Encapsulation of Antineoplastic Agents in Liposomes", Inventors: Bally, M.B., Cullis, P.R., Hope, M.J., Madden, T.D. and **Mayer, L.D.**
5. European Patent # 0231261 (1994), "Multilamellar Liposomes having Improved Trapping Efficiencies", Inventors: Cullis, P.R., Bally, M.B., Hope, M.J., Janoff, A.S. and **Mayer, L.D.**
6. US Patent # 5,409,704 (1995), "Liposomes Comprising Aminoglycoside Phosphates and Methods of Production and Use", Inventors: Bally, M.B., Bolcsak, L.E., Cullis, P.R., Janoff, A.S., **Mayer, L.D.**
7. European Patent # 0290296 (1996), "Liposomal Formulations with a High Antineoplastic Agent/Lipid Ratio" Inventors: Bally M.B., Ginsberg R.S., Mitlenes G.N., Cullis P.R., **Mayer, L.D.**
8. European Patent # 0498471 (1996), "Liposomes Comprising a Guanidino Aminoglycoside", Inventors: Bally, M.B., Bolcsak, L.E., Cullis, P.R., Janoff, A.S., **Mayer, L.D.**, Lenk, P.R., Jedrusiak, A.J.
9. US Patent # 5,543,152 (1996), "Sphingosomes for Enhanced Drug Delivery", Inventors: Webb M.S., Bally M.B., **Mayer L.D.**
10. US Patent # 5,595,756 (1997) "Liposomal Compositions for Enhanced Retention of Bioactive Agents", Inventors: Bally, M.B., Boman, N.C., Cullis, P.R., **Mayer, L.D.**
11. US Patent # 5,616,341 (1997), "High Drug: Lipid Formulations of Liposomal-Antineoplastic Agents", Inventors: **Mayer L.D.**, Bally M.B., Cullis P.R., Ginsberg R.S., Mitlenes G.N.
12. US Patent # 5,736,155 (1998), "Encapsulation of Antitumour Agents in Liposomes", Inventors: Bally, M.B., Cullis, P.R., Hope, M.J., Madden, T.D., and **Mayer, L.D.**
13. US Patent # 5,741,516 & 5,814,335 (1998), "Sphingosomes for Enhanced Drug Delivery", Inventors: Webb M.S., Bally M.B., **Mayer L.D.**, Miller J.J., Tardi P.G.

14. US Patent # 5,744,158 (1998), "Methods of Treatment Using High Drug-Lipid Formulations of Liposomal-Antineoplastic Agents", Inventor: **Mayer L.D.**, Bally M.B., Cullis P.R., Ginsberg R.S., Mitlenes G.N.
15. US Patent # 5,795,589 (1998), "Liposomal Antineoplastic Agent Compositions", Inventors: **Mayer L.D.**, Bally M.B., Cullis P.R., Ginsberg R.S., Mitlenes G.N.
16. US Patent # 6,011,041 (2000) "Use of Anhydrovinblastine" Inventors: Schmidt, B., Kutney, J., **Mayer L.D.**
17. US Patent # 6,083,530 (2000) "High Drug: Lipid Formulations of Liposomal-Antineoplastic Agents", Inventors: **Mayer L.D.**, Bally M.B., Cullis P.R., Ginsberg R.S., Mitlenes G.N.
18. US Patent # 6,326,376 (2001) "Anhydrovinblastine for the Treatment of Cancer", Inventors: Schmidt B., Kutney, J., **Mayer L.D.**
19. European Patent # 0719546 (2003) "LUV Comprising Saturated Phospholipids and Method of Making the Same", Inventors: Bally M.B., Cullis P.R., Ginsberg R.S., **Mayer L.D.**, Mitlenes G.N.
20. European Patent # 0804159 (2003) "Sphingosomes for Enhanced Drug Delivery", Inventors: Webb M.S., Bally M.B., **Mayer L.D.**, Miller J.J., Tardi P.G.
21. European Patent # 0969839 (2003) "Anhydrovinblastine for the Treatment of Cancer", Inventors: Schmidt B., Kutney, J., **Mayer L.D.**
22. European Patent #1432402 (2006) "Compositions for Delivery of Drug Combinations", Inventors: Tardi, P., Harasym, T., Webb, M., Shew, C., **Mayer, L.D.**, Bally, M.B., Janoff, A.S.

Applications

1. EP Patent Application # 472639 (filed 1990), WO Patent Application #9014105, "Liposome Compositions Containing Drugs - Where Liposome(s) Have Trans-membrane Ion Gradient", Inventors: Madden, T.D., Hope, M.J., Tilcock, C.P., Cullis, P.R., Harrigan, P.R., Mui, B.S., Tai, L. and **Mayer, L.D.**
2. US Patent Application # 20030124181 (filed 2002) "Lipid Carrier Compositions with Enhanced Blood Stability", Inventors: Webb, M., Tardi, P., **Mayer, L.D.**, Ickenstein, L.
3. US Patent Application # 20040265368 (filed 2004) "Combination Compositions of Camptothecins and Fluoropyrimidines", Inventors: **Mayer, L.D.**, Bally, M.; Webb, M.; Tardi, P.; Johnstone, S.
4. US Patent Application # 20060228694 (filed 2004) "Methods to Individualize Combination Therapy", Inventors: Janoff, A., **Mayer, L.D.**, Bally, M.
5. US Patent Application # 20070031480 (filed 2004) "Enhanced Delivery of Sphingolipids", Inventors: **Mayer, L.D.**, Shabbits, J., Bally, M.
6. WO Patent Application # 04087105 (filed 2004) "Combination Formulations of Platinum Agents and Fluoropyrimidines", Inventors: **Mayer, L.D.**, Bally, M., Webb, M., Tardi, P., Shew, C.

7. WO Patent Application # 05102359 (filed 2005) "Combination Formulations of Anthracycline Agents and Cytidine Analogs", Inventors: **Mayer, L.D.**, Johnstone, S., Harasym, T.
8. US Patent Application # 20060165577 (filed 2005) "Compositions for Delivery of Drug Combinations", Inventors: Tardi, P., Harasym, T., Webb, M., Shew, C., **Mayer, L.D.**, Bally, M.B., Janoff, A.S.
9. US Patent Application # 20070286897 (filed 2005) "Liposomal Formulations of Anthracycline Agents and Cytidine Analogs", Inventors: **Mayer, L.D.**, Johnstone, S., Harasym, T.
10. WO Patent Application # 06014626 (filed 2005) "Particulate Constructs for Release of Active Agents", Inventors: **Mayer, L.D.**, Prud'homme, R., Allen, C., Saad, W.
11. WO Patent Application # 06055903 (filed 2005) "Method for Loading Multiple Agents into Delivery Vehicles", Inventors: **Mayer, L.D.**, Webb, M., Tardi, P., Johnstone, S., Harvie, P.
12. WO Patent Application # 06081354 (filed 2006) "Lipid Carrier Compositions with Reduced Polydispersity", Inventors: Tardi, P., **Mayer, L.D.**, Cabral-Lilly, D.
13. WO Patent Application # 07035783 (filed 2006) "Combination Formulations of Cytidine Analogs and Platinum Agents", Inventors: Johnstone, S., Harvie, P., Tardi, P., Harasym, T., **Mayer, L.D.**
14. WO Patent Application # 07050784 (filed 2006) "Fixed Ratio Drug Combination Treatments for Solid Tumors", Inventors: Janoff, A., **Mayer, L.D.**, Redman, J., Swenson, C.
15. WO Patent Application # 07064978 (filed 2006) "Localized Delivery of Drug Combinations", Inventor: **Mayer, L.D.**
16. WO Patent Application # 07076117 (filed 2006) "Liposomal Formulations Comprising Secondary and Tertiary Amines and Methods of Preparing Thereof", Inventors: Dicko, A., Tardi, P., **Mayer, L.D.**, Johnstone, S.

CURRICULUM VITAE

Professor Gregory Gregoriadis, DSc.

Personal:

Born: Athens, Greece
Greek and Canadian Nationalities
Married to Susan Byron-Brown
Two children born in 1971 (Linus) and 1974 (Xenia)

Education:

1946-1952: Gymnasium, Athens
1952-1957: B.Sc. in Chemistry, Department of Chemistry,
University of Athens

1964-1966: M.Sc. in Biochemistry (Supervisor,
Prof. T.L. Sourkes). Departments of Biochemistry
and Psychiatry, McGill University

1966-1968: Ph.D. in Biochemistry (Supervisor,
Prof. T.L. Sourkes). Departments of Biochemistry
and Psychiatry, McGill University

Military Service: 1958-1960: Sublieutenant, Greek Air Force

Research Appointments:

1997-	Founder, Director and Chief Scientific Officer, Lipoxen plc
2001-	Professor Emeritus, School of Pharmacy, University of London, London
1990-2001:	Professor of Experimental Drug Delivery and Head, Centre for Drug Delivery Research, The School of Pharmacy, University of London, London; Medical Research Council Senior Scientist (until Oct. 1993)
1984-1990:	Head, Medical Research Council Group and Honorary Senior Lecturer, Academic Medicine, Royal Free Hospital School of Medicine, University of London
1972-1984:	Senior Member of Staff; Head, Liposomes Group, Medical Research Council's Clinical Research Centre, Harrow

1970-1972: Research Fellow, Department of Biochemistry, Royal Free Hospital School of Medicine, University of London

1968-1970: Post-Doctoral Research Fellow, Department of Medicine, Albert Einstein College of Medicine, New York

1964-1968: see **Education**

1963-1964: Research Assistant, Allan Memorial Institute of Psychiatry, Montreal

1963: Visiting Scientist, Max Planck Institut für Kulturpflanzenzüchtung, Hamburg

1960-1963: Research Scientist, Hellenic National Foundation of Research, Athens.

- Societies:**
- ! Biochemical Society (since 1971)
 - ! Controlled Release Society (1981-1983); 1994 (life member)
 - ! Harvey Society (1969-1976)
 - ! Hellenic Biochemical and Biophysical Society (since 1975)
 - ! Medical Research Society for Inherited Metabolic Diseases (since 1976)
 - ! U.K. Association of Pharmaceutical Scientists (since 1991)
 - ! American Association of Pharmaceutical Scientists (since 1996; Fellow (since 1998))
 - ! Hellenic Medical Association (since 1997)

Awards/Distinctions:

- ! Controlled Release Society Founders Award, (1994) "for outstanding contributions to drug targeting and delivery"
- ! Alec D. Bangham MD, FRS Achievement Award (1995) "for lifelong achievement resulting in a fundamental and sustained impact on the advancement of liposome science and technology"

- ! Elected to Fellowship status in the American Association of Pharmaceutical Scientists (1998) “for outstanding contributions to pharmaceutical sciences”
- ! Doctor of Science (DSc) award by the University of London (2001)
- ! President elect, International Liposome Society (since 2001)
Acting President, International Liposome Society (1999-2001)
- Journal of Drug Targeting Award (2008) for life-long achievements in liposome research

Other awards:

- ! Entry in WHO=s WHO (since 1999)
- ! Gordon Research Conference Grant 1977 (US \$5,000) to organize and chair the first Gordon Research Conference on “Drug Carriers in Biology and Medicine” in 1978
- ! ASI Grant from NATO's Scientific Affairs Division, 1980 (US \$40,000) to direct a NATO Advanced Studies Institute in 1981
- ! ASI Grant from NATO's Scientific Affairs Division, 1982 (US \$40,000) to direct a NATO Advanced Studies Institute in 1983
- ! ASI Grant from NATO's Scientific Affairs Division, 1984 (US \$35,000) to direct a NATO Advanced Studies Institute in 1985
- ! ASI Grant from NATO's Scientific Affairs Division, 1986 (US \$35,000) to direct a NATO Advanced Studies Institute in 1987
- ! ASI Grant from NATO's Scientific Affairs Division, 1987 (US \$42,000) to direct a NATO Advanced Studies Institute in 1988
- ! ASI Grant from NATO's Scientific Affairs Division, 1988 (US \$40,000) to direct a NATO Advanced Studies Institute in 1989
- ! ASI Grant from NATO's Scientific Affairs Division, 1989 (US \$55,000) to direct a NATO Advanced Studies Institute in 1990
- ! ASI Grant from NATO's Scientific Affairs Division, 1990 (US \$50,000) to direct a NATO Advanced Studies Institute in 1991
- ! ASI Grant from NATO's Scientific Affairs Division, 1991 (US \$45,000) to direct a NATO Advanced Studies Institute in 1992

- ! ASI Grant from NATO's Scientific Affairs Division, 1992 (US \$45,000) to direct a NATO Advanced Studies Institute in 1993
- ! ASI Grant from NATO's Scientific Affairs Division, 1993 (US \$40,000) to direct a NATO Advanced Studies Institute in 1994
- ! ASI Grant from NATO's Scientific Affairs Division, 1994 (US \$45,000) to direct a NATO Advanced Studies Institute in 1995
- ! ASI Grant from NATO's Scientific Affairs Division, 1995 (US \$45,000) to direct a NATO Advanced Studies Institute in 1996
- ! ASI Grant from NATO's Scientific Affairs Division, 1996 (US \$45,000) to direct a NATO Advanced Studies Institute in 1997
- ! ASI Grant from NATO's Scientific Affairs Division, 1998 (US \$40,000) to direct a NATO Advanced Studies Institute in 1999
- ! Recipient of exchange visits award (\$4,000) by the Anglo-German Foundation of British Council (1990-1992)
- ! Recipient of exchange visits award (\$4,000) by the Anglo-German Foundation of British Council (1993-1994)

Research Support: Research during 1972-1984, (see Research Appointments) was fully supported by the Medical Research Council (MRC)

Subsequent grants include:

- ! Research Contract (N01-CM-97171) with the National Cancer Institute (USA) 1978 (US \$188,000) (1979-1982)
- ! Medical Research Council project grant (, 95,000; 1984-1987)
- ! MRC's Clinical Research Centre support (, 100,000, 1984-93)
- ! Medical Research Council project grant (, 106,000; 1987-1990)
- ! WHO (, 12,000; 1985)
- ! Ministry of Defence (, 49,000; 1992-1993)
- ! Ministry of Defence (, 160,000; 1992-1994)

- ! Ministry of Defence (, 127,000; 1993-1995)
- ! Sequus Pharmaceuticals. (, 98,000; 1993-1996)
- ! Ministry of Defence (, 139,264; 1994-96)
- ! Ministry of Defence (, 75,000; 1996)
- ! Ministry of Defence (, 20,000; 1996)
- ! ATTA, France (, 30,000; 1995-1998)
- ! European Commission (BRITE/EURAM; 240,000 ECU, 1997-2001)
- ! European Commission: 176,000 ECU (1997-2000)
- ! ICI (, 36,000; 1996-1999) to support a Ph.D. studentship
- ! Glaxo Welcome (, 20,100; 2000-2003) to support a Ph.D. studentship
- ! Royal Society Joint Project Award (Japan) (, 10,200; 2000-2002)

Other previous support includes grants from The Leverhulme Trust, The World Laboratory, The Royal Society, the Wellcome Trust, Wellcome Biotechnology, WHO, The British Council, The British Technology Group; Speywood Laboratories Ltd; University of London Central Fund

Research and Teaching: Supervision of well over 100 Post-Doctoral workers, Scholars, Visiting Scientists, Post Graduate students, Technicians, Erasmus and Sandwich students working on various aspects of drug targeting with liposomes and other systems. Individuals who worked with Professor Gregoriadis for a minimum of three months are shown below in approximate chronological order (1972-to date):

Rosemary A. Buckland (Technician)
 Diane Neerunjun (Technician)
 Christopher D.V. Black (Ph.D. student)
 Anthony W. Segal (Visiting Scholar)
 Gerry Dapergolas (Ph.D. student; Greek Government Scholar)
 Isobel Braidman (Post doc)
 Pamela J. Davisson (Sandwich student)
 Susan Scott (Sandwich student)
 George Deliconstantinos (Post doc; Greek Government Scholar)

Peter Bonventre (Visiting scientist)
Daniel Wreschner (Post doc)
Emanuel Manesis (Post doc; NATO Scholar)
Christine Davis (Sandwich student)
Chris Kirby (Research Associate)
Roger Moore (Research Assistant)
Jackie Clarke (Technician)
Judith Senior (Technician, Ph.D. student)
Ann Meehan (Sandwich student)
Mon-Moy Mah (Sandwich student)
Catherine Lemonias (Visiting scientist)
Hishani Weeraratne (Ph.D. student)
Pamela Large (Research Assistant)
Jim Mixson (Visiting NIH scientist)
Askin Tümer (Post doc; visiting NATO Scholar)
Barbara Wolff (Post doc)
Natalie Garçon (Post doc)
David Davis (Research Assistant)
Alun Davies (Technician)
Jay R. Behari (Post doc; British Council Scholar)
Steven Seltzer (Visiting Fogarty Scholar)
Y. Pathak (Visiting British Commonwealth Scholar)
Volkmar Weissig (Visiting scientist)
Lloyd Tan (Ph.D. student; Government of Singapore Scholar)
Qifu Xiao (Ph.D. student)
Christine Panagiotidi (Technician)
K.L. Kahl (Visiting scientist)
Christine da Silva (Technician)
Brenda McCormack (Ph.D. student; Research Assistant)
M Yasar Ozden (Visiting NATO Scholar)
Natasa Skalko (Ph.D. student)
Zhen Wang (Ph.D. student)
John Giannios (Ph.D. student)
Dmitry Genkin (Visiting scientist)
Maria Georgiou (Visiting scientist)
Sophia Antimisiaris (Visiting scientist)
Becky J. Ficek (Fulbright Scholar)
Victor Kyrlyenko (Visiting scientist; Leverhulme Scholar)
Martin Brandl (Post doc; British Council Scholar)
Dieter Bachmann (Post doc; British Council Scholar)
Mayda Gursel (Ph.D. student)
Sabina Ganter (Erasmus student)
Ishan Gursel (Visiting scientist)
Cecilia D=Antuono (Erasmus student)
Ana Fernandes (Ph.D. student)

Cristina Lopez Pascual (MSc student)
Maria Velinova (Visiting scientist)
Susana Morais (Erasmus student)
Ann Young (Research Assistant)
Yannis Loukas (Research Assistant)
Vassilia Vraka (MSc. student)
Voula Kallinteri (Erasmus student)
Fatima Eraçs (Erasmus student)
Jean Marie Verdier (Erasmus student)
Dimitry Fatouros (Erasmus student)
Veronika Muller (Erasmus student)
Jean-Christophe Olivier (Research Assistant)
Janny Zhang (Ph.D. student)
Roghieh Saffie (Ph.D. student)
Irene Naldoska (Visiting British Council Scholar)
Sudaxina Murdan (Ph.D. student; shared)
Sussi Juul Hansen (Erasmus student)
Anette Hollensen (Erasmus student)
Yvonne Perrie (Ph.D. student; Research Assistant)
Maria Jose Saez Alonso (Erasmus student)
Mercedes Valdes (Erasmus student)
Laura Nasarre (Erasmus student)
Eve Crane (Marshall Scholar)
Brahim Zadi (Ph.D. student; Research Assistant)
Maria E. Lanio (Visiting Cuban Government Scholar)
Gernot Warnke (Visiting scientist)
Elizabetta Casali (Ph.D. student)
Sevtap Velipasaoglu (Visiting Turkish Government Scholar)
Sara Lauria (Erasmus student)
Oulaya Belguenani (Erasmus student)
Isabelle Gyselinck (Erasmus student)
Sigrun Lubke (Erasmus student)
Kent Lau (Ph.D. student; ICI Scholar)
Alejandro Soto (Visiting Cuban Government Scholar)
Yanin Bebelagua (Visiting Cuban Government Scholar)
Steve Yang (Ph.D. student; Taiwan Government Scholar)
Filipe Rocha da Torre Assoreira (Erasmus student)
Paola Genitrini (Erasmus student)
Guoping Sun (Visiting British Council Scholar)
Malini Mital (Ph.D. student)
Michael Schupp (Erasmus student)
Karin Gaimann (Erasmus student)
Mia Obrenovic (Ph.D. student)
Sherry Kittivoravitkul (Ph.D. student; Thailand Government Scholar)
Yoshie Maitani (Visiting Royal Society Scholar)

Irene Papanicolaou (Ph.D. student; Glaxo Scholar) (2000-2001)
Miriam Steur (Erasmus student)
Sanjay Jain (Visiting Scientist; Scholar)
Ioannis Papaioannou (Ph.D. student; Lipoxen Scholar)
Maria Verissimo (Erasmus student)
Bruno da Costa (Erasmus student)
Letizia Flores Prieto (Erasmus student)

Research Interests:

Past and present interests (see list of references) include:

- ! Metabolism and function of trace metals;
- ! Recognition groups on glycoproteins, cell receptors and catabolism of proteins;
- ! Lysosomes and lysomotropic action;
- ! Fate of liposomes in vivo and control;
- ! Mechanisms of liposomal drug action;
- ! Liposome technology;
- ! Drug delivery with liposomes in enzyme replacement therapy; cancer and antimicrobial therapy; use of liposomes for the immunopotentialization of vaccines (protein and peptide antigens and live microbes); oral administration of vitamins and peptides; drug targeting with liposomes coated with antibodies or glycoproteins to tumours, liver (hepatocytes), lymphocytes and other accessible cells; photoprotective liposomes; DNA vaccination via liposomes
- ! Polysialic acids as a means to improve the stability, reduce the immunogenicity and antigenicity when relevant, and extend the circulation time of small drugs, peptides, proteins and liposomes
- ! Polyglycolic/polylactic acid polymers as drug carriers
- ! Cyclodextrins (as such or entrapped in liposomes) as drug carriers
- ! Polyhydroxy butyric acid particles as carriers of live microbes

Collaborative Studies:

There have been numerous collaborative studies with both academic and industrial researchers worldwide on a variety of drug delivery and targeting aspects, many of them published (see list of publications, refs:

27, 28, 31, 34, 35, 39, 44, 46, 55, 61, 64, 65, 66, 69, 75, 81, 82, 86, 87, 88, 89, 109, 113, 126, 127, 147, 151, 156, 161, 164, 167, 168, 169, 173, 177, 178, 184, 186, 187, 189, 190, 199, 200, 205, 211, 212, 214, 215, 216, 219, 221, 224, 236, 241, 249, 253, 258, 260, 267, 270, 288, 289, 290, 314)

Patents:

Inventor in granted or pending patents. These include a cluster of patents on **polysialic acids** as a means to prolong the circulation time of drugs, proteins and liposomes; a cluster of patents on **liposome-mediated DNA vaccination**; and patents on **giant liposomes** as carriers of live microbial vaccines; **cyclodextrin-drug complexes** entrapped in photoprotective liposomes; **small liposomes with high drug loading capacity**; liposomes devoid of cationic lipids in **gene therapy** or **DNA vaccination**; a one step method for **high yield-entrapment of taxol** in small liposomes.

Patents on polysialic acids and liposome-mediated DNA vaccines form the basis of the two platform technologies of **Lipoxen plc** (www.lipoxen.com) a drug delivery company founded by Professor Gregoriadis in 1997.

Contribution to the Field of Drug Delivery Systems

The following is a list of key publications in “high-impact” journals that have motivated the application of liposomes in Biochemistry, Immunology, Pharmacology, Therapeutics and Vaccines

- Gregoriadis and Ryman, **Eur.J.Biochem.**, 24: 485-491, 1972 (Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases), and Gregoriadis and Ryman, **Biochem.J.**, 129:123-133, 1972 (Lysosomal localization of β -fructofuranosidase-containing liposomes injected into rats. Some implications in the treatment of genetic disorders) (**First papers to study the fate of liposomes in vivo, and demonstrate lysosomal localization. The latter paper also proposed a variety of liposomal uses, including antimicrobial and cancer treatment and gene therapy.**)
- Gregoriadis, **FEBS Lett.**, 36: 292-296, 1973 (Drug entrapment in liposomes) (**First paper to study anti-cancer and antimicrobial drug entrapment and liposomal drug fate in vivo.**)

- Gregoriadis and Buckland, **Nature**, 244: 170-172, 1973 (Enzyme-containing liposomes alleviate a model for storage disease) (**First paper to demonstrate in a model of lysosomal storage disease that liposomes containing an appropriate enzyme could potentially be used in the treatment of lysosomal storage diseases**).
- Gregoriadis et al, **Lancet**, i: 1313-1316, 1974 (Drug-carrier potential of liposomes in cancer chemotherapy) (**First study of (cancer) patients injected with liposomes**).
- Allison and Gregoriadis, **Nature**, 252: 252, 1974 (Liposomes as immunological adjuvants) (**First paper to demonstrate the immunological adjuvant properties of liposomes for protein antigens. This and subsequent extensive work by the author's group and many others culminated in the production (by Berna) and licencing of liposome-based vaccines against hepatitis A and influenza**).
- Gregoriadis and Neerunjun, **Biochem. Biophys. Res. Commun.**, 65 : 537-544, 1975 (Homing of liposomes to target cells) (**First paper to demonstrate targeting of liposomes to (tumour) cells in vitro (via antibodies against tumours) and in vivo (via a desialylated glycoprotein recognizing the galactose receptor in the liver)**).
- Gregoriadis, **New Engl. J. Med.**, 295: 704-710 and 765-770, 1976 (The carrier potential of liposomes in biology and medicine. (Medical Progress article in two parts)) and Gregoriadis, **Nature**, 265: 407-411, 1977 (Targeting of drugs (Review article)) (**First reviews on liposomes and drug targeting respectively which are thought to have helped to attract world-wide attention to the drug delivery potential of liposomes and drug targeting in general by the medical and scientific community. A subsequent Occasional Survey article in the Lancet (Gregoriadis, Lancet, ii: 241-247, 1981, Targeting of Drugs: Implications in Medicine), also contributed significantly**).
- Belchetz et al, **Lancet**, ii: 116-117, 1977 (Treatment of Gaucher's disease with liposome-entrapped glucocerebrosidase: β -glucosidase) (**First study of therapeutic use of liposomes in (Gaucher disease) patients**).
- Gregoriadis et al, **Life Sci.**, 21: 357-370, 1977 (Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues) (**First paper to demonstrate antibody-mediated targeting of liposomes to tumours in vivo**).
- Gregoriadis and Davis, **Biochem. Biophys. Res. Commun.**, 89: 1287-1293, 1979 (Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells), and Kirby and Gregoriadis, **Biochem. J.**, 186: 591-598, 1980 (Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in

vitro) (First papers to show the effect of cholesterol on liposomal bilayer stability in plasma or blood and in prolonging vesicle clearance in vivo).

- Gregoriadis and Senior, **FEBS Lett.**, 119: 43-46, 1980 (The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation) (First paper to demonstrate that vesicle clearance depends on vesicle phospholipid composition) (Together with a paper by Hwang et al published in 1980). This and subsequent extensive work by the author's group and others have led to the production (by NeXtar, now Gilead) and marketing of small, long circulating liposomes for the treatment of certain cancers (DaunoXome) and fungal disease (AmBisome).
- Kirby and Gregoriadis, **Nature Biotechnology**, 2: 979-984, 1984 (Dehydration-rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes). (Development of the dehydration/rehydration method. This widely adopted method, ensures high yield entrapment of any water-soluble solute under mild conditions in the absence of sonication or detergents. It has also led to a one step method (**J. Drug Targeting**, 3: 469-475, 1996 Gregoriadis et al, High yield incorporation of plasmid DNA within liposomes: Effect on DNA integrity and transfection efficiency) for the quantitative (>95%) entrapment of DNA within liposomes).
- Garçon et al, **Immunology**, 64: 743-745, 1988 (Targeted immunoadjuvant action of tetanus toxoid-containing liposomes coated with mannosylated albumin) (First paper to demonstrate (mannose-mediated) targeted immunological adjuvant action of liposomes in vivo).
- Gregoriadis et al, **Immunology**, 80: 535-540, 1993 (Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory) (First paper to demonstrate that a T cell epitope can provide help for a B cell epitope to raise an IgG response when the two epitopes are co-entrapped in the same liposome).
- McCormack and Gregoriadis, **Biochim. Biophys. Acta.**, 1291: 237-244, 1997 (Comparative studies of the fate of free and liposome-entrapped hydroxypropyl- β -cyclodextrin/drug complexes after intravenous injection into rats: Implications in drug delivery) (First paper to demonstrate that liposomes can control/prolong the pharmacological action of drugs in tissues by entrapping the drug in the form of complexes with cyclodextrins. For instance, liposome-entrapped cyclodextrin-included drugs taken up by the liver remain in the tissue intact and inert until they are dissociated from cyclodextrins. The rate of dissociation depends on the stability constant of the complex, which in turns depends on the types of drug and cyclodextrin used).

- Gregoriadis et al, **FEBS Lett.**, 402: 107-110, 1997 (Liposome-mediated DNA vaccination) (**First paper to show that liposomes entrapping a plasmid DNA vaccine in the aqueous phase can potentiate immune responses to the encoded antigen to a much greater extent than naked DNA or liposome-DNA complexes**). For more information see: www.lipoxen.com
- Bacon, Caparros-Wanderley, McCormack, Laing and Gregoriadis, CRS Proceedings, 30th Annual Meeting 2003, page 884. (A novel liposomal influenza vaccine) (**First paper to show that co-entrapment in liposomes of a DNA plasmid encoding a vaccine together with the protein vaccine leads to much greater immunity than that seen with either of the antigens entrapped and given separately**).
- **The use of polysialic acids as a means to improve the stability and circulatory life of drugs, peptides, and proteins and also reduce their immunogenicity and antigenicity, was first proposed in 1993** (Gregoriadis et al, **FEBS Lett** 315:271-276, 1993; Polysialic acids: Potential in drug delivery). This publication and subsequent ones (248, 254, 273, 286, 295, 300, 312, 313, 324, 325, 327, 329; see Publications) established polysialic acids as an alternative to PEGylation, especially for peptides and proteins used chronically and in increased amounts. For more information see: www.lipoxen.com

- Books:**
- ! Editor, Drug Carriers in Biology and Medicine (Academic Press, 1979)
 - ! Senior Editor (with A.C. Allison), Liposomes in Biological Systems (Wiley, 1980)
 - ! Senior Editor, (with J. Senior and A. Trouet), Targeting of Drugs (Plenum, 1982)
 - ! Editor, Liposome Technology (3 volumes)(CRC Press, Inc., 1984)
 - ! Senior Editor (with G. Poste, J. Senior and A. Trouet), Receptor Mediated Targeting of Drugs (Plenum, 1984)
 - ! Senior Editor (with J. Senior and G. Poste) Targeting of Drugs with Synthetic Systems (Plenum, 1986)
 - ! Editor, Liposomes as Carriers of Drugs: Recent Trends and Progress (Wiley, 1988)
 - ! Senior Editor (with G. Poste) Targeting of Drugs: Anatomical and Physiological Considerations (Plenum, 1988)
 - ! Senior Editor (with A.C. Allison and G. Poste) Immunological Adjuvants and Vaccines (Plenum, 1989)
 - ! Senior Editor (with A.C. Allison) Targeting of Drugs: Optimization Strategies (Plenum, 1990)
 - ! Senior Editor (with A.C. Allison and G. Poste) Vaccines: Recent Trends and Progress (Plenum, 1991)

- ! Editor, Liposome Technology (3 volumes), 2nd Edition, (CRCPress), 1993
- ! Senior Editor (with A.T. Florence and H.M. Patel) Liposomes in Drug Delivery, Harwood Academic Publishers, Reading, 1992
- ! Senior Editor (with A.T. Florence and G. Poste) Targeting of Drugs: The Challenge of Peptides and Proteins (Plenum, 1992)
- ! Senior Editor (with B. McCormack, A.C. Allison and G. Poste) New Generation Vaccines: The Role of Basic Immunology (Plenum, 1993)
- ! Senior Editor (with B. McCormack and G. Poste) Targeting of Drugs: Advances in System Constructs, (Plenum, 1994)
- ! Senior Editor (with B. McCormack and A.C. Allison) Vaccines: New Generation Immunological Adjuvants, (Plenum, 1995)
- ! Senior Editor (with B. McCormack) Targeting of Drugs: Strategies for Oligonucleotide and Gene Therapy (Plenum, 1996)
- ! Senior Editor (with B. McCormack and A.C. Allison) Vaccine Design: The Role of Cytokine Networks, (Plenum, 1997)
- ! Senior Editor (with B. McCormack) Targeting of Drugs: Stealth Therapeutic Systems, (Plenum, 1998)
- ! Senior Editor (with B. McCormack) Targeting of Drugs: Strategies for Gene Constructs and Delivery, (IOS Press, 2000)
- ! Guest Editor, J.Drug Targeting (vol 1(1), 1993) Special issue on liposomes as a drug carrier
- ! Guest Editor, J.Liposome Research (vol 6 (2), 1996) Special issue on liposomal vaccines
- ! Guest Editor, Int.J.Pharmaceutics (vol 162 (1-2), 1998) Special issue on liposomes as a drug carrier
- ! Editor, Liposome Technology, 3rd Edition (CRC Press). In press
- ! Series Co-Editor (with A.T. Florence) of books on Drug Delivery, Harwood Academic Publishers, Reading.

The following books were commissioned and published:

- Volume 1 Microencapsulation of Drugs, edited by T.L. Whateley
- Volume 2 Liposomes in Drug Delivery, edited by G. Gregoriadis, A.T. Florence and H.M. Patel
- Volume 3 Drug Absorption Enhancement: Concepts, Possibilities, Limitations and Trends, edited by A.G. de Boer
- Volume 4 Trends and Future Perspectives in Peptide and Protein Drug Delivery, edited by V.H.L. Lee, M. Hashida and Y. Mizushima
- Volume 5 Interfacial Phenomena in Drug Delivery and Targeting, edited by G. Buckton
- Volume 6 Liposomes in Biomedical Applications, edited by P.N. Shek
- Volume 7 Handbook of Biodegradable Polymers, edited by A.J. Domb, J. Kost and D.M. Wiseman
- Volume 8 Antigen Delivery Systems: Immunological and Technological Issues, edited by B. Gander, H.P. Merkle and G. Corradin
- Volume 9 Submicron Emulsions in Drug Targeting and Delivery, edited by S. Benita
- Volume 10 Advanced Gene Delivery, edited by A. Rolland
- Volume 11 An Introduction to Niosomes and Other Non-Phospholipid Systems, edited by I. Uchegbu

Journals:

- ! Editorial Board, Life Sciences (1979-1989)
- ! Editorial Board, Enzyme and Microbial Technology (1979-1986)
- ! Editorial Board, CRC Critical Reviews in Therapeutic Drug Carrier Systems (since 1983)
- ! Advisory Board, Biochemical Journal (1981 and 1982)
- ! Editor (Regional), Journal of Microencapsulation (1984-1996)
- ! Advisory Board, Journal of Liposome Research (since 1987)
- ! Editorial Board, J. Drug Targeting (1992-1999)
- ! Editorial Board, Artificial Cells, Blood Substitutes and Immobilization Biotechnology (since 1996)
- ! Editorial Board, J. Tumour Targeting (since 2000)
- ! Editorial Board, Hellenic Medical Journal (since 2000)
- ! Editorial Board, Expert Opinion on Therapeutic Patents (since 2000)

- ! Editorial Board, Current Drug Targeting - Infectious Disorders (since 2000)

Conferences and other activities:

Organizer of 24 international conferences and Summer Schools as shown below:

- ! Founder, first Chairman and Organizer (1978) of the ongoing Gordon Research Conference Series "Drug Carriers in Biology and Medicine".
- ! Founder, Director and Organizer of the following NATO Advanced Studies Institute Series on "Drug Targeting":

"Targeting of Drugs" (1981), Cape Sounion Beach, Greece

"Receptor-mediated Targeting of Drugs" (1983), Cape Sounion Beach, Greece

"Targeting of Drugs with Synthetic Systems" (1985), Cape Sounion Beach, Greece

"Targeting of Drugs: Anatomical and Physiological Considerations" (1987), Cape Sounion Beach, Greece

"Targeting of Drugs: Optimization Studies" (1989), Cape Sounion Beach, Greece

"Targeting of Drugs: The Challenge of Peptides and Proteins" (1991), Cape Sounion Beach, Greece

"Targeting of Drugs: Advances in System Constructs" (1993), Cape Sounion Beach, Greece

"Targeting of Drugs: Strategies for oligonucleotide and gene delivery in therapy" (1995), Cape Sounion Beach, Greece

"Targeting of Drugs: Stealth Therapeutic Systems" (1997), Cape Sounion Beach, Greece

"Targeting of Drugs: Strategies for Gene Constructs and Delivery" (1999), Marathon, Greece

- ! Founder, Director and Organizer of the following NATO Advanced Studies Institute Series "Vaccines":
 - "Immunological Adjuvants and Vaccines" (1988), Cape Sounion Beach, Greece
 - "Vaccines: Recent Trends and Progress" (1990), Cape Sounion Beach, Greece
 - "New Generation Vaccines: The Role of Basic Immunology" (1992), Cape Sounion Beach, Greece
 - "Vaccines: New Generation Immunological Adjuvants" (1994), Cape Sounion Beach, Greece
 - "Vaccine Design: The Role of Cytokine Networks" (1996), Cape Sounion Beach, Greece
- ! Symposium Organizer and Chairman (Membranes and Membrane Model Systems). Special FEBS Meeting on "Cell Function and Differentiation" Athens (1982)
- ! Organizer (with A.T. Florence and H. Patel): "Liposomes in Drug Delivery: 21 Years On", London, 1990
- ! Organizer (with A.T. Florence): "Liposomes in Drug Delivery: The Nineties and Beyond", London, 1993
- ! Organizer (with A.T. Florence): "Liposome Advances: Progress in Drug and Vaccine Delivery", London, 1996
- ! Organizer (with A.T. Florence): "Liposomes Advances: Progress in Drug and Vaccine Delivery", London, 1999
- ! Organizer (with A.T. Florence): "Liposomes Advances: Progress in Drug and Vaccine Delivery", London, 2001
- ! Organizer: "Liposomes Advances: Progress in Drug and Vaccine Delivery", London, 2003
- ! Organizer and Chairman of Controlled Release Society, Symposium on Lipids, Micelles and Liposomes, CRS Conference, San Diego 2001

- ! Organizer: "Liposome Advances: Progress in Drug and Vaccine Delivery", London, 2005
- Organizer: "Liposome Advances: Recent Trends and Progress in Drug and Vaccine Delivery", London, 2006
- Chairman, Organizing Committee: "Liposome Advances: Recent Progress in Drug and Vaccine Delivery", London, 2007

1

Member, Institute for International Advancement of Sciences: 1975-1977

- ! Member of Advisory Committee, NATO Scientific Affairs Division (from 1982)
- ! NATO Consultant, P.O. Infections Project, Portugal (1993-1998)
- ! Lecturer in numerous teaching courses nationally and internationally
- ! Faculty member (lecturer) of numerous seminars for Industrial staff
- ! Scientific Consultant (freelance) to numerous pharmaceutical industries
- ! Invited contributions to **Nature** (one major review and five "News and Views" articles or Reports); **Lancet** (Occasional Survey); **New Engl.J.Med.** (Medical Progress article in two successive issues); **Science** (invited letter); **Pharmacology and Therapeutics** (Review); **Clinical Immunology Newsletter** (Review); **New Scientist** (Review Article); **Drugs** (one Leading Article and one Review); **Trends in Pharmacological Sciences** (Review); **Pharmacy International** (Review); **Trends in Biotechnology** (three Reviews); **News in Physiological Sciences** (Review); **Immunology Today** (one review; two meeting reports); **Pharmaceutical Research** (Review), and many others (see attached bibliography)

Publications:

- ! Over 330 publications (see attached list)
- ! Sole Editor or Senior Editor of 28 volumes (see attached list)
- ! Numerous conference abstracts

Invited Lectures:

- ! Over 250 invited lectures (see attached list)

Other activities:

- ! British Council Lecturer (1983, 1984, 1985, 1987, 1989)
- ! Numerous book reviews.
- ! Reviewer for numerous Journals

Lipoxen Technologies Ltd Founder (1997) and Scientific Director of Lipoxen Ltd (now Lipoxen Technologies Ltd), a drug delivery company with laboratories at the School of Pharmacy, University of London, and offices at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (www.lipoxen.com)

BOOKS

1. Drug Carriers in Biology and Medicine (G. Gregoriadis, ed.), Academic Press, 1979
2. Liposomes in Biological Systems (G. Gregoriadis and A.C. Allison, eds.), Wiley, 1980
3. Targeting of Drugs (G. Gregoriadis, J. Senior and A. Trouet, eds.), Plenum, 1982
4. Liposome Technology (G. Gregoriadis, ed.), CRC Press, 1984
 - Vol. I: Preparation of Liposomes
 - Vol. II: Incorporation of Drugs, Proteins and Genetic Material
 - Vol. III: Targeted Drug Delivery and Biological Interaction
5. Receptor-Mediated Targeting of Drugs (G. Gregoriadis, G. Poste, J. Senior and A. Trouet, eds.), Plenum, 1984

6. Targeting of Drugs with Synthetic Systems (G. Gregoriadis, J. Senior and G. Poste, eds.), Plenum, 1986
7. Liposomes as Carriers of Drugs: Recent Trends and Progress (G. Gregoriadis, ed.), Wiley, 1988
8. Targeting of Drugs: Anatomical and Physiological Considerations (G. Gregoriadis and G. Poste, eds.), Plenum, 1988
9. Immunological Adjuvants and Vaccines (G. Gregoriadis, A.C. Allison and G. Poste, eds.), Plenum, 1989
10. Targeting of Drugs: Optimization Strategies (G. Gregoriadis and A.C. Allison, eds.), Plenum, 1990
11. Vaccines: Recent Trends and Progress (G. Gregoriadis, A.C. Allison and G. Poste, eds.), Plenum, 1991
12. Targeting of Drugs: The Challenge of Peptides and Proteins (G. Gregoriadis, A.T. Florence and G. Poste, eds.), Plenum, 1992
13. Liposome Technology (G. Gregoriadis, ed.), 2nd edition, CRC Press, 1993
 - Vol. I: Liposome Preparation and Related Techniques
 - Vol. II: Entrapment of Drugs and Other Materials
 - Vol. III: Interactions of Liposomes with the Biological Milieu
14. Liposomes in Drug Delivery (G. Gregoriadis, A.T. Florence and H.M. Patel, eds.), Harwood Academic Publishers, Reading, 1993
15. New Generation Vaccines: The Role of Basic Immunology (G. Gregoriadis, B. McCormack, A.C. Allison and G. Poste, eds.), Plenum, 1993
16. Targeting of Drugs: Advances in Systems Constructs (G. Gregoriadis, B. McCormack and G. Poste, eds.) Plenum 1994
17. Vaccines: New-Generation Immunological Adjuvants (G. Gregoriadis, B. McCormack and A.C. Allison, eds.) Plenum, 1995
18. Targeting of drugs: Strategies for Gene and Oligonucleotide Delivery in Gene Therapy (G. Gregoriadis, B. McCormack, eds) Plenum, 1996
19. Vaccine Design: The Role of Cytokine Networks (G. Gregoriadis, B. McCormack and A.C. Allison, eds) Plenum, 1997

20. Targeting of Drugs: Stealth Therapeutic Systems
(G. Gregoriadis and B. McCormack, eds) Plenum, 1998
21. Targeting of Drugs: Strategies for Gene Constructs and Delivery
(G. Gregoriadis and B. McCormack, eds) IOS Press, 2000
22. Liposome Technology (G. Gregoriadis, ed.), 3rd Edition, Informa Healthcare, 2007
 Vol. I: Liposome Preparation and Related Techniques
 Vol. II: Entrapment of Drugs and Other Materials into Liposomes
 Vol. III: Interaction of Liposomes with the Biological Milieu

PUBLICATIONS

1. K. Papagopoulos, K. Matsopoulos, E. Damigos, G. Kallistratos, J. Vavougiou, G. Gregoriadis and A. Pfau
 The disturbances in the mechanism of in vivo acetylation and the metabolism of pyruvic and citric acids after administration of barbiturates
Medicina Experimentalis, **6**:237-244, 1962
2. E. Phocas, C. Andriotakis, C. Panagopoulos, G. Gregoriadis et Ph. Skliros
 Les lipides et les lipoproteinogrammes des lapins apres administration d'adrenaline
La Presse Medicale **71**:117-119, 1963
3. G. Gregoriadis
 Determination of K⁺ and Na⁺ in biological fluids and tissues by paper electrophoresis
Chimika Chronika, **28**:15-17, 1963
4. G. Gregoriadis
 Simultaneous determination of K⁺, Na⁺, Cl⁻ and inorganic P in biological fluids by paper electrophoresis
Chimika Chronika, **28A**:80-82, 1963
5. K. Panagopoulos, G. Menegas, G. Gregoriadis and J. Vavougiou
 Postheparine lipolytic enzymes
Chimika Chronika, **29**:53-64, 1964
6. K. Misala, K. Lloyd, G. Gregoriadis and T.L. Sourkes
 Conversion of ¹⁴C-dopamine to cardiac ¹⁴C-noradrenaline in the copper-deficient rat
European J. Pharmacol. **1**:6-10, 1967

7. G. Gregoriadis and T.L. Sourkes
Intracellular distribution of copper in the liver of the rat
Canad.J.Biochem. 45:1841-1851, 1967
8. G. Gregoriadis and T.L. Sourkes
Role of protein in removal of copper from the liver
Nature, 218:290-291. 1968
9. A.L. Symes, T.L. Sourkes, M.B.H. Youdim, G. Gregoriadis and H. Birnbaum
Decreased monoamine oxidase activity in liver of iron-deficient rats
Canad.J.Biochem. 47:999-1002, 1969
10. G. Gregoriadis and T.L. Sourkes
Regulation of hepatic copper in the rat by the adrenal gland
Cand.J.Biochem. 48:160-163, 1970
11. G. Gregoriadis, A.G. Morell, I. Sternlieb and I.H. Scheinberg
Catabolism of desialylated ceruloplasmin in the liver
J.Biol.Chem. 245:5833-5837, 1970
12. A.G. Morell, G. Gregoriadis, I.H. Scheinberg, J. Hickman and G. Ashwell
The role of sialic acid in determining the survival of glycoproteins in the circulation
J.Biol.Chem. 246:1461-1467, 1971
13. G. Gregoriadis, P.D. Leathwood and B.E. Ryman
Enzyme entrapment in liposomes
FEBS Lett. 14:95-99, 1971
14. I. Sternlieb, G. Gregoriadis, A.G. Morell, M. Ma and I.H. Scheinberg
Catabolism of an altered protein by hepatocytes
Gastroenterology, 60:188, 1971
15. G. Gregoriadis and B.E. Ryman
Liposomes as carriers of enzymes or drugs: A new approach to the treatment of storage diseases
Biochem.J., 124:58P, 1971
16. G. Gregoriadis and B.E. Ryman
Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases
Eur.J.Biochem., 24:485-491, 1972
17. G. Gregoriadis and B.E. Ryman
Lysosomal localization of enzyme-containing liposomes injected into rats

Biochem.J. **128**:142-143P, 1972

18. G. Gregoriadis and B.E. Ryman

Lysosomal localization of β -fructofuranosidase-containing liposomes injected into rats.
Some implications in the treatment of genetic disorders

Biochem.J. **129**:123-133, 1972

19. I. Sternlieb, C.J.A. Van Den Hamer, A.G. Morell, S. Alpert, G. Gregoriadis and I.H. Scheinberg

Lysosomal defect of hepatic copper excretion in Wilson's disease (hepatolenticular degeneration)

Gastroenterology **64**:99-105, 1973

20. G. Gregoriadis and R.A. Buckland

Enzyme-containing liposomes alleviate a model for storage disease

Nature (London) **244**:170-172, 1973

21. R.A. Buckland and G. Gregoriadis

Removal of stored sucrose from cultured mouse macrophages and human fibroblast cells with β -fructofuranosidase-containing liposomes

Biochem.Soc.Trans., **1**:733-734, 1973

22. G. Gregoriadis

Drug entrapment in liposomes

FEBS Lett. **36**:292-296, 1973

23. G. Gregoriadis and B.E. Ryman

Tritiation of glycoproteins

Biochem.Biophys.Res.Comm., **52**:1134-1140, 1973

24. G. Gregoriadis and B.E. Ryman

Possible use of liposomes in enzyme replacement therapy. in: Treatment of Inborn Errors of Metabolism (J.W.T. Seakins, R.A. Saunders and C. Toothill, eds). Churchill

Livingstone, Edinburgh and London 1973, pp 203-213

25. G. Gregoriadis

Molecular Trojan Horses

New Scientist **60**:890-893, 1973

26. G. Gregoriadis

Drug entrapment in liposomes. Possibility for chemotherapy

Biochem.Soc.Trans. **2**:117-119, 1974

27. G. Gregoriadis, D. Putman, L. Louis and D. Neerunjun

Comparative fate and effect of non-entrapped and liposome-entrapped neuraminidase injected into rats

Biochem.J. 140:323-330, 1974

28. G. Gregoriadis, C.P. Swain, E.J. Wills and A.S. Tavill
Drug-carrier potential of liposomes in cancer chemotherapy

Lancet i:1313-1316, 1974

29. G. Gregoriadis and D.E. Neerunjun

Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications

Eur.J.Biochem. 47:179-185, 1974

30. C.D.V. Black and G. Gregoriadis

Intracellular fate and effect of liposome-entrapped actinomycin D injected into rats

Biochem.Soc.Trans. 2:869-871, 1974

31. G. Gregoriadis and A.C. Allison

Entrapment of proteins in liposomes prevents allergic reactions in preimmunised mice

FEBS Lett. 45:71-74, 1974

32. D.E. Neerunjun and G. Gregoriadis

Prolonged survival of tumour bearing mice treated with liposome-entrapped actinomycin D

Biochem.Soc.Trans. 2:868-869, 1974

33. G. Gregoriadis

Structural requirements for the specific uptake of macromolecules and liposomes by target tissues

In: "Enzyme Therapy in Lysosomal Storage Disease" (J.M. Tager, G.J.M. Hooghwinkel and W.Th. Daems eds.) North-Holland Publishing Co., 1974, pp 131-148

34. A.W. Segal, E.J. Wills, J.E. Richmond, G. Slavin, C.D.V. Black and G. Gregoriadis
Morphological observations on the cellular and subcellular destination of intravenously administered liposomes

Brit.J.Exp.Pathol. 55:320-327, 11 plates, 1974

35. A.C. Allison and G. Gregoriadis

Liposomes as immunological adjuvants

Nature (London) 252:252, 1974

36. G. Gregoriadis

Enzyme or drug entrapment in liposomes. Possible biomedical applications

In: "Insolubilized Enzymes" (M. Salmona, C. Saronia and S. Garattini eds) Raven Press, New York 1974, pp. 165-177

37. G. Gregoriadis

The enzyme-carrier potential of liposomes in enzyme replacement therapy
New Eng.J.Med. 292:215, 1975

38. G. Gregoriadis and D.E. Neerunjun

Treatment of tumour bearing mice with liposome-entrapped actinomycin D prolongs their survival
Res.Comm.Chem.Pathol.Pharmacol. 10:351-362, 1975

39. E. Wisse and G. Gregoriadis

The uptake of liposomes in the rat liver
R.E.S.
J.Reticul.Soc. 18, 10, 1975

40. G. Gregoriadis

Homing of liposomes to target cells
Biochem.Soc.Trans. 3:613-618, 1975

41. A.W. Segal, G. Gregoriadis and C.D.V. Black

Liposomes as vehicles for the local release of drugs
Clin.Sci.Mol.Med. 49:99-106, 1975

42. G. Gregoriadis and E.D. Neerunjun

Homing of liposomes to target cells
Biochem.Biophys.Res.Comm. 65:537-544, 1975

43. G. Gregoriadis

Catabolism of Glycoproteins. A possible role of sugars
In: "Lysosomes in Biology and Pathology". Edited by J.T. Dingle and R.T. Dean. North-Holland Publishing Co., 1975, 265-294

44. E. Wisse, G. Gregoriadis and W.Th. Daems

The uptake of liposomes by the rat liver
In: "The Reticuloendothelial System in Health and Disease: Functions and characteristics" (S.M. Reichard, M.R. Escobar and H. Friedman, eds.), Plenum Press Corporation, New York, pp. 237-245, 1976

45. G. Gregoriadis, G. Dapergolas and E.D. Neerunjun

Penetration of target areas in the rat by liposome-associated agents administered parentally and intragastrically
Biochem.Soc.Trans. 4:256-259, 1976

46. A.C. Allison and G. Gregoriadis
Liposomes as immunological adjuvants. In "Recent results in Cancer Research" (G. Mathe, I. Florentin and M.-C. Simmler, eds.) pp. 58-64, Springer Verlag, Heildenberg, 1976
47. C.D.V. Black and G. Gregoriadis
Interaction of liposomes with blood plasma proteins
Biochem.Soc.Trans. 4:253-256, 1976
48. I. Braidman and G. Gregoriadis
Preparation of glucocerebroside: β -glucosidase for entrapment in liposomes and treatment of patients with adult Gaucher's disease
Biochem.Soc.Trans. 4:259-261, 1976
49. G. Gregoriadis
Direction of liposome-associated therapeutic agents to target areas in the body
Acta Pharmaceutica Succica. 13:(Suppl): 39, 1976
50. G. Gregoriadis
Enzyme entrapment in liposomes
Methods in Enzymology (K. Mosbach, ed.) Vol. 44, pp 218-227, Academic Press, New York, 1976
51. G. Gregoriadis
Medical applications of liposome-entrapped enzymes
Methods in Enzymology (K. Mosbach, ed.) Vol. 44, pp 698-709, Academic Press, New York, 1976
52. G. Dapergolas and G. Gregoriadis
Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats
Lancet II: 824-827, 1976
53. G. Gregoriadis
The drug-carrier potential of liposomes in cancer chemotherapy
In: "Chemotherapy" (edited by K. Hellman and T.A. Connors), vol. 7, pp 75-83
Plenum Publishing Company, New York and London, 1976
54. E.D. Neerunjun and G. Gregoriadis
Tumour regression with liposome-entrapped asparaginase. Some immunological advantages
Biochem.Soc.Trans. 4:133-134, 1976
55. A.W. Segal, G. Gregoriadis, J.P. Lavender, D. Tarin and T.J. Peters

Tissue and hepatic subcellular distribution of liposomes containing bleomycin
Clin.Sci.Mol.Med. 51:421-425, 1976

56. G. Gregoriadis
The role of sialic acid in the catabolism of plasma glycoproteins
In: "Structure and Function of Plasma Proteins" (A.C. Allison, ed.) vol.2, pp. 145-162
Plenum Press, New York and London, 1976

57. G. Dapergolas, E.D. Neerunjun and G. Gregoriadis
Penetration of target areas in the rat by liposome-associated bleomycin, glucose oxidase and insulin
FEBS Lett. 63:235-239, 1976

58. G. Gregoriadis
The carrier potential of liposomes in biology and medicine
New Engl.J.Med. (Medical Progress article) 295, 704-710, 1976

59. G. Gregoriadis
The carrier potential of liposomes in Biology and Medicine
New Engl.J.Med. (Medical Progress article) 295, 765-770, 1976

60. G. Gregoriadis
Liposome-entrapped proteins in therapeutic and preventive medicine
Hind.Antibiot.Bull. 20:14-22, 1977

61. P.E. Belchetz, I.P. Braidman, J.C.W. Crawley and G. Gregoriadis
Treatment of Gaucher's disease with liposome-entrapped glucocerebrosidase: β -glucosidase
Lancet ii: 116-117, 1977

62. G. Gregoriadis, P.J. Davisson and S. Scott
Binding of drugs onto liposome-entrapped macromolecules prevents diffusion of drugs from liposomes in vitro and in vivo
Biochem.Soc.Trans. 5:1323-1326, 1977

63. G. Gregoriadis
Oral therapy with insulin
"Balance", October 1977

64. G. Gregoriadis, N. Siliprandi and E. Turchetto
Possible implications in the use of exogenous phospholipids
Life Sciences (Minireview) 20:1773-1786, 1977

65. E. Neerunjun, G. Gregoriadis and Ruth Hunt
Fate of a liposome-associated agent injected into normal and tumour-bearing rodents.
Attempts to improve localization in tumour tissues

Biochem.Soc.Trans. 5:1380-1383, 1977

66. G. Gregoriadis, D.E. Neerunjun and R. Hunt
Fate of a liposome-associated agent injected into normal and tumour-bearing rodents.
Attempts to improve localization in tumour tissues
Life Sciences, 21:357-370, 1977

67. G. Dapergolas and G. Gregoriadis
The effect of liposomal lipid composition on the fate and effect of liposome-entrapped
insulin and tubocurarine given intragastrically into rats
Biochem.Soc.Trans. 5:1383-1386, 1977

68. G. Gregoriadis
Targeting of drugs (review article)
Nature (London) 265:407-411, 1977

69. G. Deliconstantinos, G. Gregoriadis, G. Abel, M. Jones and D. Robertson
Incorporation of cis-dichlorobiscyclopentylamine platinum (II) in liposomes
Biochem.Soc.Trans. 5:1326-1328, 1977

70. G. Gregoriadis
Liposomes as carriers of enzymes and proteins in medicine
In: "Biomedical Applications of Immobilized Enzymes and Proteins" (T.M.S. Chang,
ed.), vol. 4, pp 191-218, Plenum Press, New York and London, 1977

71. I.P. Braidman and G. Gregoriadis
Rapid purification of placental glucocerebroside: β -glucosidase and its entrapment in
liposomes
Biochem.J. 164:439-445, 1977

72. G. Gregoriadis
Liposomes in Biology and Medicine
Nature 271:112-113, 1978

73. G. Gregoriadis
Liposomes in the treatment of lysosomal storage diseases
Nature 275:695-696, 1978

74. P. Bonventre and G. Gregoriadis
Killing of intraphagocytic Staph.Aureus by dihydrostreptomycin entrapped in liposomes
Antimicrobial Agents and Chemotherapy 13:1049-1-51, 1978

75. D.H. Wreschner, G. Gregoriadis, D.B. Gunner and R.R. Dourmashkin
Entrapment of mRNA into large monolamellar liposomes derived from hybrid small
monolamellar liposomes
Biochem.Soc.Trans. 6:930-933, 1978

76. D.H. Wreschner and G. Gregoriadis
Formation of hybrid liposomes from negatively and positively charged liposomes: A possible model for the study of membrane fusion
Biochem.Soc.Trans. 6:922-925, 1978
77. G. Gregoriadis
Liposomes in therapeutic and preventive medicine: The development of the drug carrier concept
Ann.N.Y.Acad.Sci. 308:343-370, 1978
78. G. Gregoriadis
Liposomes as carriers of proteins: Possible medical applications
In: "Enzyme Engineering" (eds. G.B. Brown, G. Manecke and L.B. Wingard Jr.) vol. 4, pp. 187-192, Plenum Press, New York and London, 1978
79. G. Gregoriadis
Liposomes: European Research
Science 201:211-213, 1978
80. G. Gregoriadis
Liposomes as carriers of enzymes and other proteins in medicine
J.Appl.Chem.Biotechnol. 28:218-219, 1978
81. C.V. Lemonias and G. Gregoriadis
Uptake of liposome-entrapped agents by the trypanosome Crithidia fasciculata
Biochem.Soc.Trans. 6:1241-1244, 1978
82. E.K. Manesis, C.H. Cameron and G. Gregoriadis
Incorporation of hepatitis-B surface antigen (HB_sAg) into liposomes
Biochem.Soc.Trans. 6:925-928, 1978
83. G. Gregoriadis and C. Davis
Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells
Biochem.Biophys.Res.Comm. 89:1287-1293, 1979
84. C. Davis and G. Gregoriadis
The effect of lipid composition of liposomes on their stability in vivo
Biochem.Soc.Trans. 7:680-682, 1979
85. G. Gregoriadis
Liposomes
In: "Drug Carriers in Biology and Medicine" (G. Gregoriadis, ed.) Academic Press, London, pp. 287-341, 1979

86. E.K. Manesis, C.H. Cameron and G. Gregoriadis
Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen
FEBS Lett. 102:107-111, 1979
87. G. Gregoriadis and M.F. Dean
Enzyme therapy in Genetic Diseases
Nature 278, 603-604, 1979
88. E.K. Manesis, C.H. Cameron and G. Gregoriadis
Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen
Biochem.Soc.Trans. 7:678-680, 1979
89. G. Gregoriadis, E.D. Neerunjun, T.W. Meade and G.M. Bull
Experiences after long-term treatment of an adult Gaucher's disease patient with liposome-entrapped glucocerebroside: β -glucoside
In: Enzyme Therapy in Genetic Diseases, vol. XVI, Birth Defects: Original article series pp. 383-392, 1980
90. G. Gregoriadis
Tailoring liposome structure
Nature 283, 814-815, 1980
91. C. Kirby, J. Clarke and G. Gregoriadis
Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum
FEBS Lett. 111:324-328, 1980
92. G. Gregoriadis
Targeting of drugs: possibilities in viral chemotherapy and prophylaxis
Pharmacology and Therapeutics 10:103-118, 1980
93. G. Gregoriadis and E.K. Manesis
Liposomes as immunological adjuvants for hepatitis B surface antigens
In Liposomes and Immunobiology (eds. B. Tom, E. Six)
Elsevier North-Holland, Inc. ppl 271-283, 1980
94. C. Kirby, J. Clarke and G. Gregoriadis
Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro
Biochem.J. 186:591-598, 1980
95. G. Gregoriadis
Liposomes in drug targeting
in Transfer of Cell Constituent into Eucaryotic cells

(eds. J.E. Cells, A. Grasesmann and A. Loyter) NATO Advanced Study Institute Series, pp. 173-199, Plenum Press, 1980

96. G. Gregoriadis

The liposome drug-carrier concept. Its development and future

In: "Liposomes in Biological Systems" (G. Gregoriadis and A.C. Allison, eds.). Wiley Publishing Company, pp. 25-86, 1980

97. G. Gregoriadis

Recent progress in liposome research

In Liposomes in Biological Systems

(eds. G. Gregoriadis and A.C. Allison) Wiley Publishing Company, pp. 377-398, 1980

98. G. Gregoriadis and J. Senior

The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation

FEBS Lett. 119:43-46, 1980

99. C. Kirby and G. Gregoriadis

The effect of the cholesterol content of small unilamellar liposomes on the fate of their lipid components in vivo

Life Sciences 27: 2223-2230, 1980

100. G. Gregoriadis, C. Kirby, E.K. Manesis, J. Clarke, C. Davis and E.D. Neerunjun
Liposomes: Interaction with the biological milieu and implications for their use in biology and medicine

In Cell biological aspects of disease: the plasma-membrane and lysosomes (ed. E.Th. Daems) Martinus Nijhoff Publishers, pp. 259-280, 1981

101. G. Gregoriadis

Liposomes: A role in vaccines?

Clinical Immunology Newsletter 2:33-36, 1981

102. C. Kirby and G. Gregoriadis

Plasma-induced release of solutes from small unilamellar liposomes is associated with pore formation in the bilayers

Biochem.J. 199:251-254, 1981

103. G. Gregoriadis

Targeting of Drugs: Implications in Medicine

The Lancet 2:241-247, 1981

104. G. Gregoriadis

Liposomes: Molecular Trojan Horses?

Mims Magazine, 15th June 1981

105. G. Gregoriadis, A. Meehan and M.M. Mah
Interaction of antibody-bearing small unilamellar liposomes with target free antigen in vitro and in vivo: Some influencing factors
Biochem.J. 200:203-210, 1981
106. G. Gregoriadis and A. Meehan
Interaction of antibody-bearing small unilamellar liposomes with antigen-coated cells: the effect of antibody and antigen concentration on the liposomal and cell surface respectively
Biochem.J. 200:211-216, 1981
107. G. Gregoriadis, C. Kirby, A. Meehan and J. Senior
Targeting of liposomes. Some prerequisites for success
in: Liposomes drugs and immunocompetent cell functions (C. Nicolau and A. Paraf, eds.) Academic Press, pp. 29-51, 1981
108. G. Gregoriadis, C. Kirby and J. Senior
Targeting of drugs with liposomes: Studies on optimization.
In: Optimization of Drug Delivery; Alfred Benson Symposium 17 (H.Bundgaard, A. Bagger-Hansen and H. Kofod, eds.) Munksgaard, Copenhagen, pp. 365-383, 1982
109. H. Weeraratne, G. Gregoriadis, H. Blair and P. Purkiss
Liposomes and Gaucher's disease type I.
In: Advances in the Treatment of Inborn Errors of Metabolism (M.d'A Crawford, D.A. Gibbs and R.W.E. Watts eds.). J.Wiley and Sons, Chichester, New York, pp. 143-159, 1982
110. G. Gregoriadis, C. Kirby and J. Senior
Liposomes as drug carriers.
In Topics in Pharmaceutical Sciences (D.D. Breimer and P. Speiser, eds.) Elsevier, pp. 175-190, 1981
111. J. Senior and G. Gregoriadis
Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components
Life Sciences 30:2123-2136, 1982
112. G. Gregoriadis, C. Kirby, P. Large, A. Meehan and J. Senior
Targeting of liposomes: Study of influencing factors.
Targeting of Drugs (G. Gregoriadis, J. Senior, A. Trouet, eds.) Plenum, New York, 155-184, 1982
113. G. Gregoriadis, H. Weeraratne, H. Blair and G.M. Bull
Liposomes in Gaucher type I disease: use in therapy and the creation of an animal model
In: Gaucher's Disease The most Prevalent Jewish Genetic Disease (R.J. Desnik, ed.) Alan R. Liss, Inc. pp.681-701, 1982

114. G. Gregoriadis
Use of monoclonal antibodies and liposomes to improve drug delivery: Present status and future implications (leading article)
Drugs, **24**:261-266, 1982
115. J. Senior and G. Gregoriadis
Is half-life of circulating small unilamellar liposomes determined by changes in their permeability?
FEBS Lett **145**:109-114, 1982
116. G. Gregoriadis and J. Senior
Control of fate and behaviour of liposomes in vivo
In: Cell Function and Differentiation Part A, pp. 263-279, Alan R.Liss, Inc., New York, 1982
117. G. Gregoriadis
Liposomes in haematology: tools for research and clinical application
In: Proceedings of 19th International Congress of Haematology, Plenary lecture) pp. 373-382, 1982
118. G. Gregoriadis
Liposomes as drug carriers
Pharmacy International **4**:33-37, 1983
119. C. Kirby and G. Gregoriadis
The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice
Biochem.Pharmacol., **32**:609-615, 1983
120. G. Gregoriadis
Targeting of drugs with molecules, cells and liposomes
Trends in Pharmacological Sciences **4**:304-307, 1983
121. P. Large and G. Gregoriadis
Phospholipid composition of small unilamellar liposomes containing melphalan influences drug action in mice bearing PC6 tumours
Biochem.Pharmacol **32**:1315-1318, 1983
122. G. Gregoriadis
Liposomes as a drug delivery system
In: Better Protection of Pharmaceutical Innovation: Key to New Drugs G. Cahn, ed.) John Libbey, London 1983, pp.197-203
123. G. Gregoriadis, C. Kirby and J. Senior
Optimization of liposome behaviour in vivo

Biol.Cell. 47:11-18, 1983

124. G. Gregoriadis

Drug Targeting

In: Chemotherapeutic Strategy (D.I. Edwards and D.R. Hiscock, eds.) The Macmillan Press Ltd, pp.211-221, 1983

125. A. Tumer, C. Kirby, J. Senior and G. Gregoriadis

Fate of cholesterol-rich unilamellar liposomes containing ¹¹¹Inlabelled bleomycin after subcutaneous injection into rats

Biochim.Biophys.Acta 760:119-125, 1983

126. J. Senior, G. Gregoriadis and K. Mitropoulos

Stability and clearance of small unilamellar liposomes: Studies with normal and lipoprotein-deficient mice

Biochem.Biophys.Acta 760:111-118, 1983

127. H. Weeraratne, G. Gregoriadis and J. Crow

Toxicity of sphingomyelin-containing liposomes after chronic injection into mice

Br.J.Exp.Path 64:670-676, 1983

128. G. Gregoriadis

How liposomes influenced my life and got away with it

In: Liposome Letters (A.D. Bangham, ed.) Academic Press, 1983, pp.405-407

129. C. Kirby and G. Gregoriadis

A simple novel method for efficient drug entrapment in liposomes

In: Liposome Technology (G. Gregoriadis, ed.) CRC Press Inc. vol.I, 1984, pp.19-28

130. C. Kirby and G. Gregoriadis

Incorporation of Factor VIII into liposomes

In: Liposome Technology (G. Gregoriadis, ed.) CRC Press Inc. vol.II, 1984, pp.69-82

131. J. Senior and G. Gregoriadis

Methodology in assessing liposomal stability in the presence of blood, clearance from the circulation of injected animals and uptake by tissues

In: Liposome Technology (G. Gregoriadis, ed.) CRC Press Inc. vol.III, 1984, pp.262-282

132. J. Senior and G. Gregoriadis

Role of lipoproteins in stability and clearance of liposomes administered to mice

Biochem.Soc.Trans 12:339-340, 1984

133. G. Gregoriadis and J. Senior

Targeting of small unilamellar liposomes to the galactose receptor in vivo

Biochem.Soc.Trans 12:337-339, 1984

134. C. Kirby and G. Gregoriadis
Preparation of liposomes containing Factor VIII for oral treatment of haemophilia
J.Microencapsulation 1:33-45, 1984
135. G. Gregoriadis
Controlled drug delivery: Old drugs in new clothing
Nature 32:186-187, 1984
136. B. Wolff and G. Gregoriadis
The use of monoclonal anti-Thy₁ IgG₁ for the targeting of liposomes to AKR-A cells in vitro and in vivo
Biochim.Biophys.Acta 802:259-273, 1984
137. C. Kirby and G. Gregoriadis
Dehydration-rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes
Biotechnology, 2:979-984, 1984
138. G. Gregoriadis, J. Senior, B. Wolff and C. Kirby
Fate of liposomes in vivo: control leading to targeting
In: Receptor-Mediated Targeting of Drugs (G. Gregoriadis, G. Poste, J. Senior and A. Trouet, eds.) Plenum, pp.243-266, 1984
139. G. Gregoriadis, J. Senior, B. Wolff and C. Kirby
Targeting of liposomes to accessible cells in vivo
Ann.N.Y.Acad.Sci., 446:319-340, 1985
140. J. Senior, J.C.W. Crawley and G. Gregoriadis
Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection
Biochim.Biophys.Acta 839:1-8, 1985
141. G. Gregoriadis
Use of liposomes as a drug delivery system
In: Comprehensive Biotechnology, (C.L. Cooney and A.G. Humphrey eds.) Pergamon Press, pp. 17-30, 1985
142. G. Gregoriadis and J. Senior
Liposomes as drug carriers: Conditions for in-vivo targeting
American Chemical Society, Symposium on Drug Targeting 1984
143. G. Gregoriadis
Liposomes as carriers for drugs and vaccines
Trends in Biotechnology, 3:235-241, 1985
144. G. Gregoriadis and J. Senior
Fate of liposomes in vivo
In: Targeting of Drugs with Synthetic Systems, (G. Gregoriadis, G. Poste, J. Senior and A. Trouet, eds.) Plenum, pp. 183-192, 1986

145. G. Gregoriadis, J. Senior and B. Wolff
Liposomal stability in and clearance from the blood: Optimization leading to targeting in vivo
In: Medical Applications of Liposomes (K. Yagi and Y. Nozanda, eds.) Japan Scientific Societies Press, Karger, Tokyo, pp.67-79, 1986
146. G. Gregoriadis, J. Senior and B. Wolff
Liposomes in drug targeting
In: Microinjection and Organelle Transplantation Techniques: Methods and Applications (eds. J.E. Celis, A. Graessman and A. Loyter) Academic Press, pp. 135-155, 1986
147. J. Senior, J.A. Waters and G. Gregoriadis
Antibody-coated liposomes: The role of non-specific antibody adsorption
FEBS Lett., 196:54-58, 1986
148. G. Gregoriadis
Liposomal subunit vaccine against Epstein-Barr virus-induced malignant lymphoma
Nature, 320:87-88, 1986
149. N. Garcon, J. Senior and G. Gregoriadis
Coupling of ligands to liposomes before entrapment of agents sensitive to coupling procedures
Biochem.Soc.Trans., 14:1038-1039, 1986
150. D. Davis, A. Davies and G. Gregoriadis
Liposomes as immunological adjuvants in vaccines: Studies with entrapped and surface-linked antigen
Biochem.Soc.Trans., 14:1036-1037, 1986
151. J.R. Behari, Z. Varghese and G. Gregoriadis
Use of liposome-entrapped diethylene-triamine pentaacetic acid in the treatment of mice loaded with cadmium
Biochem.Soc.Trans., 14:1197-1198, 1986
152. G. Gregoriadis, D. Davis and A. Davies
Liposomes as immunological adjuvants: Antigen incorporation studies
Vaccine, 5:143-149, 1987
153. D. Davis, A. Davies and G. Gregoriadis
Liposomes as adjuvants with immunopurified tetanus toxoid: The immune response
Immunology Letters, 14:341-348, 1987
154. D. Davis and G. Gregoriadis
Liposomes as adjuvants with immunopurified tetanus toxoid: Influence of liposomal characteristics
Immunology, 61:229-234, 1987

155. G. Gregoriadis
Encapsulation of enzymes and other agents in liposomes
In: Chemical Aspects of Food Enzymes (A.T. Andrews, ed.), Royal Society of Chemistry, London, pp. 94-105, 1987
156. S. Seltzer, G. Gregoriadis and R. Dick
Evaluation of the dehydration-rehydration method for production of contrast-carrying liposomes
Invest.Radiology, 23:131-138, 1988
157. G. Gregoriadis
Fate of injected liposomes: Observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo
In: "Liposomes as Drug Carriers: Recent Trends and Progress" (G. Gregoriadis, ed.), J. Wiley and Sons Ltd, Chichester, pp. 3-18, 1988
158. G. Gregoriadis, N. Garcon, J. Senior and D. Davis
The immunoadjuvant action of liposomes: Nature of immune response and influence of liposomal characteristics
In: "Liposomes as Drug Carriers: Recent Trends and Progress" (G. Gregoriadis, ed.), J. Wiley and Sons Ltd, Chichester, pp. 279-307, 1988
159. G. Gregoriadis
Liposomes as immunological adjuvants in vaccines: The immune response and the effect of liposomal structural characteristics
In: Biomembranes: Basic and Medical Research (Gh. Benga and J.M. Tager, eds.) Springer Verlag, New York, pp.50-60, 1988
160. G. Gregoriadis
Liposomes as immunological adjuvants: Optimization strategies
In: "Targeting of Drugs: Anatomical and Physiological Considerations" (G. Gregoriadis and G. Poste, eds.) Plenum Publishing Co., pp. 153-165, 1988
161. N. Garcon, G. Gregoriadis, M. Taylor and J. Summerfield
Targeted immunoadjuvant action of tetanus toxoid-containing liposomes coated with mannosylated albumin
Immunology, 64:743-745, 1988
162. G. Gregoriadis
The immunoadjuvant action of liposomes
European Adjuvant Group Newsletters, 4:3-21, 1988
163. G. Gregoriadis
Immunological Adjuvants and Vaccines
Drug News and Perspectives, 1:358-359, 1988
164. H.G. Eichler, J. Senior, A. Stadler, S. Gasic, P. Pfunder and G. Gregoriadis
Kinetics and disposition of fluorescein-labelled liposomes in healthy subjects

Eur.J.Clin.Pharmacology, 34:475-479, 1988

165. G. Gregoriadis

Liposomes as a drug delivery system: Optimization Studies.

In: *Biotechnological Applications of Lipid Microspherules* (J.A. Hayward and D. Chapman, eds.) Plenum Press, pp. 151-159, 1988

166. G. Gregoriadis

Liposomes as carriers of drugs: Observations on vesicle fate in vivo and its control.

In: *"Artificial and Reconstituted Systems"* (J.R. Harris and A.H. Etenadi, eds.) Plenum, New York, pp.363-378, 1989

167. J. Senior, G. Gregoriadis, Y. Pathak, D. Muller and N. McIntyre

Oral administration of liposome-incorporated liposoluble vitamins to bile-obstructed rats
Biochem.Soc.Trans., 17:121-122, 1989

168. G. Gregoriadis, V. Weissig, L. Tan, Q. Xiao and J. Lasch

A novel method for the covalent coupling of peptides and sugars to liposomes

Biochem.Soc.Trans., 17:128-129, 1989

169. L. Tan, A. Loyter and G. Gregoriadis

Incorporation of reconstituted influenza virus envelopes into liposomes: Studies of immune response in mice

Biochem.Soc.Trans., 17:129-130, 1989

170. G. Gregoriadis, D. Davis, N. Garcon, L. Tan, V. Weissig and Q. Xiao

Liposomes as immunological adjuvants.

In: *Liposomes in the Therapy of Infectious Diseases and Cancer* (G. Lopez-Berenstein and I. Fidler, eds.) Alan R. Liss, Inc., New York, pp. 35-56, 1989

171. G. Gregoriadis

Targeting of Drugs: Implications in Medicine (leader article)

In: *"Drug Carrier Systems"* (F.H. Roerdink and A. Kroon, eds.), J. Wiley and Sons Ltd., Chichester, pp. 1-31, 1989

172. L. Tan and G. Gregoriadis

The effect of positive surface charge of liposomes on their clearance from blood and its relation to vesicle lipid composition

Biochem.Soc.Trans., 17:690-691, 1989

173. Q. Xiao, G. Gregoriadis and M. Ferguson

Immunoadjuvant action of liposomes for entrapped poliovirus peptides

Biochem.Soc.Trans., 17:695, 1989

174. L. Tan and G. Gregoriadis

The effect of interleukin-2 on the immunoadjuvant action of liposomes

Biochem.Soc.Trans., 17:693-694, 1989

175. G. Gregoriadis and C. Panagiotidi
Immunoadjuvant action of liposomes: Comparison with other adjuvants
Immunology Letters, 20:237-240, 1989
176. J. Senior and G. Gregoriadis
Dehydration-rehydration vesicle methodology facilitates a novel approach to antibody binding to liposomes
Biochim.Biophys.Acta, 1003:58-62, 1989
177. V. Weissig, J. Lasch and G. Gregoriadis
Covalent coupling of sugars to liposomes
Biochim.Biophys.Acta, 1003:54-57, 1989
178. K.L. Kahl, C.A. Scott, R. Lelchuk, G. Gregoriadis and F.Y. Liew
Vaccination against murine cutaneous leishmaniasis using L.Major antigen/liposomes: Optimization and assessment of the requirement for intravenous immunization
J.Immunology, 142:4441-4449, 1989
179. D. Davis and G. Gregoriadis
Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators
Immunology, 68:277-282, 1989
180. G. Gregoriadis, Q. Xiao and L. Tan
The immunoadjuvant action of liposomes: Recent Progress
In: Immunological Adjuvants and Vaccines (G. Gregoriadis, A.C. Allison and G. Poste, eds.), Plenum, pp. 79-94, 1989
181. G. Gregoriadis
The physiology of the liposome
News in Physiological Sciences, 4:146-151, 1989
182. G. Gregoriadis
Biological behaviour of liposomes.
In: "Phospholipids: Biological, Pharmaceutical and Analytical Considerations" (G. Pepeu and I. Hanin, eds.), Plenum, pp. 123-132, 1990
183. G. Gregoriadis
Immunological adjuvants: A role for liposomes (Review)
Immunology Today, 11:89-97, 1990
184. A.C. Allison and G. Gregoriadis
Vaccines: Recent Trends and Progress
Immunology Today, 11:427-429, 1990
185. L. Tan and G. Gregoriadis
A simple method for coating liposomes with protein
Annals Academy of Medicine, Singapore, 19:827-830, 1990
186. G. Gregoriadis, H. da Silva and A.T. Florence

A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes (DRV)

Int.J.Pharmaceutics, 65:235-242, 1990

187. V. Weissig, J. Lasch and G. Gregoriadis
Kovalente Bindung von Peptiden on liposomale Oberflächen
Pharmazie, 45:849-850, 1990

188. G. Gregoriadis
Liposomes: Structure and potential for drug delivery, in: "Recenti Acquisizioni del Rilascio Direzioneamento e Somministrazione di Farmaci". Published by Divisione di Chimica Farmaceutica Societa Chimica Italiana, pp 199-221, 1990

189. V. Weissig, J. Lasch and G. Gregoriadis
A method for the preparation of liposomes with encapsulated peptide antigens and surface-linked sugar residues
Pharmazie, 46:56-57, 1991

190. J.H. Senior, C. Delgado, D. Fisher, C. Tilcock and G. Gregoriadis
Influence of surface hydrophilicity of liposomes on their interaction with plasma proteins and clearance from the circulation: Studies with polyethylene glycol-coated vesicles
Biochim.Biophys.Acta, 1062:77-82, 1991

191. G. Gregoriadis
NATO ASI: Vaccines: Recent Trends and Progress
Drugs News and Perspectives, 4:42-45, 1991

192. G. Gregoriadis and A.T. Florence
Liposomes and cancer therapy
Cancer Cells, 4:144-146, 1991

193. A.T. Florence and G. Gregoriadis
Targeting peptides and proteins
Trends in Biotechnology, 9:295-297, 1991

194. G. Gregoriadis
Overview of liposomes
J.Antimicrob.Chemother., 28: (Suppl. B): 39-48, 1991

195. L. Tan and G. Gregoriadis
A novel positively charged lipid 1,2-bis (hexadecylcycloxy)-3-trimethyl aminopropane (bishop) enhances the adjuvant effect of liposomes on encapsulated tetanus toxoid
A.P.J. Allergy Immunology, 9:21-24, 1991

196. L. Tan, V. Weissig and G. Gregoriadis
Comparison of the immune responses against polio peptides covalently and surface-linked to and internally entrapped in liposomes
A.P.J. Allergy Immunology, 9:25-30, 1991

197. J.R. Behari and G. Gregoriadis
A comparative study of free and liposome-entrapped DTPA used in the treatment of mice loaded with cadmium
Int.J.Pharmaceutics, 79:213-221, 1991
198. G. Gregoriadis
Liposomes as immunological adjuvants: Approaches to immunopotentiality including ligand-mediated targeting to macrophages
Res.Immunology, 143:178-185 and 245-246, 1992
199. C.A.W. Bate, J. Taverne, H.Z. Bootsma, R.C.St.H. Mason, N. Skalko, G. Gregoriadis and J.H.L. Playfair
Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit TNF induction by malaria exoantigens, Immunology, 76:34-41, 1992
200. G. Gregoriadis, L. Tan, E.T.S. Ben Ahmeida and R. Jennings
Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 surface antigens
Vaccine, 10:747-753, 1992
201. G. Gregoriadis
Liposomes in drug delivery: Present and future
in: Liposome Dermatics (eds. O. Braun-Falco, H.C. Korting and H.I. Maibach) Springer, Heidelberg, pp. 346-352, 1992
202. G. Gregoriadis
Liposomes as immunoadjuvants for peptide and protein antigens
in: Targeting of Drugs: The Challenge of Peptides and Proteins, (eds. G. Gregoriadis, A.T. Florence and G. Poste), Plenum, New York, pp. 59-68, 1992
203. M. Brandl and G. Gregoriadis
Hemoglobin-Liposomen: Darstellung, Charakterisierung und in vivo Verhalten eines sauren stofftransportierenden Blutersatzstoffes, Archiv.Pharmazie, 336:627, 1992
204. G. Gregoriadis
Liposomes in drug delivery: Structure, behaviour in vivo and applications,
J.Appl.Cosmetology, 10:61-64, 1992
205. C. Tilcock, J. Senior, C. Delgado, D. Fisher and G. Gregoriadis
Partitioning of liposomes in aqueous two-phase systems
in: Liposome Technology (2nd Edition) vol. 1, (ed. G. Gregoriadis) CRC Press Inc., Florida, pp. 291-314, 1993
206. V. Weissig and G. Gregoriadis
Coupling of amino group-bearing ligands to liposomes
in: Liposome Technology (2nd Edition) vol.3, (ed. G. Gregoriadis) CRC Press Inc., Florida, pp.231-248, 1993

207. G. Gregoriadis and A.T. Florence
Efficient entrapment of solutes in small liposomes prepared by microfluidization
in: Liposome Technology (2nd Edition) vol. 1, (ed. G. Gregoriadis) CRC Press Inc.,
Florida, pp. 37-48, 1993
208. G. Gregoriadis
Liposomes as immunoadjuvants for protein and peptide antigens
in: Liposomes in Drug Delivery (eds. G. Gregoriadis, A.T. Florence and H. Patel)
pp. 77-94, Harwood Academic Publishers, Reading, 1993
209. G. Gregoriadis and A.T. Florence
Liposomal drug delivery systems: Clinical, diagnostic and ophthalmic applications
Drugs, 45:15-28, 1993
210. D. Bachmann, M. Brandl and G. Gregoriadis
Preparation of liposomes using a Mini-Lab 8.30 H high-pressure homogenizer
Int.J.Pharmaceutics, 91:69-74, 1993
211. G. Gregoriadis, B. McCormack, Z. Wang and R. Lively
Polysialic acids: Potential in drug delivery
FEBS Lett., 315:271-276, 1993
212. G. Gregoriadis, N. Garcon, H. da Silva and B. Sternberg
Coupling of ligands to liposomes independently of solute entrapment: Observations on
the formed vesicles
Biochim.Biophys.Acta, 1147:185-193, 1993
213. G. Gregoriadis
Liposomes: A tale in drug targeting
J.Drug Targeting, 1:3-6, 1993
214. E.T.S. Ben Ahmeida, R. Jennings, L. Tan, G. Gregoriadis and C.W. Potter
The subclass IgG responses of mice to influenza surface proteins formulated into
liposomes
Antiviral Research, 21:217-232, 1993
215. G. Gregoriadis, Z. Wang, Y. Barenholz and M.J. Francis
Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to
overcome genetic restriction in mice and induce immunological memory
Immunology, 80:535-540, 1993
216. S. Antimisariar, P. Jayasekera and G. Gregoriadis
Liposomes as vaccine carriers: Incorporation of soluble and particulate antigens in giant
vesicles
J.Immunol.Meth., 166:271-280, 1993
217. V. Kirilenko and G. Gregoriadis
Fat soluble vitamins in liposomes: Studies on incorporation efficiency and bile salt
induced vesicle disintegration

J. Drug Targeting, 1:361-368, 1993

218. G. Gregoriadis and B. McCormack

Liposomes and polysialic acids in drug delivery

In: Encapsulation and Controlled Release, (eds. D.R. Karsa and R.A. Stephenson) pp. 75-85, Royal Society of Chemistry, Cambridge 1993

219. G. Gregoriadis, Z. Wang and M. Francis

Co-entrapment of T-cell and B-cell peptides in liposomes overcomes genetic restriction in mice and induces immunological memory

in: New-Generation Vaccines: The Role of Basic Immunology (eds. G. Gregoriadis, B. McCormack, A.C. Allison and G. Poste), Plenum, New York, pp. 43-49, 1993

220. G. Gregoriadis and A.T. Florence

Recent advances in drug targeting

Trends in Biotechnology, 11:440-442, 1993

221. E.T.S. Ben Ahmeida, G. Gregoriadis, C.W. Potter and R. Jennings

Immunopotential of local and systemic humoral immune responses by ISCOMS, liposomes and FCA: a role in protection against influenza A in mice

Vaccine, 11:1302-1309, 1993

222. G. Gregoriadis

Literature in Review

Pharmacy Spectrum, 2:7, 1993

223. G. Gregoriadis

Liposomes and anti-ageing creams: The facts beneath the face

The Biochemist, 16 (1): 8-11, 1994

224. E.T.S. Ben Ahmeida, C.W., Potter, G. Gregoriadis, C. Adithan and R. Jennings

IgG subclass response and protection against challenge following immunization of mice with various influenza A vaccines

J. Mol. Microbiol., 40:261-269, 1994

225. G. Gregoriadis

Liposomes as immunoadjuvants and vaccine carriers: Antigen entrapment

Immunomethods, 4:210-216, 1994

226. B. McCormack and G. Gregoriadis

Entrapment of cyclodextrin-drug complexes into liposomes. Potential advantages in drug delivery

J. Drug Targeting, 2:449-454, 1994

227. G. Gregoriadis

The immunological adjuvant and vaccine carrier properties of liposomes

J. Drug Targeting, 2:351-356, 1994

228. G. Gregoriadis

Liposomes in Drug Targeting

In: "Cell Biology: A laboratory Handbook", (ed. J.E. Cellis), Academic Press, Orlando, vol 3, pp. 58-66, 1994

229. G. Gregoriadis

Editorial

J.Drug Targeting, 2:349, 1994

230. B. McCormack and G. Gregoriadis

Drugs-in-cyclodextrins-in liposomes: A novel concept in drug delivery

Int.J.Pharmaceutics, 112:249-258, 1994

231. G. Gregoriadis

Liposomes as immunological adjuvants

In: "The Theory and Practical Application of Adjuvants" (ed. D.E.S. Stewart-Tull) pp 145-169, John Wiley and Sons Ltd, Chichester, 1994

232. M. Brandl and G. Gregoriadis

Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: Vesicle characterization and in vivo behaviour

Biochim.Biophys.Acta, 1196:65-75, 1994

233. G. Gregoriadis

Liposomes in vivo: Control of behaviour

In: "Targeting of Drugs: Advances in System Constructs" (eds. G. Gregoriadis, B. McCormack and G. Poste), pp. 113-118, 1994, Plenum, New York

234. B. McCormack and G. Gregoriadis

Polysialic acids: In vivo properties and possible uses

In: "Targeting of Drugs: Advances in System Constructs" (eds. G. Gregoriadis, B. McCormack and G. Poste), pp 139-145, 1994, Plenum, New York

235. G. Gregoriadis and B. McCormack

Drugs-in-cyclodextrins-in liposomes: A novel concept in drug delivery Proceed.Intern. Symp.Control.Rel.Bioact.Mater., 21: 89-90, 1994

236. Y. Loukas, P. Jayasekera and G. Gregoriadis

Novel liposome-based multicomponent systems for the protection of photolabile agents

Int.J.Pharmaceutics, 112:85-94, 1995

237. T. Yoshioka, N. Skalko, M. Gursel, G. Gregoriadis and A.T. Florence

A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: Potential uses in drug and vaccine delivery

J.Drug Targeting, 2:533-539, 1995

238. G. Gregoriadis

Preface

In: Liposomes: New Systems and New Trends in their Applications (eds. F. Puisieux, P. Couvreur, J. Delattre and J.P. Devissagnet), Editions de Santé, Paris, pp. 5-6, 1995

239. G. Gregoriadis
Liposomes as immunological adjuvants for protein and peptide vaccines
In: "Liposomes in Biomedical Applications" (ed. P. Shek), Harwood Academic Publishers, Chur, pp. 1-18, 1995
240. G. Gregoriadis
Fate of liposomes in vivo and its control: A Historical Perspective
In: "Stealth Liposomes" (eds. L. Lasic and F. Martin), CRC Press Inc., Boca Raton, pp. 7-12, 1995
241. I. Gursel, S.G. Antimisiaris, P. Jayasekera, and G. Gregoriadis
Giant liposomes as potential vesicles for live or attenuated microbial vaccines
In: "Liposomes in Biomedical Applications" (ed. P. Shek), Harwood Academic Publishers, Chur, pp. 35-50, 1995
242. M. Gursel and G. Gregoriadis
Liposomal interleukin-2 as an immunological co-adjuvant
In: Vaccines: New-Generation Immunological adjuvants (eds. G. Gregoriadis, B. McCormack and A.C. Allison) Plenum Press, New York, pp. 45-50, 1995
243. G. Gregoriadis
The discriminating liposome, Incalibre, pp. 1-8, Oct 1995
244. B. McCormack and G. Gregoriadis
Drugs-in-cyclodextrins-in liposomes: Evaluation of the concept in vivo,
Proceed.Intern.Symp.Control.Rel.Bioact.Mater., 22, 190-191, 1995
245. V. Vraha, Y.L. Loukas and G. Gregoriadis
Solubilization of haloperidol with β -cyclodextrin derivatives in solution
Proceed.Intern.Symp.Control.Rel.Bioact.Mater., 22, 388- 389, 1995
246. Y.L. Loukas and G. Gregoriadis
Novel liposome based systems for the protection of photolabile drugs
Proceed.Intern.Symp.Control.Rel.Bioact.Mater., 22, 438-439, 1995
247. M. Gursel and G. Gregoriadis
Immunoadjuvant action of liposomes containing interleukin-2 as a co-adjuvant
Proceed.Intern.Symp.Control.Rel.Bioact.Mater., 22: 572-573, 1995
248. A.I. Fernandes and G. Gregoriadis
Polysialylated enzymes: A new species of therapeutic glycoproteins with improved properties
Proc.Intern.Symp.Control.Rel.Bioact.Mater., 22: 520-521, 1995

249. Y. Loukas, P. Jayasekera and G. Gregoriadis
Characterization and photoprotection studies of a model γ -cyclodextrin-included photolabile drug entrapped in liposomes incorporating light absorbers
J.Phys.Chem., 99:11035-11040, 1995
250. G. Gregoriadis
...Twinkling guide stars to throngs of acolytes
desirous of your membrane semi-barriers
Precursors of bion, potential drug carriers..."
J.Liposome Res., 5:329-346, 1995
251. G. Gregoriadis
Demetrios Papahadjopoulos: An encounter of the Greek kind
J.Liposome Res., 5:635-639, 1995
252. G. Gregoriadis
Engineering targeted liposomes: Progress and problems
Trends in Biotechnology, 13:527-537, 1995
253. M. Velinova, N. Read, C. Kirby and G. Gregoriadis
Morphological observations on the fate of liposomes in the regional lymph nodes after footpad injection into rats
Biochim.Biophys.Acta, 1299:207-215, 1996
254. A. Fernandes and G. Gregoriadis
Synthesis, characterization and properties of sialylated catalase
Biochim.Biophys.Acta, 1293:92-96, 1996
255. G. Gregoriadis
Liposomes for drug delivery: Progress and problems
Express Pharma Pulse, (Bombay), vol. 2, No. 8: 2, 1996
256. G. Gregoriadis
Liposomes for drug delivery: Therapeutic applications
Express Pharma Pulse, (Bombay) vol. 2. No. 9:2 and 10, 1996
257. G. Gregoriadis, I. Gursel and S. Antimisialis
Microbe entrapment in giant liposomes
In: "Non-Medical Applications of Liposomes", eds: D.D. Lasic and Y. Barenholz, CRC Press, Boca Raton, pp., 263-269, 1996
- 258 N. Skalko, J. Bouwstra, F. Spies and G. Gregoriadis
The effect of microfluidization of protein-coated liposomes on protein distribution on the surface of generated small vesicles
Biochim.Biophys.Acta, 1301:249-254, 1996

259. A. Young and G. Gregoriadis
Photolysis of retinol in methanol and liposomes and its protection with tocopherol and oxybenzone
Photochem.Photobiol., **63**:344-352, 1996
260. G. Gregoriadis, R. Saffie and S.L. Hart
High yield incorporation of plasmid DNA within liposomes: Effect on DNA integrity and transfection efficiency
J.Drug Targeting, **3**:469-475, 1996
261. G. Gregoriadis
Guest Editor's Introduction
J.Lipos.Res., **6**:281-287, 1996
262. S. Murdan, G. Gregoriadis and A.T. Florence
Non anionic surfactant-based organogels incorporating niosomes
S.T.P. Pharma Sciences, **6**:44-48, 1996
263. G. Gregoriadis, I. Gursel, M. Gursel and B. McCormack
Liposomes as immunological adjuvants for protein and peptide vaccines
J.Controlled.Release, **41**:49-56, 1996
264. B. McCormack and G. Gregoriadis
Comparative studies of the fate of free and liposome-entrapped hydroxypropyl- β -cyclodextrin/drug complexes after intravenous injection into rats: Implications in drug delivery
Biochim.Biophys.Acta, **1291**:237-244, 1996
265. Y. Loukas, V. Vraha and G. Gregoriadis
Use of a non-linear least-squares model for the kinetic determination of the stability constant of cyclodextrin inclusion complexes
Int.J.Pharmaceutics, **144**:225-231, 1996
266. Y. Loukas, V. Vraha and G. Gregoriadis
Entrapment of sodium ascorbate- α -cyclodextrin inclusion complex in multilamellar liposomes containing light absorbers, greatly increases the stability of the vitamin against photochemical oxidation
Pharmaceutical Sciences, **2**:523-527, 1996
267. G. Gregoriadis, R. Saffie and S.L. Hart
Efficient incorporation of plasmid DNA within liposomes of varying structural characteristics: Liposomal DNA integrity and transfection efficiency
in: Targeting of Drugs: Strategies for Oligonucleotide and Gene Delivery in Therapy
Plenum Press, New York, pp. 143-150, 1996

268. G. Gregoriadis
Liposomes as immunological adjuvants and carriers of vaccines
Vaccine, 14:671-672, 1996
269. Y. Loukas, V. Vraha and G. Gregoriadis
Fluorometric studies for the formation of riboflavin: β -cyclodextrin inclusion complex: Determination of the stability constant by using a nonlinear least-squares model
J.Pharm.Pharmacology, 49: 127-130, 1997
270. G. Gregoriadis, R. Saffie, and B. de Souza
Liposome-mediated DNA vaccination
FEBS Lett, 402:107-110, 1997
271. M. Gürsel and G. Gregoriadis
Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo
Immunology Letters, 55:161-165, 1997
272. G. Gregoriadis
Liposomes: From a laboratory curiosity to life-saving products
Express Pharma Pulse, 3(28): pp14-15, 1997
273. A. Fernandes, and G. Gregoriadis
Polysialylated asparaginase: preparation, activity and pharmacokinetics
Biochim.Biophys.Acta, 1341: 26-34, 1997
274. Y.L. Loukas, V. Vraha and G. Gregoriadis
Novel non-acidic formulations of haloperidol complexed with β -cyclodextrin derivatives
J.Pharmaceutical and Biomedical Analysis, 16: 263-268, 1997
275. M. Gürsel and G. Gregoriadis
The immunological co-adjuvant action of liposomal interleukin 15
in: Vaccine Design: The Role of Cytokine Networks
(eds G. Gregoriadis, B. McCormack and A.C. Allison), Plenum Press, New York, pp. 175-180, 1997
276. M. Gürsel and G. Gregoriadis
Interleukin-2 as a co-adjuvant for liposomal tetanus toxoid: The effect of cytokine and antigen mode of localization in the vesicles
J.Drug Targeting, 5:93-98, 1997
277. G. Gregoriadis, B. McCormack, Y. Morrison, R. Saffie and B. Zadi
Liposomes in Drug Targeting
in: Cell Biology: A Laboratory Handbook (Second Edition) (ed. J.E. Cellis), Academic Press, Orlando, vol 4, pp. 131-140, 1998

278. N. Škalko, J. Bouwstra, F. Spies, M. Stuart, P.M. Frederik, and G. Gregoriadis
Morphological observations on liposomes bearing covalently bound protein: Studies with freeze-fracture and cryo-electron microscopy and small angle X-ray scattering techniques

Biochim.Biophys.Acta, 1370:151-160, 1998

279 B. McCormack and G. Gregoriadis

Drugs-in-cyclodextrins-in-liposomes: An approach to controlling the fate of water insoluble drugs in vivo

Int.J.Pharm., 162:59-69, 1998

280 Y.L. Loukas, V. Vraka and G. Gregoriadis

Drugs-in-cyclodextrins-in-liposomes: A novel approach to the chemical stability of drugs sensitive to hydrolysis

Int.J.Pharm., 162:137-142, 1998

281 G. Gregoriadis

Editorial

Int.J.Pharmaceutics, 162:1-3, 1998

282. G. Gregoriadis

Genetic vaccines: Strategies for optimization

Pharmaceutical Research, 15: 661-670, 1998

283. G. Gregoriadis, B. McCormack, Y. Morrison and R. Saffie

DNA vaccination: A role for liposomes

in: Medical Applications of Liposomes (eds D.D. Lasic and D. Papahadjopoulos), Elsevier, Amsterdam, pp. 61-73, 1998

284 G. Gregoriadis

Liposomes in drug delivery and targeting: Thoughts of an early participant

in: Medical Applications of Liposomes (eds D.D. Lasic and D. Papahadjopoulos), Elsevier, Amsterdam, pp. 9-13, 1998

285 G. Gregoriadis, B. McCormack, Y. Perrie and R. Saffie

Liposome-mediated DNA vaccination

In: Liposomes: Rational Design, (ed. A. Janoff), Marcel Dekker, Inc, pp 205-218, 1998

286 G. Gregoriadis, A. Fernandes, B. McCormack, M. Mital and X. Zhang

Polysialic acids: Potential for long circulating drug, protein, liposome and other microparticle constructs

In: ATargeting of Drugs: Stealth Therapeutic Systems@ (eds. G. Gregoriadis and B.McCormack), Plenum Press, New York, pp. 193-205, 1998

287. G. Gregoriadis

Long circulating liposomes: Evolution of the concept

In: A Targeting of Drugs: Stealth Therapeutic Systems@ (eds. G. Gregoriadis and B. McCormack), Plenum Press, New York, pp. 35-40, 1998

288. P. N. Soni, D. Brown, R. Saffie, K. Savage, D. Moore, G. Gregoriadis and G. Dusheiko

Biodistribution, stability and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection

Hepatology, **28**: 1402-1410, 1998

289. C. Nicolau and G. Gregoriadis

Demetrios Papahadjopoulos (1934-98)

Nature, **396**: 118, 1998

290. S. Murdan, B. van den Bergh, G. Gregoriadis and A. T. Florence

Water-in-Sorbitan Monostearate organogels (Water-in-Oils Gels)

J.Pharm.Sci., **88**, 6, 615-619, 1999

291. S. Murdan, G. Gregoriadis and A. T. Florence

Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens?

Eur.J.Pharm.Sci., **8**: 177-185, 1999

292. G. Gregoriadis

Liposomes in Drug and Vaccine Delivery

In: The Drug Delivery Companies Report, 1998/99; PharmaVentures Ltd, Oxford, pp. 60-61, 1999

293. G. Gregoriadis

DNA vaccines: A role for liposomes

Current Opinion in Molecular Therapeutics, **1**: 39-42, 1999

294. S. Murdan, G. Gregoriadis and A. T. Florence

Interaction of a nonionic surfactant-based organogel with aqueous media

Int.J.Pharm., **180**: 211-214, 1999

295. G. Gregoriadis, A. Fernandes, B. McCormack, M. Mital and X. Zhang

Polysialic Acids: Potential Role in Therapeutic Constructs

Biotechnology and Genetic Engineering Reviews, **16**: 203-215, 1999

296. S. Murdan, G. Gregoriadis and A.T. Florence

Inverse toroidal vesicles: precursors of tubules in sorbitan monostearate organogels

Int.J.Pharm **183**: 47-49, 1999

297. S. Murdan, G. Gregoriadis and A.T. Florence

Novel sorbitan monostearate organogels
Int.J.Pharm. 88: 608-614, 1999

298. G. Gregoriadis, B. McCormack, M. Obrenovic, R. Saffie, B. Zadi and Y. Perrie
Vaccine entrapment in liposomes
Methods, 19: 156-162, 1999

299. G. Gregoriadis
Commentary: Liposomes: The Future Ahead
J.Liposome Res. 9: XVII-XVIII, 1999

300. G. Gregoriadis, A. Fernandes and B. McCormack
Polysialylated proteins: An approach to improving enzyme stability and half-life in the blood circulation
S.T.P. Pharma Sciences 9: 61-66, 1999

301. G. Gregoriadis, B. McCormack, M. Obrenovic and Y. Perrie
Entrapment of plasmid DNA vaccines into liposomes by dehydration/rehydration
In: Methods in Molecular Medicine, vol 29, DNA Vaccines: Methods and Protocols (eds D.B. Lowrie and R.G. Whalen), Humana Press Inc., Totowa, NJ, pp. 305-311, 1999

302. S. Murdan, G. Gregoriadis and A.T. Florence
Vesicle-in-water-in-oil (v/w/o) organogels: microstructures and potential immunoadjuvants
In: An Introduction to Niosomes and Other Non-Phospholipid Systems, (ed. I. Uchegbu), pp. 207-226, 1999

303. C. Kirby and G. Gregoriadis
Liposomes
In: Encyclopaedia of Controlled Drug Delivery, vol. 1, (ed E. Mathowitz), 461-492, 1999

304. G. Gregoriadis
DNA vaccines
European Pharmaceutical Contractor, 100-108, 2000

305. G. Gregoriadis, B. McCormack, M. Obrenovic, Y. Perrie and J.-C. Yang
Genetic vaccines: A role for liposomes, In: Targeting of Drugs: Strategies for Gene Constructs and Delivery (eds G Gregoriadis and B McCormack), IOS Press, 2000, pp. 92-101

306. Y. Perrie and G. Gregoriadis
Liposomal DNA vaccines: Structural characteristics, In: Targeting of Drugs: Strategies for Gene Constructs and Delivery (eds G Gregoriadis and B McCormack), IOS Press, pp. 102-111

307. Y. Perrie and G. Gregoriadis

Liposome-entrapped plasmid DNA: Characterization studies
Biochim.Biophys.Acta, 1475: 125-132, 2000

308. B. Zadi and G. Gregoriadis
A novel method for high-yield entrapment of solutes into small liposomes
J. Liposome Res., 10:73-80, 2000

309. G. Gregoriadis, B. McCormack, M. Obrenovic, Y. Perrie and R. Saffie
Liposomes as immunological adjuvants and vaccine carriers
In: Methods in Molecular Medicine, vol 42, Vaccine Adjuvants: Preparation Methods and Research Protocols (ed. D.T. O'Hagan), Humana Press Inc., Totowa, NJ, pp. 137-150, 2000

310. G. Gregoriadis
Liposomes
Encyclopedia of Life Sciences
www.els.net.elsonline.html, 2000

311. G. Gregoriadis
Guest Editorial
J. Lip.Res., 10(4), ix-x, 2000

312. G. Gregoriadis, A. Fernandes, M. Mital, and B. McCormack
Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics
CMLS Cellular and Molecular Life Sciences, 57: 1964-1969, 2000

313. A.I. Fernandes and G. Gregoriadis
The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implications in its pharmacokinetics
Int. J. Pharmaceutics, 217: 215-224, 2001

314. Y. Perrie, P.M. Frederik and G. Gregoriadis
Liposome-mediated DNA vaccination: The effect of vesicle composition
Vaccine, 19: 3301-3310, 2001

315. G. Gregoriadis
Drug and vaccine delivery systems
In: PharmaTech 2001. World Markets Research Centre Ltd, pp. 172-176, 2001

316. G. Gregoriadis
Foreword
In: Drug Targeting: Organ Specific Strategies. (Eds G. Moleman and D.K.F. Meijer), Wiley-VCH, Weinheim, 2001

317. Y. Perrie, M. Obrenovic, D. McCarthy and G. Gregoriadis

Liposome (LipodineJ)-mediated DNA vaccination by the oral route
Journal of Liposome Research, 12:185-197, 2002

318. A. Bacon, W. Caparrós-Wanderley, B. Zadi and G. Gregoriadis
Induction of a cytotoxic T lymphocyte (CTL) response to plasmid DNA delivered by Lipodine
Journal of Liposome Research, 12:173-183, 2002

319. G. Gregoriadis
Guest Editorial
Journal of Liposome Research, 10(4): ix-x, 2002

320. G. Gregoriadis
Foreword
In: Business Briefing: PharmaTech 2002. World Markets Research Centre Ltd, p. 16

321. G. Gregoriadis, A. Bacon, W. Caparrós-Wanderley and B. McCormack
A role for liposomes in genetic vaccination
Vaccine, 20 (2002) B1-B9

322. G. Gregoriadis, B. McCormack, Y. Perrie, A. Bacon, W. Caparrós-Wanderley and B. Zadi
Liposome-based DNA vaccines: Procedures for entrapment
In: Liposomes - A Practical Approach, 2nd Edition, (Eds V.P. Torchilin and V. Weissig), Oxford University Press, pp. 373-380, 2003

323. G. Gregoriadis
Liposomes in drug and vaccine delivery
Drug Delivery Systems and Sciences, Vol 2, No 4, pp. 91-97, 2003

324. S. Jain, D.H. Hreczuk-Hirst, B. McCormack, M. Mital, A. Epenetos, P. Laing and G. Gregoriadis
Polysialylated insulin: synthesis, characterization and biological activity in vivo
Biochim.Biophys.Acta, 1622:42-49, 2003

325. S. Jain, A. Bacon, D.H. Hreczuk-Hirst, B. McCormack, W. Caparrós-Wanderley, A. Epenetos, P. Laing and G. Gregoriadis
The effect of polysialylation on the immunogenicity and antigenicity of insulin: Implications for its *in vitro* and *in vivo* activity
In: Proceedings of 30th Annual Meeting of the Controlled Release Society, p 441

326. A. Bacon, W. Caparrós-Wanderley, B. McCormack, P. Laing and G. Gregoriadis
A novel liposomal influenza vaccine
In: Proceedings of 30th Annual Meeting of the Controlled Release Society, p 884

327. G. Gregoriadis
Improving the pharmacokinetics of protein and peptide drugs: Nature's way

The Drug Delivery Companies Report, 44-47, 2003

328. G. Gregoriadis, A. Bacon, W. Caparrós-Wanderley and B. McCormack
Plasmid DNA vaccines: Entrapment into liposomes by dehydration-rehydration
In: Methods in Enzymology (ed N. Düzgünes), ELS, Vol_367, pp 70-80, 2003

329. S. Jain, D. Hreczuk-Hirst, P. Laing and G. Gregoriadis
Polysialylation: the natural way to improve the stability and pharmacokinetics of protein
and peptide drugs
Drug Delivery Systems and Sciences, vol 4, No 1, 3-9, 2004

330. N. Düzgünes and G. Gregoriadis
Introduction: The Origins of Liposomes: Alec Bangham at Babraham
Methods in Enzymology, vol 391, In Press, 2005

331. G. Gregoriadis, S. Jain, I. Papaioannou and P. Laing
Improving the therapeutic efficacy of peptides and proteins: A role
for polysialic acids.
International J.of Pharmaceutics 300, 125-130, 2005

332. G. Gregoriadis, A. Bacon, B. McCormack, P. Laing, B. Frisch and F. Schuber
Liposomebased DNA/protein vaccines: Procedures for entrapment and immunization
studies
In: "Liposome Technology" 3rd Edition, Ed. G. Gregoriadis, Informa Healthcare,
New York , London, Vol. 3, pp. 233-244, 2007

INVITED LECTURES (Gregory Gregoriadis)

1972

Possible use of Liposomes in Enzyme Replacement Therapy.

Tenth Symposium of the Society for the Study of Inborn Errors of Metabolism,
Cardiff

The lysosomotropic action of liposomes

Lysosome Club Meeting, Clinical Research Centre, Harrow, UK

1973

Enzyme or Drug Entrapment in Liposomes: Possible Biomedical Applications

Symposium of Insolubilised Enzymes, Mario Negri Institute for Pharmacological
Research, Milan

1974

Liposomes as carriers of drugs in cancer therapy

M.R.C. Toxicology Unit, Carshalton, UK

Structural requirements for the specific uptake of macromolecules and liposomes by
target cells. Workshop on cell biological and enzymological aspects of the therapy of
lysosomal storage diseases. Leiden, Netherlands

Liposomes as drug vectors

Gordon Conference on Lysosomes, N.H., USA

The delivery of drugs in liposomes

Medical Research Club Meeting, Clinical Research Centre, Harrow, UK

Micro-encapsulated drug therapy

Department of Nephrology, St Peter's Hospital, London

The drug-carrier potential of liposomes. MRC Cyclotron Unit, Hammersmith Hospital,
Hammersmith, London

Liposomes as carriers of drugs and enzymes

Novo Pharmaceutical Industry, Copenhagen, Denmark

1975

The carrier potential of liposomes in cancer chemotherapy

9th International Congress of Chemotherapy, London

Homing of liposomes to target cells

Joint Colloquium of the Lipid Group and Dutch Lipid Group on Interaction between
Cells, Liposomes and Micelles. University of Liverpool, UK

Drug therapy with liposomes

Pfizer Pharmaceutical Industry, Kent, UK

Role of liposomes in disease and preventive medicine

Lysosome Club Meeting, Medical College of St Bartholomew's Hospital, London

The use of modified liposomes for the development and therapy of model diseases of
glycoconjugate catabolism in specific cells. 3rd International Symposium of
Glycoconjugates: Functions in Animals, Brighton

Liposomes as carriers of enzymes

Workshop on Enzyme Engineering, Poona, India

1976

Liposomes as carriers of asparaginase in the treatment of leukemia

Royal Postgraduate Medical School, M.R.C. Leukemia Unit, Hammersmith, London

Liposomes as carriers of drugs

Merrell Pharmaceutical Industry, Strasbourg

Liposomes as carriers of drugs and enzymes

Department of Biochemistry, University of Manitoba, Manitoba

Liposomes as carriers of therapeutic agents

Research Institute, The Hospital for Sick Children, Montreal

Enzyme therapy with liposomes

Montreal Children's Hospital, Research Institute, Montreal

Direction of liposome-associated therapeutic agents to target areas in the body

Symposium on Bioactivation and Controlled Drug Release, Stockholm

Liposomes as enzyme carriers in enzyme replacement therapy

Development and Metabolic Neurology Branch, N.I.H. Bethesda

The enzyme- or drug-carrier potential of liposomes in medicine

Department of Biochemistry, University of Ottawa, Ottawa

The carrier potential of liposomes in medicine

The Wellcome Research Laboratories, Burroughs Wellcome Co., North Carolina

Organ targeting by surface modification of drug-containing liposomes

Department of Pharmacy, The University of Aston in Birmingham, Birmingham

Liposomes as carriers for pharmacologically active agents

School of Engineering and Science, The Polytechnic of Central London, London

Liposomes as immunological adjuvants

The National Bacteriological Laboratory, Stockholm

Enzyme-carrier potential of liposomes. Possible Therapeutic Applications

Department of Biochemistry, McGill University, Montreal

Liposomes as carriers of therapeutic agents

Boehringer, Mannheim

Liposomes as carriers of enzymes in therapy

Meeting of the Association of Clinical Biochemistry, The Postgraduate Medical Centre, Guildford

Liposomes as immunological adjuvants

Department of Immunology, The Middlesex Hospital Medical School, London

1977

Liposome-encapsulation of enzymes for therapy

Symposium on Pharmaceutical and Medical Aspects of enzyme Biotechnology, London

Liposomes as drug delivery systems

Department of Pharmacy, University of Nottingham, Nottingham

Liposomes

School of Natural Sciences, The Hatfield Polytechnic, Hatfield

Liposomes as carriers of pharmacologically active agents

Pharmaceutical Division, Imperial Chemical Industries Ltd., Cheshire

The carrier potential of liposomes in biology and medicine

Roche, N.J.

Liposomes in Medicine

Alza Corporation, Palo Alto

Liposomes as carriers of drugs and enzymes

A and M University, Department of Chemistry, College Station, Texas

Liposomes in biology and medicine

Merck, N.J.

Liposomes as a carrier for the oral administration of insulin

Searle, Chicago

The drug carrier potential of liposomes in cancer chemotherapy

Macromolecular Institute, Midland, USA

Liposomes as carrier of enzymes

Annual meeting of the International Federation of Institutes for the Advancement of Science, University of Pennsylvania, Philadelphia

Liposomes in therapeutic and preventive medicine

Conference on Liposomes, N.Y. Academy of Sciences, New York

The drug carrier potential of liposomes in medicine

Albert Einstein College of Medicine, Bronx, N.Y.

Liposomes in medicine

Smith Kline French, Philadelphia

Liposomes as carriers of proteins: Possible medical applications

Enzyme Engineering Meeting, Bad Neuenahr

1978

Liposomes as carriers of drugs in medicine: Current realities

Yale University, Department of Nuclear Medicine, New Haven

Liposomes: Properties and Applications, Exxon, N.J.

Drug Targeting: Molecular, cellular and synthetic systems and possible co-operation

1st Gordon Conference on Drug Cancer in Biology and Medicine
N.H. USA

A possibility for oral insulin?

17th Congress of European Paediatric Endocrinology, Athens

Interaction of liposomes with the liver

Autumn meeting of the British Society of Gastroenterology, Edinburgh

Liposomes in medicine: the development of the drug-carrier potential

Symposium on "Liposomes" Battelle, Geneva

A role for liposomes in the treatment of malaria?

WHO Workshop on the chemotherapy of malaria, Geneva

Liposomes and their uses in biology and medicine

Department of Surgery, St. George's Hospital Medical School

1979

Insulin and liposomes

Laboratoire Inserm Hopital Herold, Paris

Liposomes in biology and medicine

Société de Belgique, Brussels

Long term experiences in treatment of type I Gaucher's disease with liposome

-entrapped glucocerebrosidase: β -glucosidase

2nd International Symposium in Enzyme Therapy of Genetic Diseases, National
Foundation - March of Dimes, South Carolina

Possible clinical application of liposomes

Department of Chemistry and Molecular Sciences, University of Warwick

Liposomes as drug carriers: recent developments

Department of Biochemistry, University College, London

Perspectives in the use of liposomes in therapy

Boerhaave Course: Cell Biological Aspects of Disease. The plasma-membrane and
liposomes. University of Leiden, Leiden

Liposomes as a transport mechanism at the cellular and subcellular level

Plenary lecture at the XIth International Congress of Biochemistry, Toronto

1980

Stability of liposomes in vivo and in vitro: Implications for therapeutic use
2nd Gordon Conference on Drug Carriers in Biology and Medicine. N.H. USA

Liposomes and hepatitis B vaccine
2nd Gordon Conference on Drug Carriers in Biology and Medicine. N.H. USA

Liposomes as immunological adjuvants for hepatitis B surface antigens
Symposium on "Liposomes and Immunobiology", University of Texas at Houston, Houston

Targeting of liposomes in vitro and in vivo.
Plenary lecture at the 13th FEBS meeting, Jerusalem

Experience and perspectives of liposomes in medicine
7th International Forum on Subcellular Methodology, Guildford

Liposomes as a drug delivery system.
Symposium on "Liposomes in the study of drug activity and immunocompetent cell functions" Station de Recherches de Virologie and d'Immunologie, Thiverval-Grignon, France

Control of liposomal stability in vivo
Department of Medical Biochemistry, A and M University, Texas

Long-term treatment of Gaucher's disease Type I with liposomal glycosylceramidase
Department of Clinical Research, Scripps Clinic and Research Foundation, San Diego

Cancer chemotherapy with liposomes. Control of drug release from liposomes in vivo.
National Cancer Institute, Bethesda

1981

Drug Targeting
National Institute for Biological Standards and Control, London

Control of liposomal drug release and clearance after parenteral administration
Centre de Biophysique Moléculaire, Orléans

Liposomes as drug delivery systems
International Conference on Drug Delivery System Development, London

Targeting of drugs with liposomes: Studies on optimization
17th Symposium on "Optimization of drug delivery". Alfred Benson Fond, Copenhagen

- Targeting of drugs. A review of potential protein drug carriers
NATO Advanced Study Institute on "Targeting of Drugs", Cape Sounion Beach, Greece
- Targeting of drugs with liposomes. Factors influencing effective action
NATO Advanced Study Institute on "Targeting of Drugs", Cape Sounion Beach, Greece
- Controlled release of drugs from liposomes in vivo
8th International Controlled Radioactive Materials Symposium. Ft Lauderdale, Florida
- Liposomes in enzyme therapy of Gaucher's disease
2nd Clinical Research Centre Symposium on "Advances in the Treatment of Inborn Errors of Metabolism", Harrow, UK
- Liposomes in enzyme therapy of Gaucher's disease. A possible experimental model.
1st International Symposium "Gaucher's Disease: The most prevalent Jewish Genetic Disease", Mount Sinai School of Medicine, New York
- Liposomes as drug carriers
41st International Congress of Pharmaceutical Sciences, Vienna
- Targeting of Drugs
"Teach in" for medical journalists. Royal Society of Medicine. London
- Control of fate and behaviour of liposomes in vivo
European Science Foundation workshop on synthesis, properties and application of ordered systems in polymer chemistry and life science. Mainz, Germany
- Liposomes as adjuvants
MRC Committee on Development of Vaccines and Immunization procedures.
- Recent progress in liposomes research
Academisch Ziekenhuis, University of Amsterdam
- Targeting of liposomal drugs: Important prerequisites for success
Brunel University, School of Biological Sciences
- 1982
- Liposomes as adjuvants in hepatitis B vaccine
MRC CDVIP working party group on hepatitis vaccine
- Liposomes as a drug delivery system
World Symposium: Better protection of pharmaceutical innovation, Paris

Drug Targeting with liposomes

University of Bologna, Istituto di Patologia, Bologna

Control of fate and behaviour of liposomes in vivo

Plenary lecture, Special FEBS Meeting, Athens

Drug Targeting

2nd Symposium on Antimicrobial Chemotherapy, London

Liposomes in vivo

3rd Gordon Conference on Drug Carriers in Biology and Medicine. N.H., USA

"Liposomes in haematology: Tools for research and clinical application"

19th Congress of the International Society of Haematology, Budapest

Optimization of liposome behaviour in vivo

International Conference on Liposomes in vivo, Grignon, France

1983

Control of liposomes in vivo leading to targeting

NATO ASI "Receptor-Mediated Targeting of Drugs", Cape Sounion Beach, Greece

The galactose receptor

NATO ASI "Receptor-Mediated Targeting of Drugs", Cape Sounion Beach, Greece

Liposomes for drug delivery

Hellenic Pharmacological Society, Athens, Greece

Liposomes as drug carriers: Conditions for in-vivo targeting

186th American Chemical Society Meeting (Plenary lecture), Washington, D.C.

Targeting of liposomes in vivo

Merck, Sharp Dohme, Inc. Rahway, N.J.

Control of liposome fate in vivo: Prerequisites for targeting

Biochemical Society Symposium "Medical Application of Liposomes" (Plenary lecture), Charing Cross Hospital Medical School, London

Use of liposomes as enzyme carrier for the treatment of enzyme deficiencies

Centre de Biophysique Moleculaire, Orléans, France

Behaviour of liposomes in vivo: Control leading to targeting

Max Planck Institut für Biochemie, Munich, Germany

1984

Targeting of liposomes in vivo. Prerequisites for success

The University of Aston in Birmingham, Birmingham, UK

Liposomes as a drug delivery system

Boehringer Mannheim GmbH, Tutzing, Germany

Targeting of liposomes in vivo

New York Academy of Sciences. Conference on macromolecules as drugs and as carriers for biologically active materials

A simple method for high yield entrapment of drugs into liposomes in the absence of organic solvents, sonication and detergents

4th Gordon Conference "Drug Carriers in Biology and Medicine", USA

Liposomes as drug carriers

Parenteral Society, Autumn meeting Slough/Windsor, UK

Liposomes as carriers of drugs and vaccines

Bioscience Futures Conference (Online), London, UK

Dehydration/rehydration vesicles: A simple method for high-yield entrapment in liposomes

International Symposium "Medical Application of Liposomes", Nagoya, Japan

Liposomal stability in and clearance from the blood: Optimization leading to targeting in vivo

International Symposium "Medical Application of Liposomes", Nagoya, Japan

Possibilities for liposomes as a drug carrier

Daiichi Seiyaku Co. Ltd., Tokyo, Japan

Recent developments in liposome research.

Organising Scientific Development Group. Oss, Holland

1985

Liposomes: The myth and the reality

Pfizer Central Research, Sandwich, UK

Recent progress in liposome research: Implications in medicine

Université Libre de Bruxelles Institut Jules Bordet, Brussels, Belgium

Control of liposome fate in vivo

International Institut of Cellular and Molecular Biology (ICP) Brussels, Belgium

Liposomes in vivo: Recent progress in controlling their fate

Inserm, Leon Berard, Lyon, France

Fate of liposomes in vivo

NATO ASI "Targeting of Drugs with Synthetic Systems", Cape Sounion Beach,
Greece

Dehydration-rehydration vesicles (DRV): High yield entrapment under mild conditions
NATO ASI "Targeting of Drugs with Synthetic Systems", Cape Sounion Beach,
Greece

Control of liposomes in vivo
Kali-Chemie Pharma, Hannover

Targeting of drugs: The future
Universidad del Pais Vasco, Bilbao

Liposomes in biological systems
University of Murcia, Spain

1986

Liposomes as a drug delivery system: Optimization of behaviour in vivo
Symposium "New Technological Applications of Lipid Bilayers", Tenerife

Encapsulation of enzymes and other proteins in liposomes
Royal Society of Chemistry, Symposium "Chemical Aspects of Food Enzymes",
University of Reading, Reading

Liposome technology and applications
School of Pharmacy, London University, Brunswick Square, London
Liposomes in cancer treatment and prevention
Symposium "Lipids and Cancer", Royal Society of Medicine, London

Possibilities for liposomes in cancer therapy
International Symposium "Ether Lipids in Oncology", Deutsche Krebsgesellschaft,
Göttingen

Liposomes as immunological adjuvants for vaccines
Wellcome Biotechnology, Beckenham, Kent

1987

Fate of liposomes after intravenous injection: Control of stability and clearance
CIBA Geigy, Horsham, UK

Liposomes as Immunological Adjuvants: Possibilities for control
NATO ASI "Targeting of Drugs: Anatomical and Physiological Considerations",
Cape Sounion Beach, Greece

Technology of liposomes as immunological adjuvants

NATO ASI "Targeting of Drugs: Anatomical and Physiological Considerations",
Cape Sounion Beach, Greece

Liposomes as immunological adjuvants: The nature of immune response to entrapped
antigens and the role of liposomal characteristics
Halle Liposome Symposium, Halle, Germany

Immunoadjuvant action of liposomes: Optimization studies
Gordon Research Conference "Liposomes and other Organized Lipid Assemblies"
New London, USA

Liposomes as Drug Carriers
International Congress of Microencapsulation, Dubrovnic, Yugoslavia

Drug Delivery Systems
IV Mediterranean Congress on Chemical Engineering, Barcelona, Spain

1988

Liposomes for targeted drug delivery
Symposium "Le Medicaments de l'an 2000", Foundation Universitaire des Sciences
et Techniques du Vivant, Annecy, France

Liposomes as carriers of drugs and vaccines
Ninth European Immunology Meeting, Satellite Symposium on Immunology and
Biotechnology, Rome

Liposomes and the brain
11th Annual Scientific Meeting of the Canadian College of
Neuropsychopharmacology, Montreal

Liposomes as immunoadjuvants
UCLA Symposium "Liposomes in the Therapy of Infectious Diseases and Cancer",
Lake Tahoe, USA

Liposomes as immunological adjuvants: Optimization Studies
NATO ASI "Immunological Adjuvants and Vaccines", Cape Sounion Beach, Greece

Liposome Technology
NATO ASI "Immunological Adjuvants and Vaccines", Cape Sounion Beach, Greece

1989

Liposomes as drug carriers: Recent trends and perspectives
Department of Biological Sciences, Keele University, Keele

Targeting of drugs: A role for liposomes

Hellenic Medical Society, Royal Postgraduate Medical School, Hammersmith,
London

Biological behaviour of liposomes
5th International Colloquium on Lecithin, Cannes

Liposomes as immunological adjuvants: Role of structural characteristics and entrapped
mediators
NATO ASI "Targeting of Drugs: Optimization Strategies", Cape Sounion Beach,
Greece

Liposomal surface charge and clearance from the circulation: Reevaluation of the status
quo
NATO ASI "Targeting of Drugs: Optimization Strategies", Cape Sounion Beach,
Greece

Liposomes as drug carriers
Plenary lecture, 19th FEBS Meeting, Rome
Liposomes as immunological adjuvants in vaccines
Third Meeting on Membrane Biotechnology, A and M University, Station
College, Texas

Liposomes in immunopotentiality
33rd Harden Conference: "Cellular Barriers and Drug Targeting", Wye College,
Ashford, Kent

Liposomes: Problems and prospects
33rd Harden Conference: "Cellular Barriers and Drug Targeting", Wye College,
Ashford, Kent

1990

Liposomes in the treatment of cancer: Past, present and future
1st International Conference on "Platinum Complexes and Liposomes in the
treatment of Cancer", Barcelona

Liposomes: 21 years of progress
7th International Symposium on Microencapsulation, Glasgow

Liposomes as carriers of drugs and vaccines
First World Medical Conference of Greek Diaspora, Athens

Introduction on Drug Targeting: A Physiologic Mechanisms and Pathologies Involved
in Drug Targeting and Imaging" (Conference Co-organiser), Compiègne, June

2nd NATO Advanced Studies Institute on "Vaccines: Recent Trends and Progress" (ASI
Director and Lecturer), Cape Sounion Beach, Greece

Liposomes: Structure and Properties
X Corso Avanzato di Chimica Pharmaceutica, Bressanose

Liposomes: Recent Progress
1st International Conference on Drug Delivery, Barcelona

Liposomes as immunological adjuvants in vaccines
International Symposium on "Liposomes in Biology and Medicine",
Tashkent, Uzbekistan

Drug Delivery: Liposomes and Immunoliposomes
MRC AIDS Directed Programme: "New approaches towards the use of
oligonucleotides as anti-HIV agents", The Royal Marsden Hospital, London

Liposomes as immunological adjuvants for peptide and protein antigens
Dept of Immunology, University College and Middlesex School of Medicine,
London

Preparation of small liposomes with improved drug entrapment yield
International Conference, Liposomes in Drug Delivery: 21 Years On, London

Liposomes as immunoadjuvants for protein and peptide antigens
International Conference, Liposomes in Drug Delivery: 21 Years On, London

1991

Overview of Liposomes
Symposium on Liposomal Amphotericin B (AmBisome) in the Treatment of
Systemic Fungal Infection; Stratford-on-Avon, UK

Liposomes: A new-generation of immunological adjuvant
Texas A and M University, Dept of Molecular Biology, College Station, Texas

Liposomes as immunological adjuvants for protein and peptide antigens
NATO ASI "Targeting of Drugs: The Challenge of Peptides and Proteins", Cape
Sounion Beach, Greece

Drug incorporation into liposomes: Recent progress
NATO ASI "Targeting of Drugs: The Challenge of Peptides and Proteins", Cape
Sounion Beach, Greece

Liposomes
European Continuing Education College "Microencapsulation of Drugs", Liverpool

Liposome research: Vaccine and drug delivery
ULLA Staff meeting, Noordwijkerhout

The future of liposomes - Liposomes of the future
International Conference on Liposome Dermatics; Bad Griesbach, Germany

Use of liposomes in drug delivery
Roussel Uclaf, Romainville, France

Liposomes as topical carriers: Work in Progress
IV International Meeting on Cosmetic Dermatology, Progress in Cosmetic Dermatology: Science and Safety, Rome

Liposomes: Structure, behaviour in vivo and applications
Third International Conference on Drug Delivery and Targeting Systems: Prospects for the 90's, London

Liposomes as carriers of drugs and vaccines
Pharmaceutical Institute, University of Freiburg, Freiburg

The use of liposomes as immunological adjuvants in vaccines
Second Anglo-Egyptian Conference of Pharmaceutical Sciences, Alexandria
1992

New generation of immunological adjuvants: A role for liposomes
UMDS Guy's and St Thomas's Medical and Dental School, Division of Immunology, London

"Liposome Research Days": Chairman= Introduction, Leiden

Liposomes as immunological adjuvants
NATO ASI "New Generation Vaccines: The role of Basic Immunology", Cape Sounion Beach, Greece

Liposome technology as applied to vaccines
NATO ASI "New Generation Vaccines: The role of Basic Immunology", Cape Sounion Beach, Greece

Use of liposomes in biotechnology
"Mediterranean Universities School for Biotechnology", Ankara

Liposomes and polysaccharides as drug delivery systems
Royal Society of Chemistry Symposium "Encapsulation and Controlled Release", 14-Manchester

1993

Targeting of drugs

Institute of Pharmaceutical Research and Technology, Athens

Targeting of drugs: Liposomes and other Systems (Two lectures)

National Centre for Scientific Research "Demokritos", Athens

Liposomes as drug carriers: A historical perspective

NATO ASI "Targeting of Drugs: Advances in System Constructs", Cape Sounion Beach, Greece

Liposome Technology

NATO ASI "Targeting of Drugs: Advances in System Constructs", Cape Sounion Beach, Greece

Phospholipids vesicles (liposomes) in drug targeting

European Research Conference on Interfaces and Colloidal Systems, York, UK

Liposomes as immunological adjuvants for proteins and peptide antigens

Defence Research Liposome Workshop, Toronto

Liposomes as immunological adjuvants

Chemical and Biological Defence Establishment, Porton Down, UK

Use of liposomes as immunological adjuvants for proteins and peptide vaccines

Liposomes in Drug Delivery: The Nineties and Beyond, School of Pharmacy, London

1994

Drugs-in cyclodextrins-in liposomes: A novel concept in drug delivery

Université Paris-Sud, Centre d'Etudes Pharmaceutiques, Paris

Overview of liposomes

Symposium: Clinical Impact of Liposomal Amphotericin (AmBisome), Royal Society of Medicine, London

Drug targeting and delivery: Recent trends and progress

7th Panhellenic Pharmaceutical Congress, Athens

Liposomes as immunological adjuvants and carriers for peptides, proteins and particulate antigens: An overview

NATO ASI "Vaccines: New-Generation Immunological Adjuvants", Cape Sounion Beach, Greece

Liposome Technology

NATO ASI "Vaccines: New-Generation Immunological Adjuvants", Cape Sounion Beach, Greece

Targeting of drugs (Six lectures)

University of Coimbra, Department of Pharmacy, Coimbra

Liposomes and the development of vaccines for the 21st century

3rd World Bio-Medical Conference of the Hellenic Diaspora, Athens

1995

Liposomes as carriers of peptide, proteins and microbial vaccines

5th International Symposium on Delivery and Targeting of Peptides, Proteins and Genes, Leiden, 17-20 May

Novel liposome-DNA Constructs: In vitro and in vivo studies

NATO ASI Targeting of Drugs: Strategies for Oligonucleotides and Gene Delivery in Therapy, Cape Sounion Beach, Greece, 24 June - 5 July

Effective nucleic acid incorporation within submicron and micron size liposomes under wild conditions, NATO ASI Targeting of Drugs: Strategies for Oligonucleotides and Gene Delivery in Therapy, Cape Sounion Beach, Greece, 24 June - 5 July

A.D. Bangham MD, FRS Achievement Award Lecture

Fourth Liposome Research Days Conference, 30 August-2 September

Liposomes as immunoadjuvants and vaccines

Commet course: Liposome Technology-Clinical and Industrial Applications, Lisbon, 14-19 September

High yield incorporation of plasmid DNA within liposomes: effect on DNA integrity and transfection efficiency

School of Pharmacy, Research Day, London, 22 November

Liposomes as carriers of vaccines

6th Princeton Liposome Conference: Cellular Signals, Clinical Trials and Gene Therapy, Princeton, 28-29 November

Liposomes in drug and vaccine delivery

Symposium on Recent Advances in Drug Delivery Techniques and Testing, Bombay, 11-12 December

1996

Liposomes in immunopotentiality: The co-adjuvant action of interleukins

NATO ASI Vaccine Design: The Role of Cytokine Networks, Cape Sounion Beach, Greece, 24 June - 5 July

Incorporation of antigens and cytokines into liposomes

NATO ASI Vaccine Design: The Role of Cytokine Networks, Cape Sounion Beach, Greece, 24 June - 5 July

Liposome-entrapped vs liposome-complexed and naked plasmid DNA: Comparative studies on DNA vaccination

Liposome Advances: Progress in Drug and Vaccine Delivery, London, 16-20 December

1997

Liposome-mediated DNA vaccination

Dept of Immunology, The Medical College of St Bartholomew's Hospital, London, 11 February

A potential role for liposomes in DNA vaccination

16th Pharmaceutical Technology Conference, Athens, Greece, 15-17 April

Liposome-DNA formulations

International Working Group on the Standardization and Control of Nucleic Acid Vaccines, National Institute of Biological Standards and Control, South Mimms, Herts, 9 May

Polysialylated enzymes: Increased stability and half-lives in the circulation

NATO ASI Targeting of Drugs: Strategies for Stealth Therapeutic Systems, Cape Sounion Beach, Greece, 24 June - 5 July

Polysialylation of enzymes and liposomes

NATO ASI Targeting of Drugs: Strategies for Stealth Therapeutic Systems, Cape Sounion Beach, Greece, 24 June - 5 July

Applications of liposomes and related technology

Galenos III Intensive Course, Patras, Greece, 6-13 July

Liposomes and immunopotentiality of vaccines

Galenos III Intensive Course, Patras, Greece, 6-13 July

DNA vaccination: A role for liposomes

Galenos III Intensive Course, Patras, Greece, 6-13 July

Polysialic acids: A novel approach to drug delivery

Polysaccharide Biotechnology, National Centre for Macromolecular Hydrodynamics, Sutton Bonington, UK, 3-5 September

Liposome-Technology: Dehydration-rehydration vesicles and their application in drug and vaccine delivery

2nd Central European Symposium on Pharmaceutical Technology, Portoroz, Slovenia, 25-26 September

Liposome-entrapped DNA: A role in DNA vaccination
Third Annual Genetic Vaccines IBC Conference: Genetic Vaccines and
Immunotherapeutic Strategies, Orlando, Florida, 16-18 September

Liposome-mediated DNA vaccination
Medical Applications of Biotechnology, Havana, Cuba, 1-6 December

1998

Drug Carriers in the next millenium (Keynote Lecture)
Gordon Research Conference, Drug Carriers in Biology and Medicine, Ventura, CA,
22-27 February

Liposome as carriers of drugs and vaccines
The Hatter Institute and Centre for Cardiology, University College Medical School,
London, 19 March

Genetic vaccines: Liposome-based strategies for optimization
Research Day, School of Pharmacy, London, 2 April

Genetic vaccines: Strategies for optimization
2nd International Meeting on Pharmacy and Pharmaceutical Sciences, 6-9
September,
Istanbul

Liposomes supremolecular structures as drug delivery vectors
Conference on New Advances in Drug Delivery Systems, 13-14 October, London

Liposome-mediated DNA vaccination
European Commission meeting on Gene Therapy, 18-20 October, Coimbra

Liposomes in gene delivery
ADemocritos@ Nuclear Research Centre, 26 October, Athens

Optimising cationic liposome-mediated DNA immunization
IIR Conference on Novel Viral and Non-Viral Gene Delivery Systems, 16-17
November, London

1999

Genetic vaccines: Optimization with DNA delivery systems
Advances in Technology & Business Potential of New Drug Delivery Systems
CRS, Goa, India, 19-20 February

Strategies for the optimization of DNA vaccine delivery
Drug Delivery Systems, IIR Ltd, London, 30 March

International Working Group on the Standardization and Control of Nucleic Acid Vaccines - NAVSaC V, South Mimms, 29 March

Liposome-based vaccines

European Perspectives in the Control of Infectious Diseases; organized by Erasmus Universiteit Rotterdam, Malta, 16 April

Genetic Vaccines: Strategies for optimization

NATO Advanced Studies Institute, Targeting of Drugs: Strategies for Gene Constructs and Delivery

24 June - 5 July 1999, Marathon, Greece, 24 June - 5 July

Liposomes as carriers of DNA vaccines

NATO Advanced Studies Institute, Targeting of Drugs: Strategies for Gene Constructs and Delivery

24 June - 5 July 1999, Marathon, Greece, 24 June - 5 July

Liposome-based DNA vaccines

Protein and Gene-Based Drugs: Product Development and Delivery Challenges (workshop)

American Association of Pharmaceutical Scientists, Annual Meeting
New Orleans, 14-18 November

Liposome-mediated DNA immunization improves humoral and cell-mediated responses

4th International Conference ALiposome Advances: Progress in Drug and Vaccine Delivery@

School of Pharmacy, London, 13-19 December

2000

Liposome-mediated DNA Vaccination: Recent Progress

WHO, Geneva 23-24 May

Liposome-based DNA Vaccines

Symposium on DNA vaccines, gene therapy, and antisense oligonucleotides
Brno, Czech Republic, 18-19 May

DNA vaccines: A role for liposomes

IIR Conference on Proteins, Peptides and Drug Delivery
London, 19-20 July

Liposomes: Structural characteristics and behaviour in vivo

ECIS, University of Patras, Greece, 17-22 September

Liposome-based DNA vaccines

ECIS 2000; University of Patras, Greece, 17-22 September

DNA vaccines: A role for liposomes

Dept of Pharmaceutics, Johan Wolfgang Goethe University, Frankfurt, October

2001

DNA vaccines

IIR, 9th Annual Drug Delivery Conference, Brighton, 10-11 May

Liposome-based DNA vaccines

CRS Symposium on Lipids, Liposomes and Micelles, San Diego, 23-27 June

Improving the stability and pharmacokinetics of drugs

Drug Delivery 2001: Next Generation Technology, The Hatton, London, 1-2 October

Liposomes: Structural characteristics and optimization of behaviour in vivo

Aston School of Pharmacy, Aston University, 24 October

DNA vaccines: A role for liposomes

5th International Conference ALiposome Advances: Progress in Drug and Vaccine Delivery

School of Pharmacy, London, 17-21 December

2002

Polysialic acids in drug delivery

SMI

The Hatton, London, 13-14 February

Recent developments in liposome technology

Scientific Symposium on Vaccination against Influenza

Kemi, Finland, 21-24 March

Liposomal DNA CTL mediated responses in mice

WHO International Working Group on the Standardization and Control of Nucleic Acid Vaccines, seventh meeting

NIBSC, Potters Bar, UK, 21 June

Liposomes: A role in the delivery of DNA vaccines

AAPS Annual Meeting Short Course: Liposomes in Drug and Vaccine Delivery

Toronto, Ontario, Canada, 11-14 November

2003

Liposome-mediated DNA vaccines: Recent advances

IV Simpósio do NECF, Instituto Superior de Ciências da Saúde-Sul,

Lisbone, Portugal, 14 November

Co-delivery of plasmid DNA and the antigen it encodes via liposomes greatly enhances protective immunity: Application in the development of an influenza vaccine

6th International Conference Liposome Advances: Progress in Drug and Vaccine Delivery

School of Pharmacy, London, 15-19 December

Of the secondary documents cited by the Office, only Vaage and Saxon describe *in vivo* experiments with combinations of drugs. Since the problem to be solved by the invention is *how to*, translate the synergistic effects of combinations of drugs as ascertained *in vitro* to *in vivo* administration, the Bally document is essentially not relevant when the invention is considered in this light.¹

Turning, then, to the two secondary references that do address *in vivo* administration, it is apparent that neither took any account of *in vitro* teachings that the non-antagonistic effect of drugs in combination is affected by its ratio. Vaage simply encapsulated vincristine and doxorubicin in separate vehicles for administration in apparently arbitrarily selected amounts and attempted to overcome the observed antagonism upon simultaneous administration by spacing the administration so that each drug was given alone at alternating 3 day intervals. No attempt was made to provide a *composition* that could be administered with at least additive effects. Saxon shows no evidence either of attempting to utilize any consideration of ratios or maintaining them in preparing the co-encapsulated drugs. In any event, the co-encapsulation composition fell apart.

Seen in this light, the Vaage and Saxon papers are themselves evidence that the invention compositions represent a departure from the thinking of those skilled in the art. If the compositions of the invention were obvious, neither Vaage nor Saxon would have done what they did - Vaage

¹ Nevertheless, the preparations of Bally as described in Part C in column 15 cannot be included within the scope of the compositions of the invention, not only because the ratio of drugs is antagonistic, as described in the Supplementary Amendment filed 9 December 2005, but also because the liposomes used are incapable of stable association with any drugs at all. The compositions of Bally are LUVs composed entirely of egg phosphatidylcholine (see line 39) and egg phosphatidylcholine vesicles are inherently incapable of stable association with drugs *in vivo*. This is verified by the enclosed publication of Scherphof, G., *et al.*, *Biochim et Biophys Acta* (1978) 542:296-307, entitled "Disintegration of Phosphatidylcholine Liposomes in Plasma as a Result of Interaction with High-Density Lipoproteins." In the summary, it is stated that "massive release of entrapped labeled albumin from the liposome during incubation with plasma suggests that the observed release of phosphatidylcholine from the liposomes has a highly destructive influence on liposomal structure." Thus, the compositions of Bally are of no help with respect to the present invention.

REMARKS

The disclosure of U.S. patent 5,736,155, submitted herewith in a formal Information Disclosure Statement, has come to the attention of the undersigned. Of particular relevance is column 15 under the heading "Part C" which describes liposomes loaded with either a combination of cytosine arabinoside along with doxorubicin or a combination of methotrexate along with doxorubicin.

One of the documents from which priority is claimed, U.S. provisional application 60/341,529 filed 17 December 2001, in working Example 3, prepares liposomes with combinations in the disclosed ratios and demonstrates that they fail to meet the limitation currently in claims 5 and 15, namely that a non-antagonistic effect is exhibited over at least 5% of the concentration range such that 80-20% of the cells are effected in an *in vitro* assay. For the convenience of the Examiner, the protocol of said Example 3 and the corresponding Figure showing results are included with this Supplementary Response as Exhibit A.

Accordingly, the limitations of claims 5 and 15 have been included in claim 1 and thus also in claim 13 from which they respectively depend. As the limitations inserted into claims 1 and 13 already were present in dependent claims, it is believed that no new issues are raised.

The undersigned apologizes for failing to have brought the attention of the Office to the '155 patent earlier.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket No. 532552000100.

Respectfully submitted,

Dated: December 9, 2005

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959
MORRISON & FOERSTER LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

synergistic interaction over a wide range of doses that affect 5% to 99% of cells ($f_a=0.05$ to $f_a=0.99$). In contrast, when the same agent combination is given at a different drug ratio, the interaction is strongly antagonistic over the same f_a range (Ratio 2 in Figure 2, cisplatin: topotecan 1:1).

5 Example 3

Combination effects of doxorubicin and cytosine arabinoside or doxorubicin and mitoxantrone

Doxorubicin: cytosine arabinoside (ratio of 1:0.45) and doxorubicin: methotrexate (ratio of 1:0.36) combinations were tested for additive, synergistic or antagonistic effects using the standard tetrazolium-based colorimetric MTT cytotoxicity assay protocol (Mosmann et al (1983) J Immunol Methods 65(1-2): 55-63) described above. Results from the MTT assay were used to calculate combination effects using the median-effect analysis described in the previous examples. The abovementioned ratios tested were based on ratios used in US patent no. 5736155, Bally et al. As depicted in Figure 3, the above indicated ratios displayed antagonistic combination effects over a substantial range of f_a values. It should be noted that data lying outside f_a ranges of about 0.2 to 0.8 are not reliable.

15 Example 4

Two agent combinations that exhibit synergistic combination effects

Combinations comprising vinorelbine, cisplatin, sphingosine and edelfosine in combination with sphingosine, edelfosine, camptothecin (topotecan), cisplatin and doxorubicin were tested for additive, synergistic or antagonistic effects using the standard tetrazolium-based colorimetric MTT cytotoxicity assay protocol (Mosmann et al (1983) J Immunol Methods 65(1-2): 55-63). Results from the MTT assay were used to calculate combination effects using the median-effect analysis described in the previous examples. Results are shown in Table III:

TABLE III

Doxorubicin in Combination with Cytosine Arabinoside or Methotrexate




Figure 3

in the art and no attempt has been made in the art to obtain them. That is, there is nothing in the cited art that suggests that one even would want to obtain a composition where the administered drugs are maintained at a predetermined synergistic ratio in order to ensure delivery of a synergistic ratio at a tumor site in a clinical context. Since no one has suggested preparing a composition with these characteristics, the compositions cannot possibly be rendered obvious, they can only be inherently anticipated if, by some accident, compositions with the same characteristics were obtained. In order to defeat patentability, it is therefore necessary to provide a prior art document that describes a composition that has the same characteristics as that claimed, either explicitly or inherently. No such document has been found. In short, because no one in the art sought to obtain a composition with the required characteristics, such compositions cannot be obvious, they can only be coincidentally anticipated (which, in this case, they are not). This should be borne in mind in the context of the arguments below.

The Anticipation Rejection Over Vaage

Claims 1, 3, 6-7, 10-11, 13, 16-19, 46 and 48 were rejected as assertedly anticipated by Vaage. Applicants believe that the invention of claim 1 is distinct from Vaage thus distinguishing its dependent claims as well. The Examiner has properly raised the point that the burden is on applicants to show that the compositions taught by Vaage do not fall within the functional language claimed. Applicants are appreciative that the discussion at the interview resulted in an indication that this rejection may be withdrawn. A specific discussion of the points raised follows.

First, the composition in Vaage fails to meet the *in vitro* test specified in the claim. Enclosed herewith is a publication: Abraham, S. L, *Clin Cancer Res* (2004) 10:728-738, which shows that at all the vincristine:doxorubicin mole ratios tested against tumor cell lines (1:4, 1:7

and 1:20) were antagonistic. (See page 736 and figure 7.) Applicants have calculated the mole ratio of vincristine:doxorubicin in Vaage as 1:9.5. Thus, the ratio administered in the Vaage article is in the range reported antagonistic by Abraham.

And the drugs are antagonistic *in vivo* as well. The relevant data are shown in figure 5. This figure plots tumor volume against time. Doxil (liposomal doxorubicin) and S-VCR (liposomal vincristine) were simultaneously injected on days 3, 10 and 17 (Table V). The results for this combination are shown on line 6 as a dramatic increase in tumor volume exceeded only by placebo (line 1) and S-VCR (line 2). The result for the combination was even worse than that obtained when doxil was administered alone (line 3). Thus, the combination of liposomal vincristine and liposomal doxorubicin was clearly antagonistic.

In an attempt to overcome this, Vaage did not attempt to adjust the ratio of vincristine to doxorubicin, as is done in the present invention. Rather, Vaage teaches away from using a single composition by attempting (successfully) to overcome this antagonism by administering the drugs separately with a 3-day interval between administration of vincristine and administration of doxorubicin.

Thus, not only do the compositions of Vaage not meet the claim limitation of using non-antagonistic drug ratios, Vaage teaches away from even trying to use a single composition containing both drugs. This is evident from the data set forth above.

Applicants believe the foregoing meets their burden to demonstrate lack of anticipation, and are gratified that there is apparent agreement on this point. It is thus believed that the rejection for anticipation by Vaage can be withdrawn with respect to claim 1, and therefore with respect to all claims dependent thereon.

Docket No : 532552000100
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Paul IARDI et al.

Application No : 10/264,538

Confirmation No : 5304

Filed: October 3, 2002

Art Unit: 1615

For: COMPOSITIONS FOR DELIVERY OF DRUG
COMBINATIONS


Examiner: G Kishore

DECLARATION OF LAWRENCE D. MAYER

MS AF
Commissioner for Patents
P O Box 1450
Alexandria, VA 22313-1450

I, Lawrence D. Mayer, declare as follows:

- 1 I am President and Head of Research at Celator, the assignee herein. I conducted or supervised the conduct of the experiments described below.
- 2 In this study, CD-1 nude mice bearing Capan-1 tumors were administered IRI:FLOX in a 1:1 ratio as a free drug cocktail. Blood ratios were measured as a function of time. The results are shown in the graph below.




The original 1:1 ratio, which is non-antagonistic, becomes dramatically distorted almost immediately in the blood. After less than 1 hour, the IRI:FLOX ratio increased to 6:1, which is antagonistic

3. These results clearly show that unless drugs are formulated so as to control their pharmacokinetics, because of their differences in metabolism, an initially administered ratio will not be maintained *in vivo* and can in fact invert from non-antagonistic to antagonistic

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by

fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

Executed at Vancouver, CANADA, on April 26, 2006



Lawrence D. Mayer